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Abstract
Ubiquitylation of cellular proteins alters protein function and half-life to impact cell signaling and fate
decisions. In T cells, ubiquitylation events, mediated by substrate-specific E3 ubiquitin ligases and
deubiquitylating enzymes, can promote or limit T cell activation and alter function. For example, the
catalytic E3 ligase Nedd4 is required for robust T cell activation, while a related Nedd4 family member,
Itch, negatively regulates T cell signaling. Several Nedd4 family ligases are activated by binding Nedd4
family interacting protein 1 (Ndfip1) and/or Ndfip2. I have determined that ligase activity depends nonredundantly on both Ndfip1 and Ndfip2. Unlike Ndfip1, Ndfip2 is not a prominent negative regulator of T
cell activation or TH2 polarization. However, loss of Ndfip2 in Ndfip1 deficient cells leads to a T cellintrinsic expansion of pathogenic TH2 effector cells. Defining substrates of critical ubiquitylation events
in activated T cells can enhance our understanding of T cell function in both health and disease. Thus, I
took a targeted approach to identify new substrates of Nedd4 family catalytic E3 ligases in activated T
cells, developing a proteomics workflow for unbiased quantification of differential ubiquitylation in T cells.
I identified Jak1 as a substrate for Ndfip-dependent E3 ligases, and determined that Ndfip-mediated Jak1
degradation limits cytokine signaling during TCR engagement. Having successfully used proteomics for
substrate-identification, I considered the utility of quantitative proteomics in globally assessing
ubiquitylation in T cells. I developed a mass spectrometry-based approach pairing immunoprecipitation of
“ubiquitin remnant” peptides (with di-glycine modified lysine residues) and whole proteome analysis to
quantify changes in protein-specific ubiquitylation in activated CD4+ T cells. I observed dynamic changes
in ubiquitylation of hundreds of proteins, including key signal transducers, during TCR stimulation.
Comparing changes in ubiquitylation with changes in protein abundance in stimulated CD4+ T cells I
propose to identify proteins for which ubiquitylation is tightly linked to protein abundance and/or function
in a signal-dependent manner. This profiling effort, in combination with targeted studies similar to those
undertaken to identify substrates of Ndfip-dependent E3 ligases, will facilitate a more global
understanding of how ubiquitylation events in activated T cells finely tune the T cell response.
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ABSTRACT
UBIQUITYLATION REGULATES CD4+ T CELL ACTIVATION AND EFFECTOR
DIFFERENTIATION TO SHAPE THE IMMUNE RESPONSE
Claire E. O’Leary
Paula Oliver, PhD

Ubiquitylation of cellular proteins alters protein function and half-life to impact cell signaling and
fate decisions. In T cells, ubiquitylation events, mediated by substrate-specific E3 ubiquitin
ligases and deubiquitylating enzymes, can promote or limit T cell activation and alter function. For
example, the catalytic E3 ligase Nedd4 is required for robust T cell activation, while a related
Nedd4 family member, Itch, negatively regulates T cell signaling. Several Nedd4 family ligases
are activated by binding Nedd4 family interacting protein 1 (Ndfip1) and/or Ndfip2. I have
determined that ligase activity depends non-redundantly on both Ndfip1 and Ndfip2. Unlike
Ndfip1, Ndfip2 is not a prominent negative regulator of T cell activation or TH2 polarization.
However, loss of Ndfip2 in Ndfip1 deficient cells leads to a T cell-intrinsic expansion of pathogenic
TH2 effector cells. Defining substrates of critical ubiquitylation events in activated T cells can
enhance our understanding of T cell function in both health and disease. Thus, I took a targeted
approach to identify new substrates of Nedd4 family catalytic E3 ligases in activated T cells,
developing a proteomics workflow for unbiased quantification of differential ubiquitylation in T
cells. I identified Jak1 as a substrate for Ndfip-dependent E3 ligases, and determined that Ndfipmediated Jak1 degradation limits cytokine signaling during TCR engagement. Having
successfully used proteomics for substrate-identification, I considered the utility of quantitative
proteomics in globally assessing ubiquitylation in T cells. I developed a mass spectrometry-based
approach pairing immunoprecipitation of “ubiquitin remnant” peptides (with di-glycine modified
lysine residues) and whole proteome analysis to quantify changes in protein-specific
ubiquitylation in activated CD4+ T cells. I observed dynamic changes in ubiquitylation of

v

hundreds of proteins, including key signal transducers, during TCR stimulation. Comparing
changes in ubiquitylation with changes in protein abundance in stimulated CD4+ T cells I propose
to identify proteins for which ubiquitylation is tightly linked to protein abundance and/or function in
a signal-dependent manner. This profiling effort, in combination with targeted studies similar to
those undertaken to identify substrates of Ndfip-dependent E3 ligases, will facilitate a more global
understanding of how ubiquitylation events in activated T cells finely tune the T cell response.
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CHAPTER 1: INTRODUCTION1
CD4+ T helper cells are critical orchestrators of functional immunity
During an immune response, CD4+ T helper cells produce cytokines that direct the host
response to eliminate the pathogen and also promote long lasting immunological memory,
thereby protecting against re-exposure. To acquire these functions in host defense, T cells are
first activated via their T cell receptor (TCR) by an antigen-presenting cell (APC) presenting an
antigenic peptide on MHC (pMHC). The number of CD4+ T cells in the naïve T cell pool
expressing a TCR with the proper specificity for antigenic peptides derived from any given
pathogen is small. However, upon stimulation these cells clonally expand and, via their ability to
produce cytokines, mobilize an appropriate immune response (O'Shea and Paul, 2010; Tubo et
al., 2013)
Engagement of the TCR with pMHC, together with concomitant signaling via co-receptors
and cytokine receptors, activates these antigen-specific CD4+ T cells and directs CD4+ T helper
cell differentiation, allowing acquisition of effector function. During activation, quantitative
(strength) as well as qualitative (presence or absence) signals are integrated to specifically tailor
the T cell response to the host’s need to clear a specific type of pathogen or limit collateral
damage from other responding immune cells. The combination of signals from engagement of the
TCR, costimulatory molecules, and cytokine receptors (also known as, respectively, signals one,
two, and three), allows appropriate, contextual activation and differentiation of CD4+ T cells
(Curtsinger and Mescher, 2010; Hubo et al., 2013; O'Shea and Paul, 2010; Tubo and Jenkins,
2014; Zhu et al., 2010).
Distinct populations of effector CD4+ T cells have been identified based on their ability to
produce different cytokines (TH1, TH2, TH17 among others), suppress the function of other T cells
1

Portions of this chapter appear in the Frontiers in Immunology review article entitled
“Ubiquitylation as a rheostat for TCR signaling: from targeted approaches towards global
th
profiling,” accepted November 26 , 2015, with the following authors: Claire E. O’Leary, Emma L.
Lewis, and Paula M. Oliver.
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(regulatory T cells, or Tregs), and provide help to germinal center B cells (follicular helper cells, or
TFH) (Zhu et al., 2010). Early studies defined two types of effector T helper cells based on
the observation that murine T cell clones could produce either interferon γ (IFNγ) or interleukin-4
(IL-4), and that production of these cytokines was mutually exclusive. These cells were called TH1
cells, in the case of IFNγ producers, while IL-4 producers were deemed TH2 cells (Mosmann et
al., 1986; O'Garra, 1998; Reiner, 2007). Subsequent studies in both animal models and humans
defined a regulatory cell population, CD25+FoxP3+ Tregs, that could repress T helper cell
responses, and an additional major effector CD4+ T cell population, TH17 cells, characterized by
production of IL-17A and expression of RORγT (Hori et al., 2003; Ivanov et al., 2006; Park et al.,
2005; Sakaguchi et al., 1995; Suri-Payer et al., 1998). Recently, T follicular helper cells have
emerged as a key CD4+ T cell population in promoting long lasting immunity. TFH are defined
contextually by their location in the germinal center in close apposition to B cells where they can
promote B cell antibody class switch and somatic hypermutation; whether TFH are a distinct
cytokine producing lineage, or derived from differentiated T effectors (i.e.: TH1 or TH2 cells) is as
yet unresolved (Crotty, 2014). Additional TH lineages have been proposed based on predominant
expression of other cytokines not typically associated with TH1, TH2, or TH17 cells, and this
lineage differentiation is further complicated by emerging data on the plasticity of these helper T
cell subsets (O'Shea and Paul, 2010; Zhou et al., 2009).
These different effector CD4+ T cell fates can be specified by the initial strength of
activating signal upon TCR engagement, the presence or absence of costimulatory receptor
signaling, and exposure to distinct cytokine milieus (O'Shea and Paul, 2010; Tubo and Jenkins,
2014; Zhu et al., 2010). Integration of these signals promotes the expression and function of
lineage defining transcription factors that are required for the downstream effector function of
distinct lineages of T effector cells. These so-called “master” regulators are not sufficient to
specify T cell fate and must work in concert with “pioneering” transcription factors and chromatin
remodelers, many of which are important in specifying diverse T helper lineages (Wang et al.,
2015a). Lineage specificity is then maintained by signaling through the dominant cytokines
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produced by the differentiated effector cell, which continues to promote the function of the master
regulator (Wang et al., 2015a; Zhu et al., 2010). The basic paradigm for differentiation of T
effector cells from a naïve CD4+ T cells is shown in Figure 1.1.
The requirement of multiple signals for full T cell activation and effector cell differentiation
also provides a fail-safe mechanism to limit aberrant T cell responses, e.g., to self-antigen or
innocuous environmental antigens. Inappropriate signaling in these downstream pathways can
lead a T cell to respond aberrantly, resulting in hypo- or hyper-responsiveness to antigenic
stimulation (Benczik and Gaffen, 2004; Brownlie and Zamoyska, 2013; Zikherman and Au-Yeung,
2015). The expression levels and function of cellular proteins that relay signals initiated
downstream of the TCR, costimulatory molecules, and cytokine receptor engagement are
therefore tightly regulated to prevent T cell responses in the absence of receptor ligands and to
promote appropriate effector cell specification upon stimulation.

Ubiquitylation is a post-translational modification that impacts CD4+ T cell
activation and effector function
Post-translational modifications play critical roles in regulating signal transduction
pathways engaged during T cell activation. In this regard, phosphorylation and dephosphorylation
events have been a primary focus of research on TCR signaling pathways, particularly TCRproximal signaling. Several examples of critical phosphorylation events in activated T cells are
shown in Figure 1.2 (Weiss and Littman, 1994).
In addition to phosphorylation, there is growing appreciation that covalent attachment of
the 8.5 kDa protein ubiquitin, either singly or in chains, is another key post-translational
modification driving T cell signaling. The most commonly considered outcome of ubiquitylation is
protein degradation via the proteasome. However, monoubiquitylation or polyubiquitylation of
accessible target protein lysines can alter protein fate and function in diverse ways: resulting in
protein degradation, activation or inhibition of function, altered trafficking, or providing a scaffold
for protein-protein interactions (Komander, 2009; Kulathu and Komander, 2012). In T cells,
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Figure 1.1. Differential signaling drives TH lineage specification.
Multiple signaling pathways are engaged during T cell activation. Upon encountering an APC
presenting cognate antigen on MHC II, CD4+ T cells with specificity for this antigen are engaged
(signal one). Signal two is provided by activating costimulatory molecules (such as CD80/CD86),
which engage receptors on the T cell (CD28 in the case of CD80/CD86). Expression of these
costimulatory molecules only occurs on mature “professional” APCs, which were stimulated by a
pathogen or inflammatory environment during antigen uptake. Signal three is provided by local
cytokine cues. Presence or absence of any of these signals, as well as the strength of signal—
modulated by affinity or time of interaction for receptor and ligand, or by abundance and
functional state of intracellular signaling proteins—dictates helper T cell differentiation.
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Figure 1.2. Simplified model of critical phosphorylation cascades in T cell activation.
The TCR and costimulatory proteins contain ITAM motifs—inducible tyrosine activation motifs—
that are phosphorylated by associated tyrosine kinases upon ligand-induced receptor clustering
of the receptors at the immunological synapse. These phosphorylated tyrosines then serve as
docking sites for recruitment of additional tyrosine kinases and scaffolding proteins that initiate
MAP kinase signaling, calcium release and NF-κB activation. JAK-STAT signaling is initiated by
JAK phosphorylation of the cytokine receptor intracellular domains upon ligand binding, which
promotes STAT recruitment and phosphorylation.
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In T cells, ubiquitylation can affect T cell activation and anergy, as well as helper T cell
differentiation, cytokine production and cell cycle progression (Friend et al., 2014; Park et al.,
2014).
Conjugation of ubiquitin to lysines on target proteins (substrates) occurs in a series of
steps, illustrated in Figure 1.3a. First, ubiquitin is activated in an ATP-dependent manner by
conjugation to an E1, or ubiquitin activating enzyme. Second, in a trans-thiolation reaction,
ubiquitin is transferred from the E1 to the catalytic cysteine of an E2, or ubiquitin conjugating
enzyme. The ubiquitin-conjugated E2 then interacts with an E3 ubiquitin ligase, allowing
ubiquitylation of accessible lysine residues on the substrate (Clague et al., 2015; Komander,
2009). E3 ubiquitin ligases bring substrate specificity to this reaction. There are two types of E3
ubiquitin ligases: homologous to E6AP carboxyl terminus (HECT) and really interesting new gene
(RING)-between-RING ligases have intrinsic catalytic activity, while RING and U-box ligases do
not (Ardley and Robinson, 2005). RING or U-box E3 ligases serve a scaffolding function, bringing
the ubiquitin-loaded E2 into close proximity to target protein lysines to facilitate covalent bond
formation between the target lysine and the C-terminal glycine of ubiquitin. HECT-type ligases
also bind to substrate and ubiquitin-loaded E2, but, in a second trans-thiolation reaction, ubiquitin
is passed from the catalytic cysteine of the E2 to the catalytic cysteine of the E3, which then
catalyzes ubiquitylation of the target lysine directly (Rotin and Kumar, 2009). RING-betweenRING (RBR) ligases have HECT-like catalytic activity in one RING domain while the other retains
the more common RING function, namely the capacity to bind an E2 (Wenzel et al., 2011).
Ubiquitylation of a protein substrate can result in monoubiquitylation—the addition of a
single ubiquitin to one or many accessible lysines of the substrates (known as multimonoubiquitylation)—or can lead to formation of polyubiquitin chains on the substrate (Figure
1.3b). These distinct post translational modifications are recognized as unique signals by proteins
containing ubiquitin binding domains (Dikic et al., 2009). Polyubiquitylation occurs when ubiquitin
is processively conjugated to itself via one of its seven solvent accessible lysines (Komander,
2009; Kulathu and Komander, 2012). It is worth noting that “head to tail” linked linear polyubiquitin
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chains, in which ubiquitin is linked via its N-terminal methionine were recently characterized,
although literature on this type of polyubiquitylation is more limited (Iwai and Tokunaga, 2009).

a

b
E1
E2

E2

E1

S

multi-monoUb

S

monoUb

E3
polyUb
chain

S

non-catalytic
E3
(RING)
E3s

S

substrate

E2

catalytic
(HECT and RBR)
E3s

S
branched Ub
chain

S
ubiquitin (Ub)

Figure 1.3. The ubiquitylation cascade.
a) Free ubiquitin is conjugated to the catalytic cysteine of the E1 ubiquitin activating enzyme in an
ATP-consuming reaction. In a transthiolation, energy neutral reaction, the E1 associates with an
E2 to transfer ubiquitin to the E2 catalytic cysteine. E2 ubiquitin conjugating enzymes then
associate with a catalytic or non-catalytic E3 ubiquitin ligase that brings a protein substrate in
close proximity to the E2, facilitating covalent bond formation between the methionine of ubiquitin
and a solvent accessible target lysine. If the E2 interacts with a catalytic E3 ligase, a second
transthiolation occurs (called ubiquitin charging) to transfer the ubiquitin to the E3 catalytic
cysteine for E3 mediated covalent bond formation between the target lysine and ubiquitin. b)
Several types of ubiquitylation are possible, with distinct cellular consequences for the
ubiquitylated protein. Ubiquitin chain formation occurs by covalent attachment of ubiquitin
molecules to one of the seven lysines of ubiquitin itself, creating homotypic chains (linkage via the
same lysine), or heterotypic/branched chains (mixed linkages).
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Polyubiquitin chains linked via different lysines have distinct macromolecular structures;
these distinct conformations are recognized by ubiquitin binding proteins specific for certain
polyubiquitin structures, ultimately directing distinct downstream protein fates. For example, K63
chains can provide a scaffold for protein complex formation. In contrast, “canonical” K48 chains
are recruited to the proteasome and thus promote degradation. However, distinct chains can
target a protein for the same fate: all “atypical” ubiquitin linkages except lysine 63 (i.e., lysine 6,
11, 27, 29 or 33) are recognized by proteasomal ubiquitin binding domain proteins (Xu et al.,
2009). The purpose of this redundancy is as yet unknown, and is further complicated by the fact
that more complex, branched chains of mixed linkages (heterotypic chains) also occur, although
few downstream effects of these mixed linkages have been determined in cells (Komander and
Rape, 2012; Kulathu and Komander, 2012).
Ubiquitylation involves formation of covalent bonds; however, as with other posttranslational modifications ubiquitylation is reversible. Ubiquitin can be removed from proteins by
deubiquitylating enzymes (DUBs), which can be specific for certain types of ubiquitin linkages
and/or ubiquitylated protein substrates (Clague et al., 2015; Komander et al., 2009). DUB activity
is also required to generate a pool of free ubiquitin monomers from ubiquitin precursors,
establishing these enzymes as key to initiating the ubiquitylation cascade (Monia et al., 1989).
Thus, ubiquitylation is a highly dynamic, complex and controlled form of molecular regulation, and
a form of post-translational modification that impacts almost all proteins in the cell.
To deal with such a vast array of possible targets, the substrate specific components of
the ubiquitylation cascade—E3 ligases and DUBs—show extensive diversity, while E1 and E2
enzymes are highly conserved and limited in number. Putative and verified ubiquitin cascade
proteins in the mammalian genome are predicted to number more than 700, with E1 and E2
enzymes representing less than 10% of this diversity (Clague et al., 2015). Understanding how
ubiquitylation acts during specific signaling cascades, then, requires understanding when, and
how, substrate-specific E3 ligases and DUBs are activated, what their targets are, and what
consequence the ubiquitylation or deubiquitylation event has on the target protein’s cellular fate.
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Our understanding of how ubiquitylation modulates signaling during T cell activation is
still in its infancy. Genetic loss-of-function studies are beginning to reveal some of the key
enzymes and accessory proteins involved. Based on these studies, we now know that E3 ligases
and DUBs affect many steps within the signaling cascades downstream of the TCR, costimulatory
molecules, and cytokine receptors (Figure 1.4, page 27). These ubiquitylation events impact
activation of critical transcription factors that direct T cell fate and function by either directly or
indirectly affecting function or half-life of the transcription factors themselves or upstream
signaling mediators. Indeed, ubiquitylation proteins are emerging as key players in activation and
differentiation of CD4+ T cells.

Deubiquitylating enzymes in CD4+ T cell activation and function
The deubiquitylating enzymes (DUBs) are a class of proteases that cleave ubiquitin from
its target protein, thus allowing ubiquitylation to be a reversible process. At this time, 95 putative
DUB genes have been reported within the human genome based on having one of five ubiquitinspecific protease domains: ubiquitin specific protease (USP), ubiquitin C-terminal hydrolase
(UCH), ovarian tumor (OTU), Machado-Josephin (MJD), or JAB1/MPN/Mov34 metalloenzyme
(JAMM) (Nijman et al., 2005). These five domains define the five subclasses of DUBs. Most
DUBs act as cysteine proteases, relying on a cysteine followed by a histidine in the catalytic site.
The histidine allows for the deprotonation of the cysteine residue, which then cleaves the Cterminus of ubiquitin by nucleophilic attack (Komander et al., 2009; Nijman et al., 2005). The
substrate of a DUB can be a specific ubiquitin chain or a specific target protein, but targets for
most DUBs are currently unknown. Mass spectrometry-based studies using epitope tagged
proteins has identified factors that interact with DUBs and have elucidated potential roles for
DUBs in specific biological processes, many of which are relevant in T cells (Sowa et al., 2009).
These types of studies will no doubt complement more traditional, targeted mechanistic studies to
expand our understanding of DUB function in T cells.
Ubiquitin Specific Proteases (USPs)
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USPs are one of the four main families of cysteine proteases, and the largest family of
DUBs. Since cleavage occurs between two ubiquitins within a polyubiquitin chain, most USPs
contain at least two ubiquitin-binding sites, one for the distal ubiquitin, and one for the proximal
ubiquitin (Eletr and Wilkinson, 2014). Several USP family DUBs have been shown to regulate
TCR signaling including USP9x, USP15, USP7 and USP18.
Usp9x is highly expressed in the spleen and thymus of mice (Mouchantaf et al., 2006;
Naik et al., 2014; Park et al., 2013), indicating a possible function in T cells. T cells from chimeric
mice with shRNA knock down of Usp9x demonstrate defective proliferation and reduced IFN-γ,
IL-2, IL-4 and IL-17 production, indicating an inhibition of helper T cell differentiation or function
(Park et al., 2013). This inhibition seems to be due to a decrease in NF-κB activation following
TCR stimulation in Usp9x knockdown T cells. Jurkat T cells depleted of Usp9x show decreased
phosphorylation of IκBα, nuclear p65, decreased Bcl10 interaction with Carma1, and increased
ubiquitylation of Bcl10 (Park et al., 2013). Thus, Usp9x may be acting on the NF-κB pathway via
deubiquitylation of Bcl10. Specifically, Usp9x appears to deubiquitylate K48 ubiquitin linkages on
Bcl10 following TCR stimulation (Park et al., 2013). However, experiments in mice with a
conditional knockout of Usp9x in T cells contradict this finding. Although T cells lacking Usp9x
have diminished proliferation following TCR stimulation, they show no decrease in nuclear
translocation of p65 or in the interaction between Bcl10 and Carma1 (Naik et al., 2014). Rather,
this study demonstrated decreased phosphorylation of LAT and PLC-γ1 following TCR
stimulation. Mice lacking Usp9x in T cells ultimately develop a lupus-like autoimmune disease
with splenomegaly and anti-nuclear antibodies (Naik et al., 2014). Usp9x has also been shown to
deubiquitylate the E3 ligase Itch, protecting Itch from degradation in the proteasome after autoubiquitylation. Thus, increased degradation of Itch in the absence of USP9x could provide an
alternative explanation for the onset of autoimmunity in Usp9x deficient mice. However, the
experiments examining Itch have been carried out in vitro in HEK-293T cells and COS-7 cells, not
in T cells (Mouchantaf et al., 2006).
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Recently, several additional USP DUBs have been published as having roles in T cells.
USP15 is abundantly expressed in T cells, and T cells lacking this enzyme show increased IL-2
and IFNγ production. USP15 deubiquitylates MDM2, an E3 ligase that ubiquitylates and degrades
P53 as well as NFATc2. In the absence of USP15, MDM2 levels are decreased and NFATc2
levels in the nucleus consequently increase, likely accounting for elevated IL-2 and IFNγ
production (Zou et al., 2014). In vivo, this increased T cell responsiveness led to improved
pathogen clearance and reduced tumor-induced lethality (Zou et al., 2014). USP7 also negatively
regulates immune activation by binding to and stabilizing FoxP3 in regulatory T cells; this may
counteract the actions of the E3 ubiquitin ligases Stub1 and Cbl-b, discussed below, which can
promote FoxP3 ubiquitylation (Chen et al., 2013; van Loosdregt et al., 2013). Though USP7 and
Stub1/Cbl-b have not been investigated together, this post-translational regulation of FoxP3 may
be an example of ubiquitin editing. USP18, originally though to be a deISGylation enzyme
(Ritchie et al., 2004) due to the accumulation of ISG15 in Usp18-/- mice, was recently described
to have deubiquitylation roles in NF-κB signaling, specifically limiting K63 polyubiquitylation of
Tak1 and IKKγ/NEMO (Liu et al., 2013; Yang et al., 2015). In cytokine receptor signaling, USP
DUBs have also been identified as mediators of appropriate signaling, although limited work has
been done in T cells. USP17 (also called DUB2) was observed to increase lymphocyte survival
after cytokine withdrawal (Migone et al., 2001), while USP13 stabilizes STAT1 during interferon
responses (Yeh et al., 2013). Undoubtedly, future work will uncover additional USP family
members that play important roles in modulating receptor signaling and responsiveness during T
cell activation and differentiation.

E3 ubiquitin ligases in CD4+ T cell activation and function
E3 ubiquitin ligases have one common feature—the ability to select the protein
substrates in the cell that will be covalently ‘tagged’ with ubiquitin, thereby imparting substrate
specificity to the ubiquitin cascade. Each E3 contains one or more domains that allow substrate
binding, as well as a domain that binds a ubiquitin conjugated E2. In the case of E3 ubiquitin
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ligases containing a catalytic HECT domain, E2 binding occurs within the HECT domain, while
among RING type ligases E2 binding occurs via the RING domain. Currently, there are only a few
catalytic HECT-type ligases with known functions in T cells—all of these are members of the
Nedd4-family discussed below. All other E3 ubiquitin ligases with known roles in TCR signaling
are non-catalytic, RING-type ligases.
Casitas B-lineage lymphoma (Cbl) family
Cbl-b and c-Cbl were among the first E3 ubiquitin ligases implicated in TCR signaling
(Bachmaier et al., 2000; Chiang et al., 2000). The third family member, Cbl-c, is not known to be
expressed in T cells. These three highly homologous Cbl proteins, Cbl (c-Cbl, Cbl2, or RNF55),
Cbl-b (also termed RNF56), and Cbl-c/Cbl-3 (also termed Cbl-SL or RNF57) have a RING
domain, which allows interactions with E2s (Joazeiro et al., 1999; Zheng et al., 2000), and
multiple protein-protein interaction domains to facilitate their selection of substrates (Schmidt and
Dikic, 2005; Staub and Rotin, 2006). These protein-protein interaction regions include a tyrosinekinase-binding domain (TKB), a Src homology (SH2) domain, a proline-rich motif, a ubiquitinassociated (UBA) domain, and additional motifs known to be phosphorylated in a signal
dependent manner. This diversity of interaction motifs make Cbl-b and c-Cbl particularly well
suited for binding mediators of signaling cascades, such as those downstream of the TCR.
Cbl-b negatively regulates T cell activation. Mice lacking Cbl-b spontaneously develop
autoimmune disease as they age, and are more susceptible to induced forms of autoimmune
disease. This is not due to a defect in the thymic selection of Cbl-b deficient T cells, as Cbl-b is
predominantly expressed in T cells only after they have completed thymic development (Liu and
Gu, 2002). Rather, T cells lacking Cbl-b can become fully activated in the absence of CD28 costimulation (Bachmaier et al., 2000; Chiang et al., 2000; Jeon et al., 2004). Additionally, in vitro,
Cbl-b deficient CD4+ T cells show increased IL-2 production and proliferation in response to
TCR/costimulation (Bachmaier et al., 2000; Chiang et al., 2000). In peripheral T cells, TCR
engagement drives activation of NFAT, which in turn leads to Cbl-b expression (Heissmeyer et
al., 2004). Once expressed, Cbl-b has been proposed to mediate ubiquitylation of multiple TCR
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signaling mediators including PLC-γ, the PI3 kinase subunit p85, and PKCθ (Bachmaier et al.,
2000; Chiang et al., 2000; Fang and Liu, 2001; Fang et al., 2001; Heissmeyer et al., 2004;
Yasuda et al., 2002). However, whether these are the relevant substrates remains somewhat
controversial (Liu et al., 2014), and the precise means through which Cbl-b regulates TCR
signaling via these and other substrates remains to be defined.
c-Cbl, like Cbl-b, negatively regulates TCR signaling. Unlike Cbl-b, c-Cbl is expressed
predominantly in the thymus where it regulates levels of the TCR and signal strength upon
receptor ligation. T cells lacking c-Cbl have enhanced Zap-70 phosphorylation, elevated TCR
levels and altered thymic selection (Naramura et al., 1998; Thien and Langdon, 1998). Following
TCR ligation, Zap-70 recruits c-Cbl to ubiquitylate the TCRζ chain (Wang et al., 2001).
Interestingly, Zap-70 deficient thymocytes do not show defects in TCR surface expression
(Kadlecek et al., 1998; Myers et al., 2006), supporting that other molecules, such as SLAP, may
help recruit c-Cbl to the TCR complex (Dragone et al., 2009; Myers et al., 2005; Sosinowski et al.,
2001; Sosinowski et al., 2000; Tang et al., 1999). Once ubiquitylated, the TCR is degraded within
lysosomes, as degradation is blocked by use of lysosomal inhibitors (Dragone et al., 2009) or
deficiency in lysosomal associated proteins, such as LAPTM5 (Kawai et al., 2014; Ouchida et al.,
2008). Although c-Cbl has been shown to ubiquitylate other substrates, such as WASP
(Watanabe et al., 2013), p85 (Thien et al., 2010), and CD5 (Roa et al., 2013), the relevance of
ubiquitylation of these substrates in TCR signal modulation is less well-defined.
The similar yet non-redundant roles of c-Cbl and Cbl-b in T cells is emphasized by the
exacerbated phenotype of mice with doubly deficient T cells (Naramura et al., 2002). Conditional
deletion of both c-Cbl and Cbl-b in T cells leads to robust T cell-mediated inflammation in mice
due to defective surface TCR down regulation, which, in doubly deficient CD4+ T cells, leads to
prolonged signaling and T cell hyper-responsiveness (Naramura et al., 2002).
More recently, Cbl-b has been described to work with other E3 ligases. Cbl-b can bind to
the prototypic member of the Nedd4-family of E3 ubiquitin ligases, Nedd4 (Magnifico et al., 2003;
Yang et al., 2008). Nedd4 and Cbl-b have been shown to regulate each other’s function, either
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through degradation or by recruitment of the ligase to other factors (Magnifico et al., 2003; Yang
et al., 2008). Additionally, as described below, Cbl-b can work with Stub1 to ubiquitylate FoxP3
(Magnifico et al., 2003; Yang et al., 2008; Zhao et al., 2015a).
Tripartite motif proteins (TRIMs)
TRIM E3 ligases are named for the presence of the tripartite motif, which contains a
RING domain, one or two B-Box domains, and a coiled coil domain (Meroni and Diez-Roux,
2005). This unique motif is invariably located at the N terminus, while there is broad heterogeneity
in the C terminal domains (Micale et al., 2012). TRIMs interact to generate homotypic and
heterotypic multimers, forming discrete macromolecular structures in specific cellular
compartments (Meroni and Diez-Roux, 2005; Napolitano and Meroni, 2012; Reymond et al.,
2001). TRIMs are a large, heterogeneous family in mammals, consisting of approximately 70
proteins in both mice and humans. Analysis of the C terminal domains suggests that TRIMs have
diversified extensively in vertebrates, perhaps in response to pathogens (Marin, 2012; Sardiello et
al., 2008). The E3 ligase function of TRIMs is not limited to ubiquitin—although TRIMs can
promote ubiquitylation through their interaction with E2 ubiquitin conjugating enzymes, TRIM
RING domains can also mediate sumoylation and ISGylation with a variety of other E2s (Chu and
Yang, 2011; Napolitano et al., 2011; Zou and Zhang, 2006). Much work has focused on a role for
TRIMs in pathogen responses, particularly in promoting antiviral responses in innate immune
cells (Gack et al., 2007; Narayan et al., 2014; Qiu et al., 2013; Rajsbaum et al., 2014; Shen et al.,
2012; Tsuchida et al., 2010; Weng et al., 2014; Wynne et al., 2014; Zhao et al., 2012a; Zhao et
al., 2012b; Zurek et al., 2012). However, little is known about the role of TRIMs in adaptive
immune cells.
The best characterized TRIM in CD4+ T cells is TRIM28 (also called KAP/TIF1α), which
contains histone interacting domains in addition to the tripartite motif, and is inducibly
phosphorylated during TCR signaling (Chikuma et al., 2012). TRIM28

fl/fl

CD4Cre+ mice have

defective TCRα rearrangement and reduced peripheral T cell numbers; TRIM28 deficient T cells
have impaired cell proliferation and IL2 production (Chikuma et al., 2012; Zhou et al., 2012).
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Somewhat surprisingly, these mice develop autoimmune disease, characterized by high
percentages of TH17 cells and defective Tregs (Chikuma et al., 2012).
Several other TRIM family members have known or suggested roles in CD4+ T cells.
TRIM27 is a negative regulator of CD4+ T cell activation by promoting degradation of PI3KC2β,
thereby limiting calcium release and preventing a sustained calcium signal after TCR
engagement (Cai et al., 2011). Similarly, Trim30 also appears to negatively regulate TCR signals,
as CD4+ T cells from TRIM30-/- mice show a loss of co-stimulatory molecule dependence and
increased homeostatic proliferation upon transfer into Rag1-/- recipients (Choi et al., 2014).
Within innate cells, TRIM21 promotes ubiquitylation of IRF3, IRF7, and IRF8, with either pro or
anti-inflammatory effects on cytokine production (Higgs et al., 2010; Kong et al., 2007; Yoshimi et
al., 2009). One study of TRIM21-/- mice determined that several dysregulated cytokines are
related to TH17 development (Espinosa et al., 2009); however, whether this is due to T cell
intrinsic hyper-cytokine production remains to be seen. While many TRIMs have particularly high
expression in innate cells, some are preferentially expressed within CD4+ T cells at the RNA
level, including: TRIM1, TRIM9, TRIM18 and TRIM46 (Rajsbaum et al., 2008). To date, no
findings on these TRIMs in T cells have been published.
Cullin RING Ligases (CRLs)
The cullin RING ligases are the largest known family of E3 ligases. Translational
research on cullins has primarily focused on their potential role in cancer because they are known
to affect genes involved in cell cycle progression, cell proliferation, apoptosis, and DNA repair
(Zhao and Sun, 2013). Despite the relevance of these processes to T cell function, minimal work
has been done on cullins in immune cells. Cullin proteins themselves do not possess an E3
ligase domain, or E3 ligase function. Rather, cullins are the central scaffold of cullin RING ligase
(CRL) complexes. CRLs are composed of the cullin scaffold, a RING-box protein, a substrate
recognition protein, and, in most cases an adapter protein linking the cullin to the substrate
recognition protein. There are eight cullin family members, but there are over 200 CRLs due to
the modular nature of these complexes (Bulatov and Ciulli, 2015; Zhou et al., 2013b). The RING-
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box protein, Rbx1 or Rbx2, binds to the globular C-terminal domain (CTD) of the cullin and
promotes CRL enzymatic activity by interaction with an E2 conjugating enzyme. The cullin CTD
also contains a conserved lysine that must be NEDDylated in order for the cullin to be in its active
form (Zhao and Sun, 2013). Within the cullin N-terminal domain (NTD), cullin repeats either bind
directly to a substrate binding protein or indirectly via an adapter protein (Bulatov and Ciulli, 2015;
Zheng et al., 2002).
The most well studied member of the cullin family is cullin 1 (Cul1). Cul1 expression in
human tissues is highest in the spleen, blood, and tonsils, suggesting a possible immune function
(Kawaida et al., 2005). Cul1 CRLs, also known as the SCF complex, are a complex of the
adaptor Skp1, Rbx1, and one of nearly 70 different F-box proteins. The substrate specificity of the
SCF complex is thought to be determined by the F-box protein (Zhou et al., 2013b). Of these 70
Cul1 CRLs, only three have been fully characterized in terms of substrate and function (Skaar et
al., 2009; Zhou et al., 2013a). Substrates of the SCF are within known TCR signaling pathways,
and include the IFNα receptor 1 and IκBα (Fuchs et al., 1999; Kawaida et al., 2005; Kumar et al.,
2003; Nakayama et al., 2003). However, only one study has specifically examined at the role of
Cul1 in TCR signaling. Appleman and colleagues determined that TCR stimulation leads to the
ubiquitylation of p27

kip1

by SCF

skp2

. p27

kip1

ubiquitylation and subsequent degradation allows T

cells to proceed into S phase. TCR stimulation increases expression of Skp2, the F-box protein
which targets the ligase activity of SCF to p27

kip1

; in contrast, transcription of Cul1 is not affected

(Appleman et al., 2014).
In addition to Cul1, cullin 2 (Cul2) and cullin 3 (Cul3) are also though to play roles
downstream of TCR engagement, although the substrates of Cul2 and Cul3 complexes in TCR
signaling cascades are unknown. Recently it was shown that knockdown of Cul2 and Cul3 in a T
cell line led to a robust increase in IL-2 production following TCR stimulation (Friend et al 2013).
Cul3 is the only member of the cullin family for which a T-cell specific knockout mouse exists.
Ratios of thymic CD4 and CD8 T cells are normal in these mice, but specific effector cell
populations are disrupted. Levels of TFH cells are abnormally high and NKT cells are significantly
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reduced in number (Mathew et al., 2012). Cul3 associates with the BTB-ZF family of transcription
factors to make epigenetic changes that direct the differentiation of these two T cell populations.
Cul3 leads to the promotion of the NKT cell lineage and the inhibition of TFH cells by associating
with PLZF and Bcl6, respectively (Mathew et al., 2014; Mathew et al., 2012). This phenotype was
shown to be independent of TCR signaling (Mathew et al., 2014), so it remains unclear how, or
whether, Cul3 regulation of TCR signaling regulates T cell biology.
Cullin 5 plays an important role in cytokine signaling. Cul5 binds SOCS (suppressor
cytokine signaling) proteins, in which the SOCS-box recruits elongins B and C to form a functional
CRL complex (Babon and Nicola, 2012). Despite their known roles in negative regulation of
cytokine signaling however, the SOCS proteins SOCS1 and SOCS3 have low affinity for Cul5
compared to other SOCS-box proteins, suggesting that their main suppressive function may not
be through nucleating the CRL complex to promote ubiquitylation of JAK proteins or cytokine
receptors (Babon and Nicola, 2012). However, in spite of this low affinity, it has been shown that
SOCS1 targets Jak2 for polyubiquitylation upon cytokine stimulation (Ungureanu et al., 2002).
Further mechanistic studies will be needed to determine the role of Cul5 in cytokine responses.
Gene related to anergy in lymphocytes (GRAIL)
As indicated by its name, GRAIL is a RING-type E3 ubiquitin ligase that is crucial for the
induction of anergy in T cells. Resting T cells generally express low levels of GRAIL; these levels
are further decreased following TCR/CD28 stimulation (Lin et al., 2009). Conversely, expression
of GRAIL is rapidly increased following anergic stimulation of T cells. Resting T cells that overexpress GRAIL produce greatly reduced IL-2 in response to TCR stimulation—this reduced IL-2
production depends on GRAIL E3 ligase activity (Anandasabapathy et al., 2003). GRAIL overexpressing Jurkat and DO11.10 T cells exhibit impaired actin polarization at the immunological
synapse following TCR stimulation, and also demonstrate impaired lymphocyte function
associated antigen (LFA) polarization and JNK phosphorylation downstream of TCR stimulation
(Schartner et al., 2009).
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GRAIL knockout BALB/c mice have normal numbers and ratios of lymphocytes.
However, established methods of inducing oral tolerance in these mice are ineffective (Kriegel et
al., 2009). Aged GRAIL knockout mice develop autoimmune disease with infiltration of
lymphocytes into their lungs and kidneys (Nurieva et al., 2010). CD4+ T cells from GRAIL
knockout mice are more sensitive to TCR stimulation, exhibiting hyperproliferation and increased
production of IL-2 and IFN-γ (Kriegel et al., 2009). The CD3ζ chains have been implicated as a
possible target of GRAIL’s E3 ligase activity. Following stimulation with αCD3 alone, there are
fewer TCRs on the cell surface and a concordant increase in ubiquitylation of CD3ζ; in the
absence of GRAIL, this downregulation of the TCR does not occur (Nurieva et al., 2010).
Pellino 1 (Peli1)
The three Peli family members are highly homologous and all contain a RING domain
that is critical to their function. In T cells, Peli1 acts as a negative regulator of T cell activation via
its interaction with the NF-κB pathway. Cells deficient in Peli1 are hyper-responsive following
TCR stimulation, with increased production of IL-2 and IFN-γ. These cells are also resistant to
TGF-β or Treg-mediated suppression (Chang et al., 2011). The hyper-responsive phenotype of
Peli1-/- cells correlates with increased protein levels of NF-κB and increased nuclear c-Rel
following TCR stimulation. Peli1 has been shown to ubiquitylate c-Rel, forming K48 chains that
initiate its degradation (Chang et al., 2011). Peli1 knockout mice have increased numbers of
memory T cells in both the spleen and lymph nodes. Similar changes in T cell populations are
seen among Peli1 deficient T cells in mixed bone marrow chimeras, indicating that Peli1 acts
intrinsically on these T cell populations. Aged Peli1 mice develop autoimmune disease with
antinuclear antibodies in the serum, immune complexes in the kidneys, and lymphocyte infiltrates
in the kidneys, liver, and lungs (Chang et al., 2011).
STIP1 homology and U-box containing protein 1 (Stub1)
The U-box E3 ubiquitin ligase Stub1 has been shown to regulate NF-κB activation
following TCR ligation, suggesting a role in tuning T cell activation. Stub1 also limits the levels of
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FoxP3 after TCR stimulation, supporting a role in Treg cell fate. Specifically, Stub1 is thought to
amplify NF-κB signaling through ubiquitylation of CARD-containing MAGUK protein 1 (CARMA1),
a critical component of the CARMA1-MALT1-Bcl10 complex that promotes function of IκB kinase
(IKK) and downstream NF-κB activation. Jurkat T cells with Stub1 knocked-down via RNAi show
decreased phosphorylation of IκBα, ubiquitylation of CARMA1 and transcription of IL-2 mRNA in
vitro (Wang et al., 2013). Following TCR ligation of regulatory T cells, Stub1 has been shown to
ubiquitylate FoxP3. In Jurkat T cells constitutively expressing FoxP3, degradation of FoxP3
following TCR and inflammatory cytokine signaling depends on Stub1 ubiquitylation of FoxP3.
Accordingly, knockdown of Stub1 led to the accumulation of FoxP3 in this cell line (Chen et al.,
2013). Stub1 also associates with FoxP3 upon TCR stimulation of naïve T cells from BALB/c
mice. Both Stub1 and Cbl-b can ubiquitylate FoxP3 following TCR stimulation, but Stub1 may
play a more dominant role as T cells deficient in Cbl-b show reduced ubiquitylation, whereas T
cells deficient in Stub1 have a complete lack of FoxP3 ubiquitylation (Zhao et al., 2015b).
However, much of the work thus far on Stub1 has been performed using cell lines or overexpression systems. While it remains unclear whether or how these mechanisms regulate T cell
function in vivo, given that Stub1-/- mice develop spontaneous atopic lung inflammation (Wei et
al., 2014) an intrinsic role for Stub1 in regulation of activated T cells seems likely.
TNF receptor associated factor (TRAF) family
TRAF proteins are defined by their association with membrane-bound receptors in the
tumor necrosis factor receptor (TNFR) family. All TRAF proteins have a conserved TRAF domain
at their C-terminus which interacts both with these associated membrane receptors and with
other TRAF proteins to form hetero- and homodimers. All TRAF proteins except TRAF1 have an
N-terminal RING domain (Lee and Lee, 2002). TRAF proteins facilitate K63 polyubiquitylation of
their substrates, and thus facilitate protein-protein interactions as opposed to targeting the
substrate for proteasomal degradation (Martinez-Forero et al., 2009).
While multiple TRAF E3 ligases are expressed in T cells, the best characterized in
regards to TCR signaling is TRAF6. TRAF6 is required for NF-κB pathway activation following
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TCR stimulation. Knockdown of TRAF6 in Jurkat T cells greatly reduces NF-κB activation, likely
due to loss of IκBα phosphorylation. TRAF6 can ubiquitylate MALT1 oligomers via K63 linkages
that promote protein-protein interactions (Sun et al., 2004). The ubiquitylation of MALT1 leads to
the recruitment of IKKγ/NEMO to the CARMA1-MALT1-BCL10 (CMB) complex (Oeckinghaus et
al., 2007). TRAF6 also ubiquitylates IKKγ/NEMO (Sun et al., 2004) and recruits Caspase8 to lipid
rafts. All of these steps are required for effective NF-κB signaling in T cells following TCR ligation
(Bidère et al., 2006). Somewhat surprisingly, although TRAF6 activates NF-κB in vitro, the
primary phenotype of T cell specific TRAF6 knockout mice is systemic autoimmune disease and
a failure to induce anergy (King et al., 2008; King et al., 2006). T cells from these mice are
resistant to suppression by Treg cells and do not require CD28 co-stimulation for their activation.
These cells also have constitutively activated Akt and enhanced phosphorylation of p85 following
TCR stimulation (even without co-stimulation). This hyperactivation of PI3K pathway components
may be responsible for the resistance to anergy in TRAF6 deficient T cells (King et al., 2006).
Additionally, TRAF6 deficient T cells have reduced Cbl-b expression following anergizing
conditions (King et al., 2008). Although the specific connection between TRAF6 and Cbl-b
remains unknown, dysregulation of Cbl-b could also contribute to the loss of anergy in TRAF6
deficient T cells. TRAF6 has additionally been reported to ubiquitylate and degrade STAT3 (Wei
et al., 2012).
TRAF2 is also involved in activation of the NF-κB pathway in T cells, but the underlying
mechanism is poorly understood. TRAF2 acts on the non-canonical NF-κB pathway through a
signaling complex termed the OX40 signalsome. TCR and OX40 signaling leads to an
association between OX40 and protein kinase B (PKB). This association is reduced in TRAF2knockdown T cells resulting in decreased PKB activation and reduced IL-2 expression (So et al.,
2011a). The OX40 signalosme can also activate the CMB complex leading to NF-κB activation.
TRAF2 knockdown T cells fail to fully activate NF-κB likely due to defecting formation of the
signalsome complex (So et al., 2011b).
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Genetic loss of function studies for other TRAFs hint towards a role in T cell function, but
mechanisms are broadly lacking. For example, TRAF1 deficient mice have increased numbers of
lymphocytes in peripheral lymphoid compartments and an increased T/B cell ratio. T cells from
these mice are hyper-proliferative in response to TCR stimulation, and/or when stimulated with IL2 (Tsitsikov et al., 2001). However, the lack of a RING domain in TRAF1 suggests that, if
ubiquitylation is related to the molecular mechanisms behind this phenotype, TRAF1 may function
as part of a larger complex. In contrast, T cell-specific TRAF3 knockout mice show normal
numbers of total T cells but increased numbers of Treg cells and CD4+ effector/memory T cells
with reduced numbers of CD8+ T cells (Xie et al., 2011; Yi et al., 2014). In vitro, CD4+ T cells
from these mice showed reduced phosphorylation of ERK, LAT, PLCγ1, and ZAP70, and reduced
proliferation and cytokine production in response to TCR stimulation (Xie et al., 2011). This is
quite different from what is seen in TRAF5 knockout mice. These mice show no obvious
phenotype or immune deficiency, but when challenged using a model of airway hypersensitivity,
they show increased TH2 lung inflammation compared to WT mice. In vitro, T cells from these
mice preferentially differentiate into TH2 cells following TCR/OX40 signaling (So et al., 2004).
Neuronal precursor cell expressed and developmentally down-regulated protein 4 (Nedd4)
family
The Nedd4 family of catalytic HECT-type E3 ubiquitin ligases is highly conserved, with an
orthologue in budding yeast (Huibregtse et al., 1995). These catalytic E3 ubiquitin ligases serve
double duty in the ubiquitin cascade—providing both substrate specificity and catalyzing the final
transfer of ubiquitin to accessible lysines on the target protein. As with other catalytic E3 ubiquitin
ligases, Nedd4-family members are regulated by autoinhibition and activated by phosphorylation
or through interactions with accessory proteins (Gay et al., 2008). The nine Nedd4-family proteins
expressed in mammals share a modular architecture consisting of 2-4 WW domains that facilitate
protein-protein interactions, a lipid and calcium binding C2 domain, and the catalytic HECT
domain. These nine Nedd4 family members constitute approximately 1/3 of the known HECT type
E3 ligases in mice and humans (Rotin and Kumar, 2009; Yang and Kumar, 2010). Of the nine
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family members, evidence exists in the literature for expression of four of these in T cells: Nedd4,
Nedd4-2 (or Nedd4L), WWP2, and Itch. The similarity of the Nedd4 family members has made
mechanistic studies particularly challenging. In many cases, substrates identified for one family
member are capable of being ubiquitylated by most other family members in vitro. While certain
substrates have been described as being shared or context specific, cases of mistaken identity
have also occurred (Gay et al., 2008; Heissmeyer et al., 2004).
Nedd4, the archetypal family member, was originally characterized, along with the highly
homologous Nedd4-2, as a negative regulator of epithelial sodium channel (ENAC) expression
(Henry et al., 2003; Kamynina et al., 2001; Snyder et al., 2004; Staub et al., 1996). Follow-up
studies revealed numerous additional shared and unique substrates for these E3s, including
other ion channel and growth factor receptors (Yang and Kumar, 2010). These substrates have
not been specifically investigated in T cells, despite clear relevance for many of these proteins in
T cell survival and TCR signaling. In the case of Nedd4, homozygous deletion resulted in
embryonic lethality (Yang et al., 2008). As no T cell specific knockout has been made, studies of
Nedd4 function in T cells have been limited. Using fetal liver chimeras, Yang et al found that
Nedd4 promotes TCR signaling via degradation of Cbl-b, and T cells lacking Nedd4 were hyporesponsive to stimuli (Yang et al., 2008). An additional substrate of Nedd4, and perhaps WWP2
and Nedd4-2 as well (Fouladkou et al., 2008; Maddika et al., 2011; Yang and Kumar, 2010),
PTEN, is also thought to have a role in Nedd4-/- T cell hyporesponsiveness. Guo et al proposed
that, in the absence of Cbl-b, Nedd4 promotes PTEN inactivation via degradation, leading in part
to the hyperresponsive phenotype of Cbl-b-/- T cells (Guo et al., 2012). There is some evidence
that Nedd4 can also negatively regulate T cell responses—together with Itch, Nedd4 was
proposed to degrade Bcl10 in order to limit NF-κB responses after TCR stimulation (Scharschmidt
et al., 2004).
A thorough characterization of the role for Nedd4-2 in T cells is also lacking, as knockout
mice show lethality at 3 weeks of age (Kimura et al., 2011) and no T cell specific knockout mouse
has been made. In CD4 T cells, however, Nedd4-2 was recently published to degrade JunB, a
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transcription factor previously published as a substrate of the Nedd4 family member Itch
(Heikamp et al., 2014). This remains to be validated and described in more detail.
WWP2 is a much less studied family member, and to-date no phenotype for knockout
animals has been published. Using exogenous over-expression in T cells, one study identified
WWP2 as a positive regulator of T cell activation, similar to Nedd4, as WWP2 was found to
degrade the transcription factor Egr2, thereby limiting activation induced cell death (Chen et al.,
2009). However, a more recently characterized role for Egr2 in promoting peripheral T cell
differentiation and CD4+ T cell effector function suggests that deficiency in WWP2, and perhaps
subsequent accumulation of Egr2, might lead to aberrantly increased effector cell cytokine
production (Du et al., 2014). The finding that that PTEN can be degraded by WWP2 in certain
transformed cell lines (Maddika et al., 2011), suggests that WWP2 could regulate PTEN levels
and/or function during T cell activation. Thus, the current literature suggests conflicting roles for
WWP2 in T cells, which warrants further investigation by in vivo study.
Of the Nedd4 family members, Itch is the best studied in immune cells due to the striking
immunological phenotype of Itchy mutant mice, which develop fulminant auto-inflammatory
disease, characterized by TH2 skewing of CD4+ T cells (Fang et al., 2002; Perry et al., 1998).
Along with GRAIL and Cbl-b, Itch is considered to be a tolerogenic E3 ligase with important
functions in restraining inappropriate immune responses. In activated T cells, Itch has been
proposed to degrade PKCθ and PLCγ1 (Heissmeyer et al., 2004). In mouse peripheral T cells,
one well-characterized substrate of Itch is JunB, an IL-4 transcription factor that accumulates in
the absence of Itch, contributing to the TH2-type inflammation in Itchy mice (Fang et al., 2002;
Oliver et al., 2006). However, overexpression of JunB only partially recapitulates the Itchy mouse
phenotype (Li et al., 1999), suggesting that other factors are also targets of Itch E3 ligase activity.
Prior to the description of Itch as an E3 ligase for JunB, Itch was shown biochemically to degrade
Notch. This may explain why Itchy mutant hematopoietic stem cells display increased proliferation
and long-term self-renewing properties characterized by increased Notch1 signaling (Aki and Liu,
2011; Matesic et al., 2008; Qiu et al., 2000; Rathinam et al., 2011). FoxO1 was recently described
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as a target of Itch in vaccinia responsive TFH, but how FoxO1 is regulated in other T cell
compartments has yet to be addressed (Xiao et al., 2014). Itch also has direct relevance to
human disease, as humans with loss-of-function mutations in Itch also show immunological
defects, including autoimmunity, aberrant immunoglobulin responses, and recurrent respiratory
infections (Lohr et al., 2010). However, the molecular mechanisms within human immune cells
leading to aberrant immune responses have not been described; indeed, unlike in mice, in
humans it remains unclear if loss of Itch function in T cells or in other immune cell types is causal
in the disease phenotype observed.
Nedd4 family interacting proteins (Ndfips)
Likely due to their intrinsic catalytic activity, all Nedd4 family E3 ligases are auto-inhibited
by intramolecular interactions. This autoinhibition can be relieved in a number of ways, including
by phosphorylation, calcium binding, and interaction with PY containing adaptor proteins that bind
to WW domains (Beal et al., 2012; Bruce et al., 2008; Gallagher et al., 2006; Gao et al., 2004;
Kathania et al., 2015; Mund and Pelham, 2009, 2010; Oliver et al., 2006; Persaud et al., 2014;
Ramon et al., 2012; Wiesner et al., 2007; Yang et al., 2006). Within the Nedd4 family of E3
ligases, Itch, WWP2 and Nedd4-2 show strong reliance on interaction with the adaptor proteins
Nedd4 family interacting protein 1 (Ndfip1) and Ndfip2 for in vitro catalytic function (Mund and
Pelham, 2009; Riling et al., 2015).
The Nedd4 family interacting proteins (Ndfips) were first identified in a far western screen
for proteins that could interact with the Nedd4 WW domains (Jolliffe et al., 2000). Ndfips are
evolutionarily conserved three-pass transmembrane proteins that contain three canonical PPXY
motifs and one LPXY motif; the two Ndfip family members found in all mammalian species,
Ndfip1 and Ndfip2, are highly homologous, particularly in regions surrounding their PY motifs
(Cristillo et al., 2003; Harvey et al., 2002; Konstas et al., 2002). Ndfips have an orthologue in
yeast, Bsd2, which is thought to promote the E3 ligase activity of the Nedd4 orthologue Rsp5 by
increasing substrate binding and localizing Rsp5 to intracellular membranes (Hettema et al.,
2004; Sullivan et al., 2007). Studies of the mammalian Ndfip1/Ndfip2 proteins have shown that, in
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vitro, Ndfips act in a similar way to Bsd2, serving to activate or potentiate the E3 ligase function of
Nedd4 family E3 ligases and to localize these ligases to intracellular membranes (Cristillo et al.,
2003; Harvey et al., 2002; Konstas et al., 2002; Mund and Pelham, 2009). Biochemically, these in
vitro binding and ubiquitylation assays indicate that Ndfip1 and Ndfip2 function similarly, and that
Ndfip1 and Ndfip2 bind and activate/potentiate the E3 ligase function of the majority of
mammalian Nedd4 family members in a manner dependent on their PY motifs (Mund and
Pelham, 2009, 2010).
The molecular mechanism by which Ndfip1 activates the Nedd4 family E3 ligase Itch,
which shows robust autoinhibition in in vitro ubiquitylation assays, was recently determined. In the
case of Itch, Riling et al found that multiple Ndfip1 PY motifs are required to relieve Itch
autoinhibition, and that this occurs by interruption of WW domain-HECT binding, which otherwise
prevents Itch from being charged with ubiquitin by ubiquitin-loaded E2 (Riling et al., 2015). These
data indicate that Ndfip1 is required for Itch catalytic activity.
Consistent with a critical role for Ndfip1 in promoting function of Itch in vivo, Ndfip1
deficient mice develop inflammatory disease with striking similarities to what is observed in Itchy
mutant mice, namely: T cell activation in the absences of costimulation, hyperproliferation of
activated CD4+ T cells, and aberrant TH2 skewing (Altin et al., 2014; Beal et al., 2012; Oliver et
al., 2006; Ramon et al., 2012; Ramos-Hernandez et al., 2013). Several of the T cell defects
observed in Ndfip1 deficient mice have been attributed to increased IL-4 production from CD4+ T
cells in which accumulation of the Itch substrate, JunB, drives aberrant TH2 cytokine production
(Beal et al., 2012; Oliver et al., 2006; Ramon et al., 2012; Ramos-Hernandez et al., 2013).
However, Ndfip1 deficient mice develop disease at a much earlier age than Itchy mutant mice.
This suggests that Ndfip1 might activate additional Nedd4 family E3 ligases to negatively regulate
T cell mediated inflammatory responses, and that additional Nedd4 family E3 substrates beyond
JunB are dysregulated in the absence of Ndfip1. Despite the similarities between Ndfip1 and
Ndfip2, whether Ndfip2 is also sufficient to activate the E3 ligase function Itch or related ligases is
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unknown; furthermore, a role for Ndfip2 in Nedd4 E3 ligase activation in vivo has yet to be
investigated.

E3 ligases and DUBs can function together or in opposition
The relationship between E3 ligases and DUBs parallel that of kinases and
phosphatases. The antagonistic functions of E3 ligase and DUBs can quickly create and modify
posttranslational modifications, and the balance of their functions sets the signaling state of the
cell. Ubiquitin, however, is not simply an on/off switch. The fate of the substrate depends not only
on the presence or absence of ubiquitin, but also on the length and specific linkage type of the
attached ubiquitin chain. The number and diversity of E3 ligases and DUBs make ubiquitylation
an incredibly dynamic posttranslational modification, as E3 ligases and DUBs can act together or
in opposition to add or remove ubiquitin chains of different linkages to the same substrate. This
alteration of ubiquitin chains is known as ubiquitin editing. While limited evidence of ubiquitin
editing exists to date in primary CD4+ T cells, the opportunity for interplay and co-regulation of
certain substrates by E3 ligases and DUBs during T cell activation is clear, providing an exciting
opportunity for further defining how T cell activation signals are regulated. Figure 1.4 highlights
known roles in T cells for ubiquitin cascade proteins. However, because the precise substrates of
many E3 ligases and DUBs are still unknown, the exact molecular interactions involved in the
regulatory relationships shown remain, in many cases, controversial or unverified.
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Figure 1.4. Known roles for ubiquitylation proteins in T cell activation.
During T cell activation, engagement of the TCR, coreceptors, and cytokine receptors leads to
activation of phosphorylation cascades to promote nuclear localization and function of AP-1,
NFAT, STAT, and NF-κB transcription factors. Work in vitro and in vivo has elucidated roles for
E3 ubiquitin ligases and ubiquitylation in activation of all of these transcription factors, either by
action on the transcription factor itself or on signaling intermediates. This ubiquitylation can either
limit or promote signals transduced from cell surface receptors to the nucleus.
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Use of proteomics to identify ubiquitylation targets in primary CD4+ T cells
For most E3 ligases with described roles in the immune system, the specific substrate(s)
that regulate the impacted signaling pathways have yet to be identified. Indeed, for many E3
ubiquitin ligases and DUBs that have been less studied in T cells, whether substrate binding or
enzymatic function is required for the observed function in T cells has yet to be directly tested.
The paucity of mechanistic information demonstrates the need for new tools, techniques and
further research to reveal how ubiquitylation regulates substrate fate and function and how this
impacts TCR signaling events. Genomic and transcriptomic analyses of T cells lacking these
various proteins are likely to suggest only indirect effects, i.e. downstream of changes that result
from alterations in a substrate proteins levels or function. Proteomics, specifically the analysis of
proteins using mass-spectrometry, is the logical high-throughput method for studying posttranslational modifications. New proteomic approaches to probe the ubiquitylome of activated
CD4+ T cells will aid in unbiased screening of substrates, a critical element in understanding how
enzymes and accessory proteins involved in ubiquitylation affect T cell activation and
differentiation.
Two general strategies have been described for E3 ligase substrate identification:
interaction of a substrate with the E3 ligase/DUB of interest, or screens to identify ubiquitylated
proteins. These are both mass spectrometry-based approaches that require high protein input.
This presents a unique challenge for immunologists dealing with the limiting quantities of protein
that can be obtained from primary lymphocytes. While limited studies have been done to date in
primary T cells, ubiquitin specific proteomic methods can be adapted for primary cells. Figure 1.5
schematizes several strategies, described below, for probing ubiquitylation in primary T cells via
LC-MS/MS based approaches.
The simplest proteomic approach to indirectly identify effects of perturbations in the
ubiquitylation cascade is to compare levels of protein in experimental and control cells by LCMS/MS analysis. Such whole proteome analyses have been performed successfully on
unmanipulated primary mouse and human cells (Graessel et al., 2015; Pagani et al., 2015;
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Zanker et al., 2015), though not to probe explicitly for ubiquitylated proteins. This proteomic
approach needs to be paired with control experiments to dissect transcriptional vs. posttranscriptional/translational effects. As ubiquitylation does more than lead to degradation of
substrate proteins, altered protein abundance for specific substrates between experimental and
control cells may not be observed. In this regard, reconstruction of a “virtual western blot” to
identify poly-ubiquitin or ubiquitin-like chains on substrates by observing mass shifts in gel
fractionated LC-MS/MS datasets may have some utility (Seyfried et al., 2008). Analysis of relative
protein abundance is an important technique that is readily applicable to immune cells, as it
requires little starting material for appropriate fractionation and good depth of coverage of the
identified proteins. Although the detection of peptides from any given protein is dependent on the
sample fractionation, the protein size, and trypsin (or other protease) cleavage sites, this type of
relative abundance measurement can provide important insights into the relative expression of E3
ligases or DUBs as well as how these proteins are altered in distinct T cell subsets or under
various T cell stimulation conditions.
A common approach to identify enzymes and their ubiquitylated substrates is to express
tagged versions of ubiquitin or the enzyme of interest. After immunoprecipitation against the tag,
ubiquitylated proteins or proteins in complex are analyzed by LC-MS/MS (Meierhofer et al., 2008;
Peng et al., 2003). For E3 ligase immunoprecipitations, this can be coupled with in vitro
ubiquitylation of bound proteins to identify putative substrates from non-substrate interaction
partners. As substrate interactions may be fleeting, a more robust approach is to express a
mutated “substrate-trapping” form of the ligase, which has been done successfully for SCF ligase
complexes in cell lines (Harper and Tan, 2012). Isotope labeling and other specificity controls are
critical to minimize false positives. In most cases, this type of approach requires
transfection/transduction, making it less feasible for primary immune cell applications, particularly
in analysis of naïve cells. Utilization of CRISPR technology to engineer mice with epitope-tagged
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Figure 1.5. Proteomics approaches to investigate ubiquitylation events in primary T cells.
Use of proteomic methods to probe ubiquitylation events in primary T cells requires consideration
of the requisite starting material (mgs of protein), feasibility of transfection or transduction, and
availability of downstream analytic tools. Here, the proteomics approaches discussed are listed in
order of required starting material, where ~100 million activated CD4+ T cells yields 1.5-2.5mgs
of total protein depending on lysis used. Replicates, relevant control samples (i.e.: IgG control or
vector control for epitope tagged affinity purifications), the type of data that will be generated
(counts, ratios), and the desired analysis workflow should be considered in advance.
Tfx=transfected, Tdx=transduced.
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E3 ligases or ubiquitin may make these types of experiments more accessible for primary cell
studies.
Alternative approaches exist for substrate screening based on modification by ubiquitin,
as opposed to ligase binding. In lieu of expressing tagged ubiquitin, enrichment of
polyubiquitylated proteins using ubiquitin binding domains (such as tandem ubiquitin binding
entities or TUBEs) is an option for un-manipulated cells (Aillet et al., 2012; Hjerpe et al., 2009;
Lopitz-Otsoa et al., 2010; Lopitz-Otsoa et al., 2012). With these reagents, validation of direct
ubiquitylation on protein “hits” is required. A more direct approach is based on observation of
modified lysines identified in LC-MS/MS peptides. Lysines covalently modified by ubiquitin, or the
ubiquitin-like proteins Nedd8 and ISG15 (UBLs), are protected from trypsin cleavage, and carry a
diglycine motif (K-ε-GG) after trypsin cleavage at the C-terminal arginine of ubiquitin, Nedd8, or
ISG15 (Peng et al., 2003). These peptides are relatively rare in whole proteome analyses, even
following enrichment based on ubiquitin (~0.5-1% of proteins identified). However, recent
advances allow antibody enrichment of K-ε-GG peptides to aid in the identification of proteins that
are post-translationally modified by, among other events, ubiquitylation (Kim et al., 2011; Udeshi
et al., 2012; Udeshi et al., 2013b; Wagner et al., 2011; Xu et al., 2010). Additionally, considering
that many E3 ubiquitin ligases autoubiquitylate lysines within their own sequence, this method
can also provide insight into the activity of the ligases or DUBs downstream of TCR activation.
Application of this technique is more limited in primary immune cells due to the large amount of
starting material required for efficient peptide immunoprecipitation; however, it is likely that further
improvements on the technique will address this.
Demonstrating the power of combination approaches, recently it was shown that
expression, and subsequent immunoprecipitation, of TUBEs in cells protects effectively against
DUB activity, thereby allowing for a significant increase in the recovery of K- ε-GG peptides after
diglycine immunoprecipitation—this method was successfully used to identify substrates of a
previously uncharacterized F-box protein (Yoshida et al., 2015). However, this method requires
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transfection of the TUBE as well as the ligase of interest, and therefore will require significant
optimization before achieving utility in primary T cells.
For all ubiquitin based enrichment techniques, it is common to include proteasomal
inhibitors, such as MG132, in cell culture prior to LC-MS/MS analysis. However, use of these
inhibitors carries important caveats. Firstly, during T cell stimulation, degradative events may be
critical for additional activation signaling to occur. Second, use of these inhibitors creates
ubiquitin-proteasomal stress, and, while it is predicted that only about 6% of all K-ε-GG peptides
come from UBL linkages, use of inhibitors can lead to depletion of free ubiquitin and an increased
entry of UBL proteins into the ubiquitin conjugation cascade (Kim et al., 2011). Finally, in
comparison to efficient protection against DUB activity, pharmacological inhibition of the
proteasome may only incrementally increase the pool of ubiquitylated proteins in a cell (Yoshida
et al., 2015).
Activity based assays for E3 ligases utilize ubiquitylation in vitro to define new substrates.
These assays are often dependent on recombinant expression of a range of possible substrates,
and are therefore more suited to specific hypothesis testing. Although there are commercially
available protein microarrays suitable for discovery purposes, these currently exist in a largescale format only for human proteins (Persaud et al., 2009; Persaud and Rotin, 2011). Unlike the
E3 ligases, where screens seek to identify substrates, unbiased screens for DUBs have relied
primarily on activity profiling using chemical probes to identify isopeptidase activity of DUBs in cell
lysates (Borodovsky et al., 2002; Claessen et al., 2013; de Jong et al., 2012; Fonovic and Bogyo,
2008; Hemelaar et al., 2004; Love et al., 2009). Such probes can also be used to tag ubiquitin
conjugating enzyme activity. For many E3 ligases and DUBs, characterized as such largely on
the basis of domain homology, activity profiling generates important data on the relevance of
enzymatic activity in cells.
Currently, proteomics approaches for investigating ubiquitylation in primary T cells lag
behind more developed workflows for examining other posttranslational modifications in primary T
cells (e.g., phosphorylation events). Technical challenges, such as reagent specificity and the
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requirement for large amounts of starting material, and analytic challenges, including likelihood of
false positives and minimal depth of coverage, represent major hurdles to successful use of these
proteomics approaches in primary T cells. Furthermore, as ubiquitin is a variable modification,
addition, elongation, and removal of ubiquitin chains all affect a protein in distinct ways. Thus,
even upon identification of a regulated ubiquitylation event, elucidating the downstream function
of these ubiquitylation events is challenging.

Conclusions and this present work
Ubiquitylation is a posttranslational modification with critical roles in immune cell
homeostasis and function that are only now being elucidated. Far from leading only to the
degradation of proteins as part of cellular “maintenance,” ubiquitylation of target substrates can
effect protein activity, localization, and half-life. The type of ubiquitin modification and the
presence of ubiquitin binding proteins and DUBs, which cooperate with or antagonize E3 ubiquitin
ligases, dictate these diverse consequences.
For the majority of ubiquitylation proteins with known roles in T cells, the molecular
mechanism(s) by which they impact T cell signaling, or the immune system more broadly,
remains unknown. Indeed, in some cases, it is still unclear whether the E3 ligase or DUB in
question is acting via its ligase or DUB domains, as structure-function assays are largely lacking
in T cells. New proteomics techniques are now available for use in primary T cells to aid both
hypothesis driven and exploratory experiments. Such studies will provide a more thorough
understanding of how ubiquitylation pathways regulate TCR and other signaling pathways in
CD4+ T cells. However, many of these techniques remain to be optimized for use in primary T
cells, and analytic workflows in primary T cells are lacking.
In the present work, I address the role of the catalytic Nedd4 family E3 ubiquitin ligases in
primary T cells, using mice and T cells deficient in Ndfip1 and/or Ndfip2, as a model for exploring
Nedd4 family E3 function. I first examine a role for Ndfip2 in immune function, and then probe
how Ndfip1 and Ndfip2 might work in a coordinated fashion to regulate these catalytic E3 ligases.

33

Then, I bring to bear several proteomic approaches, developing a workflow for proteomic-based
identification of E3 ligase substrates in primary T cells. Using this approach I identify and validate
a new substrate for Nedd4 family ligases, Jak1, and determine that, in the absence of
Ndfip1/Ndfip2, differential regulation of this critical cytokine signal transducer promotes T cell
hyperactivity via persistent cytokine signaling. Taking several observations from my initial
proteomics efforts, I then assess more globally if one can identify key ubiquitylation events during
activation of primary T cells using proteomics. This ongoing effort combines identification of
quantitative changes in the abundance of K-ε-GG peptides with observed changes in the whole
proteome abundance of the modified protein over the course of stimulation. This proteomic study
suggests ubiquitylation proteins that are likely active during T cell stimulation; supports previously
published targets of ubiquitylation in activated T cells; and has the potential to uncover new
proteins for which ubiquitylation is a primary regulator of protein abundance in primary T cells.
Together, these studies support the critical importance of ubiquitylation and regulation of
ubiquitylation events in the establishment and maintenance of effector T cell responses.
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CHAPTER 2: BOTH NDFIP1 AND NDFIP2 ARE REQUIRED TO
LIMIT PATHOLOGIC EXPANSION OF CD4+ EFFECTOR T CELLS
IN VIVO2
Introduction
Posttranslational modification of proteins by covalent attachment of ubiquitin plays a
critical role in maintenance of T cell tolerance, limiting T cell hyperactivity, and promoting CD4+ T
cell differentiation. During ubiquitylation, substrate specificity is determined by E3 ubiquitin
ligases. Depending on their structure, these ligases can either serve as a scaffold, bringing a
substrate into close proximity with an ubiquitin charged E2 conjugated enzyme, or can catalyze
the final transfer of ubiquitin onto an accessible substrate lysine directly (Rotin and Kumar, 2009).
Loss of function studies of many catalytic and non-catalytic E3 ligases have defined critical roles
for E3 ligases in CD4+ T cells (Friend et al., 2014; Gay et al., 2008; Park et al., 2014), although in
many cases the specific molecular mechanism whereby these proteins act to promote or dampen
T cell activation/effector function is unknown.
The known catalytic E3 ubiquitin ligases with published roles in T cells are members of a
single, highly conserved family of homologous to the E6-AP carboxy terminus (HECT) type E3
ligases known as the Nedd4 family. Nedd4 family ligases share a common modular architecture
consisting of a calcium sensitive/lipid binding C2 domain, two to four WW domains which bind
PPxY (PY) motifs, and the catalytic HECT domain (Rotin and Kumar, 2009). Nedd4 family ligases
are evolutionarily conserved, with an orthologue in yeast (Fang et al., 2014; Huibregtse et al.,
1995; Ingham et al., 2004; Wang et al., 1999). Among the nine Nedd4 family ligases in
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mammalian cells, four have published functions in T cells (Chen et al., 2009; Fang et al., 2002;
Gay et al., 2008; Heikamp et al., 2014; Heissmeyer et al., 2004; Perry et al., 1998; Yang et al.,
2008). In mice, loss of function of the Nedd4 family member Itch results in CD4+ T cell
hyperactivation and TH2 cytokine production, leading to spontaneous inflammation (Fang et al.,
2002; Perry et al., 1998). Similar immunopathology is observed in humans with a loss of function
mutation in Itch (Lohr et al., 2010).
In vitro, catalytic activity of Itch and related ligases is potentiated by, or requires
interaction with, Nedd4 family interacting protein 1 (Ndfip1) and Ndfip2 (Mund and Pelham, 2009).
These three-pass transmembrane proteins contain three WW domain-binding PPXY/LPXY (PY)
motifs, and are highly conserved evolutionarily, with an orthologue in yeast (Cristillo et al., 2003;
Harvey et al., 2002; Hettema et al., 2004; Konstas et al., 2002; Sullivan et al., 2007). In vitro
binding and ubiquitylation assays suggest that Ndfip1 and Ndfip2 are both sufficient to activate
the catalytic function of the majority of mammalian Nedd4-family E3 ligases, and that this is
dependent on their PY motifs (Cristillo et al., 2003; Harvey et al., 2002; Konstas et al., 2002;
Mund and Pelham, 2009, 2010). Studies of Ndfip1 deficient mice indicate that Ndfip1 activates
Itch in vivo to limit T cell activation and TH2 differentiation (Altin et al., 2014; Beal et al., 2012;
Oliver et al., 2006). However, an in vivo role for Ndfip2 has yet to be established.
Here I establish a role for Ndfip2 in regulating immune responses. While Ndfip2-/- mice
show no overt immunopathology, animals with T cells lacking both Ndfip1 and Ndfip2 have a
dramatically increased pool of activated CD4+ T cells compared to mice with T cells lacking only
Ndfip1. This expansion of activated effector CD4+ T cells is intrinsic to CD4+ T cells lacking both
Ndfip1 and Ndfip2, and these cells are more pathogenic in vivo. However, loss of Ndfip2 in Ndfip1
deficient T cells does not significantly enhance the aberrant activation or TH2 polarization of naïve
CD4+ T cells. Rather, my in vivo and in vitro studies indicate that double deficiency in Ndfips
leads to increased expansion of pathogenic effector CD4+ T cells. Thus, while Ndfip1 plays a
dominant role in limiting aberrant naïve CD4+ T cell activation and TH2 differentiation, both Ndfip1
and Ndfip2 are required to limit the effector pool of activated CD4+ T cells.
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Results
Generation of Ndfip2 knockout/GFP knock-in mouse
Given that deficiency in either Itch or Ndfip1 leads to hyperactive T cells and TH2mediated pathology (Altin et al., 2014; Fang et al., 2002; Oliver et al., 2006), and Ndfip1 and
Ndfip2 have similar functions in vitro (Cristillo et al., 2003; Harvey et al., 2002; Konstas et al.,
2002; Mund and Pelham, 2009, 2010), I investigated whether Ndfip2 might also play a role in T
cells. I successfully generated Ndfip2 knockout mice by insertion of GFP into exon 2 of the Ndfip2
gene, putting subsequent exons out of frame (Figure 2.1a-c). I observed Mendelian frequencies
of Ndfip2-/- mice (Figure 2.1d), in contrast to the sub-Mendelian frequency of Ndfip1-/- mice
(Figure 2.1e).
Using Ndfip2+/- mice, which express one copy of GFP under the Ndfip2 promoter, I
analyzed GFP expression as a reporter of Ndfip2 expression. In splenocytes, I observed the
highest GFP expression in T cells (Figure 2.2a). In stimulated Ndfip2+/- CD4+ T cells, GFP
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cells increased in abundance over the course of stimulation, corresponding with CD44 and CD25
expression, but preceding cell division (Figure 2.2b,c).

Ndfip2-/- mice have normal lymphoid compartments and do not develop
inflammation
As the GFP reporter indicated high Ndfip2 expression in T cells, I focused my analysis of
Ndfip2-/- mice on the T cell compartment. Ndfip2-/- mice had normal thymic populations and
normal CD4+ and CD8+ T cell percentages in lymph nodes and spleens (Figure 2.3a,b). Ndfip2/- mice showed no signs of inflammation, no increase in percent or number of CD44+ T cells, and
no increase in cytokine production upon ex vivo stimulation (Figure 2.3b,c, and Figure 2.4a). Thelper differentiation, measured by expression of lineage defining transcription factors and
cytokine production, was similar to control cells after stimulation in vitro (Figure 2.4b,c).
If Ndfip1 and Ndfip2 have overlapping molecular functions, expression of Ndfip1 might
mask effects of Ndfip2 in immune cells. Ndfip1 mRNA expression is increased upon T cell
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activation, consistent with its role limiting aberrant activation and cytokine production in stimulated
naïve CD4+ T cells (Oliver et al., 2006; Ramos-Hernandez et al., 2013). Comparing expression of
Ndfip1 and Ndfip2 mRNA during CD4+ T cell stimulation revealed that Ndfip1 was much more
robustly induced upon initial stimulation than Ndfip2 (Figure 2.3d). However, Ndfip1 and Ndfip2
showed similarly increased expression following re-stimulation. Together with the GFP reporter,
these data support that Ndfip2 expression is increased in newly activated CD4+ T cells, but more
strongly induced during stimulation of previously activated T cells.

Figure 2.1. Generation of Ndfip2 knockout/GFP knock-in mice
a) Targeting vector used for insertion of GFP into exon 2 of the Ndfip2 locus. Gene targeting
resulted in the insertion of GFP into exon 2, partial deletion of exon 2, and deletion of exons 3
and 4. Downstream exons are out of frame. (b,c) Homozygous gene targeted mice were
identified by PCR (b), and (c) further analyzed for Ndfip2 expression by qPCR. (d) PCR
genotyping results of 58 pups from heterozygous Ndfip2+/- breeders. (e) PCR genotyping results
of 64 pups from heterozygous Ndfip1+/- breeders.
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Figure 2.2. Analysis of Ndfip2 GFP reporter expression.
a) GFP expression in Ndfip2+/- cell was analyzed using flow cytometry on ex vivo splenic B and T
cells, and compared to GFP negative WT CD4+ T cells as a control (Ctrl). (b,c) Ndfip2+/- CD4+ T
cells were labeled with a cell proliferation dye (ef670) and stimulated with plate-bound
αCD3/CD28 for the indicated time periods. GFP, CD44, and CD25 expression, and ef670 dilution,
were assessed daily by flow cytometry. (b) Quantification of GFP MFI relative to ex vivo GFP
expression in Ndfip2+/- splenic CD4+ T cells, average shown +/- SEM, two biologic replicates. (c)
Representative flow plots of GFP expression relative to expression of CD44, CD25, and dilution
of proliferation dye. Previously gated on CD4+ live singlets.

39

Figure 2.3. Ndfip2-/- mice do not show signs of inflammation.
a,b) Representative flow cytometry analysis of T cell populations from thymus and spleen of 5-7
week old Ndfip2-/- and age-matched control mice: (a) CD4+ and CD8+ cells, (b) CD44 and
CD62L expression on these cells, as noted. (c) Intracellular cytokine staining for IL-4 and IFNγ in
CD4+ T cells from Ndfip2-/- and WT spleens stimulated ex vivo with PMA and ionomycin in the
presence of BFA. Representative of at least 5 mice per genotype, 5-7 weeks of age. (d) CD4+ T
cells were stimulated in vitro for the indicated time periods with αCD3/CD28. Ndfip1 and Ndfip2
expression was analyzed by qPCR. Ndfip1/Ndfip2 expression relative to beta actin was
normalized to expression in unstimulated CD4+ T cells. Representative of a minimum of three
independent experiments.
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Figure 2.4. No alterations in Ndfip2-/- immune cell populations or Ndfip2-/- CD4+ T cell
differentiation.
a) Quantification of T cell percentages in thymus, lymph nodes and spleen; % CD44+ CD4 and
CD44+ CD8 T cells in spleen and lymph nodes; B cell percentages in bone marrow. Averages
shown +/- SEM n=5-6 16 week old Ndfip2-/- mice and age-matched controls. No significant
differences by paired t-test. (b,c) Naïve CD4+ T cells were sorted from 6 week old Ndfip2-/- and
WT mice and stimulated with plate-bound αCD3/CD28 for 5 days in the presence of iTreg (b),
TH17 (b), TH1 (c), or TH2 (c) polarizing cytokine. On day 5, expression of FoxP3, T-Bet and
GATA3 was examined by intracellular staining. Production of IL-17A (TH17) was analyzed after
PMA/ionomycin stimulation in the presence of brefeldin A. Flow plots representative of at least 3
experiments.
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Ndfip2 deficiency exacerbates inflammatory disease caused by Ndfip1 deficient CD4+ T
cells
To test whether Ndfip1 expression in Ndfip2-/- mice masked effects of Ndfip2 deficiency, I
attempted to generate mice doubly deficient in Ndfip1 and Ndfip2. The number of double
knockout (DKO) pups was unexpectedly low at weaning, and fetal analysis indicated subMendelian frequencies (Table 1). I next generated mice doubly deficient for Ndfip1 and Ndfip2 in
fl/+

fl/fl

T cells by crossing Ndfip2-/- mice to Ndfip1 CD4 Cre+ mice. Ndfip1 CD4 Cre+ mice (cKO)
exhibit T cell-mediated, TH2-biased inflammation similar to that observed in Ndfip1-/- mice
(Ramos-Hernandez et al., 2013). I hypothesized that further loss of Ndfip2 in Ndfip1 cKO mice
would worsen the Ndfip1 cKO phenotype if Ndfip2 acts, perhaps with Itch or Nedd4-2, to prevent
aberrant T cell responses. Alternatively, if Ndfip2 works in opposition of Ndfip1, perhaps
promoting activity of Nedd4 to increase T cell activation or effector responses, then mice with T
cells lacking both Ndfip1 and Ndfip2 might exhibit an amelioration of the inflammation observed in
Ndfip1 cKO mice.

Table 1. Fetal genotyping of intercrossed Ndfip2-/-Ndfip1+/-, Ndfip2+/-Ndfip1+/- mice
Ndfip1, Ndfip2

a,b

Observed

Expected

-/- -/-

7.5%

12.5%

+/- -/-

22.5%

25.0%

+/+ -/-

10.0%

12.5%

-/- +/-

12.5%

12.5%

+/- +/-

25.0%

25.0%

+/+ +/-

22.5%

12.5%

a

c

Genotyping results from tail biopsy gDNA, embryonic day 18-20 fetuses
40 pups genotyped
c
Expected frequency based on Mendelian inheritance of Ndfip1 and Ndfip2 alleles
b
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Consistent with a negative regulatory role for Ndfip2 in regulating immune responses, I
fl/fl

observed that Ndfip2-/-Ndfip1 CD4 Cre+ (referred to as cDKO) mice showed robustly increased
inflammation at barrier surfaces, increased spleen size, and decreased body weight relative to
age-matched cKO, Ndfip2-/- and control mice (Figure 2.5a-c). Splenic CD4+ T cells from cDKO
mice were more likely to express CD44 (Figure 2.5d) and produce IL-4 (Figure 2.5e,i). Similar
data was obtained from analysis of lung homeogenates (Figure 2.6a,b). Additionally, I observed
a significantly increased number of CD4+ T cells in spleens from cDKO mice (Figure 2.5f). This
was due solely to an increased number of CD44+ CD4+ T cells (Figure 2.5g), as the number of
CD62L+ CD4+ T cells was unchanged in cDKO mice relative to age-matched cKO and control
mice (Figure 2.5h).
To separate the observed increase in IL-4 producing T cells from the expanded
population of activated CD4+ T cells in cDKO mice, I examined cytokine production by CD44+
effector CD4+ cells. cDKO CD44+ CD4+ T cells were somewhat more likely to produce IL-4 than
cKO CD44+ CD4+ T cells (Figure 2.5j), but this was not statistically significant. Among cDKO,
cKO, and control mice there was no difference in the likelihood of CD44+ CD4+ T cells to
produce IFNγ (Figure 2.5k). Cytokine production from CD44+ CD4+ T cells isolated from the lung
paralleled what was observed in splenocytes (Figure 2.6c,d); the similarity in TH2 skewing of
CD44+ CD4+ T cells from cKO and cDKO mice was even more apparent in the lung, further
supporting a dominant role for Ndfip1 in preventing aberrant TH2 differentiation. Thus, the
observed increase in Ndfip doubly deficient CD4+ T cells that can produce IL-4 during upon T cell
restimulation is primarily due to an increase in the size of the previously activated, CD44+ effector
CD4+ T cell population.
In order to begin assessing whether the increase in effector CD44+ CD4+ T cells in
cDKO mice was related to expansion/persistence of activated cells or an increase in activation of
naïve cells, which is known to occur in the absence of Ndfip1 (Ramos-Hernandez et al., 2013), I
assessed CD69 expression ex vivo. CD69 is an early activation marker that is rapidly expressed
after TCR engagement, within one hour, and is not expressed in the absence of active TCR
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fl/fl

Figure 2.5. Ndfip2 deficiency exacerbates inflammation in Ndfip1 CD4Cre+ mice.
a) H&E stained sections of esophagus, lung, and skin from representative 8 week old control,
fl/fl
fl/fl
Ndfip1 CD4 Cre+ (cKO) and Ndfip2-/- Ndfip1 CD4 Cre+ (cDKO) mice (bar represents 100mm).
(b,c) Body weight (b) and (c) spleen cell count from 5-7 week old WT, cKO, Ndfip2-/- (N2-/-) and
cDKO mice. Mean +/- SEM n=5-15 mice. (d,e) Representative flow cytometry analysis of splenic
CD3+CD4+ T cells, showing (d) expression CD44 and CD62L, and (e) intracellular levels of IL-4
after ex vivo stimulation with PMA/ionomycin in the presence of BFA. (f-i) Quantification of (f) the
high
number of CD4+ T cells, (g) naïve CD62L
CD4+ T cells, (h) CD44+ CD4+ T cells, and (i) IL-4+
CD4s from spleen analyzed by flow cytometry. Mean +/- SEM, n=7-12 mice. (j,k) Quantification of
percent IL-4+ or IFNγ+ CD4+ T cells among CD44 high T cells. Mean +/- SEM, n= 4-7 mice. P
values calculated by one way ANOVA with Holm-Sidak test for multiple comparisons: *p<0.05, **
p<0.01, ***p<0.001, ****p<0.0001.
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Figure 2.6. Mice with Ndfip doubly deficient T cells have increased CD44+ and IL-4+ CD4+
T cells in lung, but are not more likely to express CD69.
a-f) Lung homogenates or spenocytes from 5-7 week old WT, Ndfip1 cKO and cDKO mice were
examined by flow cytometry ex vivo. (b-d) Intracellular levels of IL-4 of IFNγ after ex vivo
stimulation with PMA/ionomycin in the presence of BFA. (a-f) Quantification of the percent of (a)
CD44+ cells, (b) IL-4+ cells (f) CD69+ CD3+ CD4+ T cells from lung analyzed by flow cytometry.
Mean +/- SEM, n=7-11 mice. CD69 was also analyzed in spleen (e). Mean +/- SEM, n=5-7 mice.
(c,d) Quantification of percent IL-4+ or IFNγ+ CD4+ T cells among CD44 high T cells in lung.
Mean +/- SEM, n= 7-9 mice. P values calculated by one way ANOVA with Holm-Sidak test for
multiple comparisons: *p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001.
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signaling (Hara et al., 1986). In both spleen and lung I observed that Ndfip1 cKO mice had
significantly higher percentages of CD69+ CD4+ T cells than age-matched WT controls, but
Ndfip2 deficiency did not further exacerbate this (Figure 2.6.e,f). This indicates that Ndfip doubly
deficient CD4+ T cells are not more likely to undergo TCR activation than Ndfip1 deficient cells,
and that the increased percent and number of CD44+ CD4+ T effector cells observed in cDKO
mice relative to cKO mice is not likely due to an increased proportion of naïve T cells becoming
activated.
Taken together, these data indicate that loss of Ndfip2 in mice with Ndfip1 deficient T
cells drives expansion of effector CD4+ T cells with pathogenic TH2 activity. However, loss of both
Ndfip1 and Ndfip2 does not significantly increase the aberrant TH2 polarization or aberrant
activation of naïve CD4+ T cells which observed in the absence of Ndfip1 alone. Rather,
compared to Ndfip1 cKO mice, cDKO mice have an expanded population of previously activated
CD44+ effector CD4+ T cells. Thus, Ndfip2, like Ndfip1, negatively regulates T cell immune
responses, but may act preferentially in previously activated effector CD4+ T cells.

Ndfip doubly deficient CD4+ T cells show intrinsic hyperactivation
fl/fl

My phenotypic analysis of Ndfip2-/-Ndfip1 CD4Cre+ mice suggested two possible roles
for Ndfip2: loss of both Ndfip1 and Ndfip2 in T cells could lead to expansion of pathogenic TH2
effector T cells, or loss of Ndfip2 in non-T lineage cells could drive increased expansion and
pathogenicity of Ndfip1 deficient T cells. To test this, I generated mixed fetal liver chimeras,
utilizing fetal liver from germline deleted Ndfip1-/-Ndfip2-/- and Ndfip1-/- embryos to normalize for
effects of Ndfip2 loss in other hematopoietic compartments. Six weeks after reconstitution with
mixed WT and DKO cells, Rag1-/- hosts developed visible signs of inflammation, severe weight
loss, and in some cases death (Figure 2.7a).
High percentages of CD44+ T cells were observed in all chimeras, likely due to continued
homeostatic proliferation at this early time post-reconstitution. However, in these chimeras, DKO
CD4+ T cells were much more likely to be CD44+ compared to WT CD4+ T cells within the same
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host. The likelihood of being CD44+ was significantly higher for DKO CD4+ T cells compared to
WT cells in the same host, but only trended to be higher for Ndfip1-/- CD4+ T cells relative to their
WT counterparts (Figure 2.8a,b). Additionally, CD44+ DKO CD4+ T cells were significantly more
proliferative, as indicated by Ki67 staining (Figure 2.8a-c). This was also true for Ndfip1-/- CD4+
T cells compare to WT cells in the same host, though to a lesser extent. This was unique to CD4+
T cells—while CD8+ T cells were more likely to be CD44+ in Ndfip1-/- or DKO chimeras
compared to WT and Ndfip2-/- chimeras, this was cell-extrinsic (Figure 2.7b-g), in agreement
with what was previously shown for loss of Ndfip1 in CD8+ T cells (Kurzweil et al., 2014). No
significant differences were observed via Ki67 staining in CD8+CD44+ T cells. These data
indicate that hyperactivation and hyperproliferation, specifically of previously activated T cells, is
unique to Ndfip deficient CD4+ T cells.
As previously published, loss of Ndfip1 was sufficient to drive IL-4 production (Altin et al.,
2014); further loss of Ndfip2 resulted in an increased proportion of CD4+ T cells producing IL-4,
even among CD44+ cells, relative to Ndfip1 deficient cells (Figure 2.8d-f). Despite the excess IL4 production in DKO chimeras, there was not a significant increase in IL-4 producing WT cells in
the DKO chimera compared to the WT-WT chimera. These data show that T cells lacking both
Ndfip1 and Ndfip2 are much more likely than either their WT counterparts or T cells lacking only
Ndfip1 to have an effector cell phenotype in vivo, and that these effector cells are more
proliferative and more likely to produce cytokine.
The increased percent of activated Ndfip deficient CD4+ T cells suggested that activated
Ndfip deficient CD4+ T cells might have a competitive advantage over activated Ndfip sufficient
CD4+ T cells. I analyzed this by determining the relative frequencies of CD45.2/CD45.1 cells in
different T cell populations, normalizing to the chimerism observed in IgM+ B cells from bone
marrow. I found a significant increase in the relative frequency of CD45.2+ CD44+ CD4+ DKO T
cells isolated from spleen or lung, but no change among thymocytes or naïve cells (Figure 2.8g
and data not shown). I observed a similar pattern for Ndfip1-/- and, surprisingly, Ndfip2-/- CD4+ T
cells, although this did not achieve statistical significance. Thus, the population of previously
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Figure 2.7 Activated phenotype of Ndfip deficient CD8+ T cells is cell extrinsic.
a-g) Mixed fetal liver chimeras using CD45.2 WT, Ndfip1-/-, Ndfip2-/- or Ndfip1/Ndfip2 DKO fetal
liver were analyzed 6 weeks following reconstitution. (a) Mice were weighed weekly after
injection. (b) Representative CD44 and CD62L staining of splenic CD8+ T cells from WT and
DKO mixed chimera previously gated on live, singlet CD3+CD8+ cells. (c) Representative CD44
and CD62L staining of splenic CD8+ T cells from DKO mixed chimera previously gated on live,
singlet CD3+CD8+ CD45.1 or CD45.2+ cells. (d,e) Representative histograms of DKO chimera
CD45.1+ and CD45.2+ splenic CD8+ T cells (d) stained for CD44, and examining Ki67 on CD44+
cells (e). (f) Percentages of CD44+ CD45.1 or CD45.2 CD8+ T cells. (g) Percentages of CD44+
that are Ki67+. Data shown in (f) were pooled from two experiments, 7-8 chimeras per group;
(a,g) have 4-5 chimeras per group. Quantifications are average +/- SEM. P values calculated by
two way ANOVA with Holm-Sidak test for multiple comparisons: *p<0.05, ** p<0.01, ***p<0.001,
****p<0.0001.
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Figure 2.8. Ndfip deficiency causes intrinsic CD4+ effector T cell expansion.
a-g) Mixed fetal liver chimeras using CD45.2 WT, Ndfip1-/-, Ndfip2-/- or Ndfip1/Ndfip2 DKO fetal
liver were analyzed 6 weeks following reconstitution. (a) Representative CD44 and CD62L
staining of splenic CD4+ T cells from Ndfip1-/- mixed chimera (top) and DKO mixed chimera
(bottom), previously gated on live, singlet CD3+CD4+CD45.1 or CD45.2+ cells. (b,c) Flow
cytometry analysis of CD45.1+ and CD45.2+ splenic T cells from chimeras showing (b)
percentages of CD44+ cells and (c) percentages of CD44+ that are Ki67+. (d-f) Ex vivo
stimulated splenocytes were stained for IL-4. (d) Representative flow plots of IL-4+ CD4+ T cells,
(e) combined data from (d), (f) percentages of CD44+ CD4 T cells that are IL-4+. (g)
Percentages of CD45.2 cells among various T cell subsets, normalized for reconstitution, as
determined by the ratio for CD45.2:CD45.1 IgM+B220+ B cells in the bone marrow.
Compartments analyzed are as follows: A=IgM+B cells in bone marrow, B=double positive
thymocytes, C=single positive CD4+ thymocytes, D=CD44+ CD4+ T cells in spleen, E=CD44+
CD4+ T cells in lung. Data shown in (b,e) were pooled from two experiments, 7-8 chimeras per
group; (c,f,g) have 4-5 chimeras per group. Quantifications are average +/- SEM. P values
calculated by two way ANOVA (b,c,e,f) or repeated measures one way ANOVA (g), with HolmSidak test for multiple comparisons: *p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001.
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activated CD4+ T effector cells is significantly expanded when both Ndfip1 and Ndfip2 are
lacking.

No additional loss of peripheral regulatory T cells in Ndfip1/Ndfip2 knockout mice
The severe inflammation seen in cDKO mice and in DKO mixed chimeras is suggestive
of a failure in regulatory T cells to maintain peripheral tolerance. Previously, it was demonstrated
that Ndfip1-/- mice have decreased FoxP3+ Tregs in the small bowel, a site of peripheral Treg
differentiation, and that exposure of differentiating regulatory T cells to IL-4 prevented sustained
upregulation of FoxP3 (Beal et al., 2012). Therefore, I assessed whether double deficiency in
Ndfip1 and Ndfip2 further impacted the generation of peripheral Tregs as determined ex vivo, or
differentiation of inducible regulatory Tregs (iTregs) in vitro.
I first examined FoxP3+ CD4+ T cell percentages in spleen, thymus, lung and small
bowel (Figure 2.9a-d). While spleen and lung of Ndfip1 cKO mice had Treg percentages
comparable to age-matched WT controls, I observed a significant decrease in FoxP3+ CD4+ T
cells in the lung of cDKO mice. However, within the small bowel there was no additional decrease
in the percentage of FoxP3+ cells in cDKO mice compared to cKO mice. Furthermore, there was
a significant increase in thymic Tregs in both cKO and cDKO mice relative to WT controls. Taken
together, this suggests that in vivo thymic Treg generation is intact in the absence of both Ndfip1
and Ndfip2, but that in peripheral tissues the loss of Ndfips negatively affects regulatory T cells.
However, while these data suggest a further impact of loss of Ndfip2 on regulatory T cells in the
lung, it remained unclear if this was an intrinsic effect on Treg differentiation or an extrinsic effect
of increased effector TH2 cells in cDKO mice, as IL-4 producing lung CD4+ T cells were
significantly more abundant in cDKO mice compared to cKO mice (Figure 2.6b).
To determine if the loss of both Ndfip1 and Ndfip2 impacted the differentiation of
regulatory T cells more severely than loss of Ndfip1 alone, I turned to in vitro Treg generation.
When sorted naïve CD4+ T cells were activated in the presence of TGFβ and IL-2 to generate
FoxP3+ cells in vitro, there was no significant difference in the ability of Ndfip1 deficient cells and
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Figure 2.9. Ndfip1/Ndfip2 deficient T cells show equivalent loss of iTreg conversion as
Ndfip1 cKO T cells.
a-d) Lung homogenates, splenocytes, digested small bowel and thymocytes from 5-7 week old
WT, Ndfip1 cKO and cDKO mice were examined by flow cytometry ex vivo. Live, singlet,
CD3+CD4+ cells were assessed for the percentage of CD25+FoxP3+ cells. Quantification shows
percent FoxP3+ cells among parent CD3+CD4+ cell gate. Mean +/- SEM, n=3-7 for small bowel
and thymus, n=7-14 for lung and spleen. P values calculated by one way ANOVA with HolmSidak test for multiple comparisons. (e,f) iTreg conversion was induced by addition of 5ng/ml
TGFβ and 50U/ml IL-2 to naïve sorted CD4+ T cells during 5 day culture with plate-bound
αCD3/CD28. (e) Representative flow plots showing FoxP3 induction on day 5 of cells stimulated
in the absence (top) or presence (bottom) of 20µg/ml αIL-4. (f) Quantification of the percent
FoxP3+ cells induced by day 5. Mean +/- SEM, n=2-7. P values calculated by one way ANOVA
with Holm-Sidak test for multiple comparisons. Treatment groups (+/- αIL-4) were assessed
separately. (g) Quantification of the percent FoxP3+ cells among CD3+CD4+CD45.1 or CD45.2
cells in mixed fetal liver chimeras. Mean +/- SEM, n= 7-9 mice. No significant differences as
determined by two way ANOVA with Holm-Sidak test for multiple comparisons: *p<0.05, **
p<0.01, ***p<0.001, ****p<0.0001.
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Figure 2.10. No intrinsic differences in thymic maturation of CD4+ T cells in Ndfip deficient
mice.
a-c) Mixed fetal liver chimeras using CD45.2 WT, Ndfip1-/-, Ndfip2-/- or Ndfip1/Ndfip2 DKO fetal
liver were analyzed 6 weeks following reconstitution. (a) Gating scheme for analysis of CD4+ T
cell maturation in thymus. Cells were first gated on live singlets, CD4 single positive and then
assessed fro maturation by CD69 and CD124 staining, as well as FoxP3 and CD25 expression.
low
low
low
CD69 C24 cells are defined as mature, CD24+CD69 cells are immature, and CD24+CD69+
cells are undergoing positive selection. (b) Ratio of CD45.2/CD45.1 cells among various CD4+ T
cell thymic subsets, normalized to the CD45.2/CD45.1 ratio observed in total single positive CD4
cells. (c) Quantification of thymic populations without subsetting by CD45.1/CD45. 4-5 chimeras
per group. Quantifications are average +/- SEM. P values calculated by one way ANOVA with
Holm-Sidak test for multiple comparisons: *p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001.
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cDKO cells to differentiate into iTregs, but both were significantly impaired relative to experiment
matched WT cells (Figure 2.9e,f). Consistent with previous data (Beal et al., 2012), blocking IL-4
in these cultures rescued iTreg differentiation, and while a slight but significant defect in iTreg
conversion was still observed in doubly deficient T cells, this was not significantly different from
cells lacking only Ndfip1 (Figure 2.9f). Thus, as was observed in Ndfip1-/- and Ndfip1 cKO CD4+
T cells previously, IL-4 signaling negatively impacts Treg generation and this is not further
exacerbated in vitro by loss of Ndfip2. Corroborating this in vivo, I observed no significant
differences in the percent of FoxP3+ CD4+ T cells identified in the lung of mixed fetal chimeras
(Figure 2.9g).
I extended this analysis to the thymus to identify intrinsic effects of loss of Ndfip1 and/or
Ndfip2 on CD4+ T cell selection or thymic regulatory cell generation (Figure 2.10a). I observed
no significant differences in the percentage of thymic Tregs in the mixed chimeras, and also did
not observe any intrinsic effects of Ndfip deficiency on the maturation of CD4+ T cells in vivo
(Figure 2.10b), although there were subtle changes in the thymus associated with increased
inflammation (Figure 2.10c). Thus, these data indicate that the increased inflammation, number,
and percent of activated CD4+ effector T cells in cDKO mice relative to mice only lacking Ndfip1
in T cells cannot be explained by a further loss of the regulatory T cell population or defects in
thymic selection.

Ndfip1/Ndfip2 doubly deficient CD4+ T cells cause more severe colitis
My data indicate that both Ndfip1 and Ndfip2 control effector cell numbers and
pathogenicity, but that Ndfip2 has minimal effects on helper T cell differentiation. To test this I
transferred naïve WT, Ndfip2-/-, Ndfip1 cKO, and cDKO CD4+ T cells into Rag1-/- recipients to
induce colitis. cDKO CD4+ T cells caused severe pathology: recipients had high spleen/body
weight ratios, contracted colons, and increased colon crypt depth (Figure 2.11a-d). Recipients of
Ndfip2-/- CD4+ T cells showed equivalent pathology to Ndfip1 cKO recipients; both cohorts
developed more severe inflammation than WT cell recipients as measured by inflammation index.
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While pathology caused by these two genotypes was comparable, Ndfip2-/- T cells, like WT cells,
were IL-17A producers, while Ndfip1 deficient T cells produced IL-4 (Figure 2.11e). cDKO cells,
like cKO cells, made IL-4. This indicates again that, while Ndfip1 plays a dominant role in limiting
TH2 differentiation, after initial activation both Ndfip1 and Ndfip2 limit the pathogenic potential of
activated CD4+ T cells by limiting their expansion and function.

Ndfip1/Ndfip2 deficient T cells outcompete WT cells in vitro
I next tested whether I could model these phenotypic findings in vitro. When naïve CD4+
T cells were examined after five days of in vitro stimulation, cDKO cells showed high GATA3
expression and increased proliferation relative to control cells (Figure 2.12a-c). I also observed a
marked increase in cDKO viability relative to experiment matched control cells (Figure 2.12d).
Therefore, I next tested whether Ndfip deficient CD4+ T cells could outcompete WT cells within
the same cytokine environment. WT cells co-cultured with cDKO CD4+ T cells had increased
GATA3 expression and proliferation, but I observed statistically significant differences between
control and cDKO cells within the same culture (Figure 2.12e-i). In this competitive environment
cDKO cells continued to show enhanced viability—on day five cDKO CD4+ T cells significantly
out-numbered WT cells in the same culture (Figure 2.12h,i). Thus, increased cytokine production
in the absence of Ndfips is insufficient to explain increased viability and proliferation. Notably,
cells deficient in Ndfip1 or Ndfip2 alone did not show significantly enhanced survival in co-culture
with WT cells (data not shown).
These data suggest that loss of both Ndfip1 and Ndfip2 leads to increased survival and
proliferation of activated CD4+ T cells, resulting, in vivo, in an expanded population of previously
activated effector cells. Furthermore, Ndfip deficient CD4+ T cells outcompete WT cells within the
same cytokine milieu, suggesting that Ndfip-deficient T cells are more competent to respond to
cytokines promoting division and survival.
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Figure 2.11. Ndfip1/Ndfip2 deficient CD4+ T cells cause increased colitis.
a-e) 0.5x10^6 sorted naïve CD4+ T cells from WT, Ndfip2-/-, cKO and cDKO mice were
transferred into 6 week old Rag-/- recipients. Mice were weighed twice weekly (data not shown)
and sacrificed 6 weeks after transfer when 20% weight loss was observed in multiple mice. At
sacrifice, spleen weight and body weight were compared to generate an inflammation index (a)
and colons were measured (b). H&E stained sections of the distal colon were imaged on the 20x
objective, and crypt depth was quantified (c,d). Splenocytes were stained for intracellular IL-4 and
IL-17 after ex vivo stimulation and analyzed by flow cytometry (e). Previously gated on live
singlets, CD4+, dump gate-. Quantifications shown +/- SEM n=5-7 mice. P values calculated by
ordinary one way ANOVA with Holm-Sidak test for multiple comparisons: * p<0.05, ** p<0.01,
***p<0.001, ****p<0.0001.
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Discussion
Fine-tuned control of signaling downstream of the TCR, co-receptors, and cytokine
receptors is critical in activated T cells. Perturbed signaling can alter T cell function,
differentiation, survival and proliferation with life threatening consequences. One layer of control
is degradation of key signal transducers via ubiquitylation to attenuate activating signals.
Consistent with this, prior work has detailed the aberrant CD4+ T cell responses that occur in the
absence of the E3 ligase Itch and one of its known activators, Ndfip1 (Altin et al., 2014; Beal et
al., 2012; Fang et al., 2002; Oliver et al., 2006; Ramon et al., 2012; Xiao et al., 2014). The only
other catalytic E3 ubiquitin ligases with known expression in T cells are closely related to Itch,
and have also been shown to work with Ndfip1 in vitro (Chen et al., 2009; Heikamp et al., 2014;
Mund and Pelham, 2009, 2010; Yang et al., 2008)
Here, I uncover a role for Ndfip2, another activator of Itch and related E3 ligases. I have
determined that Ndfip2 plays a role in preventing T cell immunopathology by limiting the
abundance of effector cell CD4+ T cells. Unlike Ndfip1, Ndfip2 does not impact naïve T cell
activation or differentiation; however, together Ndfip2 and Ndfip1 limit the expansion/persistence
of effector CD4+ T cells, leading to exacerbation of the inflammatory phenotype observed in the
absence of Ndfip1 alone. My data indicate that Ndfip1 plays a unique role in limiting activation of
naïve CD4+ T cells and in preventing aberrant TH2 differentiation, or can fully compensate in
these pathways for loss of Ndfip2. However, in activated effector cells, control of effector CD4+ T
cell division/persistence and cytokine production requires both Ndfip1 and Ndfip2. While
expression of both Ndfip1 and Ndfip2 is increased during T cell stimulation, my data indicate
distinct magnitude and kinetics, providing one possible explanation for why Ndfip2 knockout mice
do not mimic mice lacking Ndfip1. Thus, in previously activated CD4+ T cells Ndfip1 and Ndfip2
act in a coordinated, but perhaps non-redundant, fashion to prevent aberrant T cell responses.
Previous in vitro work suggests that Ndfip1 and Ndfip2 activate Nedd4 family E3 ligases
in a similar fashion (Mund and Pelham, 2009, 2010). It remains to be determined if this is true in
vivo, although my data suggest that this is the case in previously activated effector CD4+ T cells.
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One intriguing hypothesis is that Ndfip1 and Ndfip2 work with distinct Nedd4 family E3 ligases in
vivo, based on either temporal expression patterns or spatial constraints. Itch and Nedd4-2 are
the most likely candidate E3 ligases, as Nedd4 and WWP2 have both been published to degrade
negative regulators of T cell activation/expansion and thereby enhance T cell responses (Chen et
al., 2009; Yang et al., 2008). However, more recent data on the previously characterized
substrate of WWP2, Egr2, suggests that in peripheral T cells Egr2 is a positive regulator of
expansion and cytokine production (Du et al., 2014). Thus, accumulation of Egr2 in the absence
of fully functional WWP2 could also fit with the observed phenotype of Ndfip1/Ndfip2 deficient
effector CD4+ T cells. A better understanding of when these different E3 ligases are expressed
and active in CD4+ T cells could inform future experiments to analyze specific substrates in Ndfip
deficient cells.
These studies do not address what impact loss of Ndfip1/Ndfip2 has on the ubiquitylation
of Nedd4 family substrates, and how this altered ubiquitylation impacts T cell function. It is
possible that Ndfip1 and Ndfip2 play a role in substrate recruitment, and might differentially
activate cognate E3 ligases by altering substrate selection. Additionally, while the majority of
previously published Nedd4 family substrates are thought to be targeted for proteasomal
degradation, there is structural data to support that Nedd4 ligases form K63 ubiquitin chains that
would be more likely to serve a scaffolding function (Maspero et al., 2011). In the absence of
Ndfip-mediated activation, substrates of relevant Nedd4 E3 ligases might accumulate, if typically
targeted for degradation by ubiquitylation, or they might lose function, if they are ubiquitylated
with K63 ubiquitin chains.
Taken together, these data support a previously unknown role for Ndfip2 in negatively
regulating T cell mediated immune responses. While the molecular mechanism underlying the
hyperactivity of Ndfip deficient T cells remains to be elucidated, this work indicates that, together
with Ndfip1, Ndfip2 limits pathologic T cell effector function.
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Figure 2.12. Ndfip1/Ndfip2 deficient T cells outcompete WT cells in vitro.
a-d) Naïve CD4+ T cells were sorted from age-matched cDKO and control mice, CFSE labeled,
and stimulated for 5 days with plate-bound αCD3/CD28. (a) GATA3 and CFSE dilution were
evaluated on day 5 by flow cytometry. Previously gated on live singlets, CD4+. (c,d)
Quantification of (a). (e) Viability was determined by % of cells negative for viability dye multipled
by % of cells within lymphocyte gate. (f-i) Naïve CD4+ T cells were sorted from age-matched
cDKO and congenic CD45.1 WT mice, mixed in a 1:1 ratio, CFSE labeled, and stimulated for 5
days with plate-bound αCD3/CD28. (f) GATA3 and CFSE dilution were evaluated on day 5 by
flow cytometry. Previously gated on live singlets, CD4+, CD45.2+ or CD45.1+. (g,h)
Quantification of (f). (g) Representative flow plot showing %CD45.2+ and %CD45.1+ live CD4+
cells on day 5. Percent CD45.2 or CD45.1 quantified in (h). All quantifications except (g) done
relative to experiment matched WT cells, average shown +/-SEM, (a-d) n=14-17, (f-i) n=6-7. P
values calculated by one sample t-test against the normalized WT value of 1, except for (g), in
which a paired t-test was used. * p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001.
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CHAPTER 3: NDFIP-MEDIATED DEGRADATION OF JAK1 TUNES
CYTOKINE SIGNALING TO LIMIT EXPANSION OF CD4+
EFFECTOR T CELLS3
Introduction
Integration of signals from T cell receptor (TCR), co-receptors, and cytokine receptors
directs proliferation, survival and differentiation of T cells. Cross talk among these pathways is
essential to prevent aberrant T cell responses. One example of such cross talk is TCR-induced
down regulation of cytokine receptor signaling to limit cytokine responses (Huang and August,
2015; Katz et al., 2014; Lee et al., 1999; Zhu et al., 2000). Ubiquitylation of protein substrates by
E3 ubiquitin ligases can regulate signaling events downstream of the TCR, costimulatory
receptors and cytokine receptors to tune T cell responses. E3 ubiquitin ligases, which provide
substrate specificity to the ubiquitylation cascade, impact T cell activation, induction and
maintenance of anergy, and helper T cell differentiation; in effector cells, E3 ligases also regulate
cytokine production and cell cycle progression (Friend et al., 2014; Park et al., 2014).
Of the catalytic E3 ubiquitin ligases known to be functional in primary T cells, all are
members of one conserved protein family. Members of the catalytic HECT-type Nedd4 family of
E3 ligases are known to limit TH2 differentiation, regulate activation, and promote anergy (Chen et
al., 2009; Fang et al., 2002; Heikamp et al., 2014; Xiao et al., 2014; Yang et al., 2008). However,
as unbiased screens for identification of E3 ligase substrates, particularly in primary cells, are
generally lacking, only a handful of protein targets for Nedd4 E3 ligases have been identified
despite clear roles for these ligases in certain molecular processes. To date, published substrates
of these E3 ligases include TCR signaling intermediates and TCR-activated transcription factors
(Chen et al., 2009; Fang et al., 2002; Heikamp et al., 2014; Xiao et al., 2014; Yang et al., 2008).

3

Portions of this chapter appear in “Ndfip-mediated degradation of Jak1 tunes cytokine signaling
to limit expansion of CD4+ effector T cells,” currently under review at Nature Communications,
with the following authors: Claire E. O’Leary, Christopher Riling, Lynn Spruce, Hua Ding, Suresh
Kumar, Guoping Deng, Yuhong Liu, Steven H. Seeholzer, and Paula M. Oliver.
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Nedd4 family ligases share a similar modular architecture (Rotin and Kumar, 2009), but
despite their similar structures these ligases can have opposing effects on T cells. WWP2 and
Nedd4 have published roles as activators of T cell activation via degradation of their substrates:
respectively, Egr2 and Cbl-b (Chen et al., 2009; Yang et al., 2008). In contrast, Itch and Nedd4-2
(also known as Nedd4L) are proposed to be negative regulators of T cell activation and TH2
differentiation, perhaps via limiting accumulation of the same AP-1 family transcription factor,
JunB (Fang et al., 2002; Heikamp et al., 2014). Of these ligase, only Itch has been extensively
studied in T cells, due to availability of a viable loss-of-function mouse model; as such, several
additional protein substrates have been proposed for Itch (Heissmeyer et al., 2004; Venuprasad,
2010; Venuprasad et al., 2008; Xiao et al., 2014), although many of these have yet to be verified.
In vitro, Itch and related Nedd4 family E3 ligases require interaction with Nedd4 family
interacting proteins (Ndfips) for optimal function (Mund and Pelham, 2009; Riling et al., 2015). In
the previous chapter, I determined that both Ndfip1 and Ndfip2 are required to limit pathologic
expansion of effector CD4+ T cells in vivo. Here, I probe the mechanism behind the expanded
population of pathogenic effector CD4+ T cells observed in Ndfip deficient mice. Targeted
analysis of previously published substrates of Nedd4 family E3 ligases, specifically the AP-1
transcription factor JunB, did not reveal increased protein half-life in the absence of both Ndfip1
and Ndfip2 compared to cells lacking Ndfip1 alone. Therefore, to determine the mechanism
whereby loss of Ndfip1/Ndfip2 drives expansion of effector cells I developed an unbiased,
reproducible proteomic workflow for use in primary T cells. Using this proteomic approach I
identified the E3 ligases Itch and Nedd4-2 as active, and Ndfip-dependent, in stimulated effector
T cells. Furthermore, I identified Jak1 as a substrate for Ndfip-dependent E3 ubiquitin ligases.
Jak1 is ubiquitylated on multiple lysine residues and degraded following TCR stimulation of WT
cells; this degradation is aborted in Ndfip deficient cells. Consistent with increased stability of
Jak1, T cells lacking Ndfip1/Ndfip2 fail to undergo TCR-mediated downregulation of cytokine
responsiveness, a Jak1-dependent process, as measured by STAT5 phosphorylation following
exposure to IL-2. Increased Jak1 signaling leads to increased survival and proliferation of Ndfip-
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deficient cells in vitro, while in vivo this drives an expanded population of pathogenic effector T
cells.
These data reveal that TCR induced cytokine non-responsiveness requires Ndfipdependent ubiquitylation and degradation of Jak1. This is a previously unknown function for
Ndfip-dependent E3 ligases in restricting cytokine signaling to limit expansion, and, consequently,
pathogenicity, of CD4+ effector T cells.

Results
Identification of differential ubiquitylation in Ndfip deficient CD4+ T cells by proteomics
Having previously determined that Ndfip1 and Ndfip2 both negatively regulate activated
effector CD4+ T cells, I sought to understand the mechanism underlying the increased
proliferation and survival of Ndfip deficient CD4+ T cells. Both Ndfip1 and Ndfip2 have been
shown in vitro to bind and activate several members of the Nedd4 family of E3 ubiquitin ligases,
however only four of the nine family members, namely Nedd4, Nedd4-2, Itch, and WWP2, have
published roles in T cells (Chen et al., 2009; Fang et al., 2014; Gay et al., 2008; Heikamp et al.,
2014; Yang et al., 2008). Reviewing published substrates of these E3 ligases, I initially took a
targeted approach to determine which, if any, of the published substrates showed aberrant
degradation in Ndfip1-/-, Ndfip2-/-, or doubly deficient CD4+ T cells. I found no reproducible
differences in these substrates in Ndfip doubly deficient cells, but confirmed previous findings that
JunB is stabilized in the absence of Ndfip1 (data not shown). In primary lymphocytes unbiased
screens to identify substrates of ubiquitin ligases are lacking. To address this need, I developed a
three-part proteomic workflow to identify candidate substrates of Ndfip-dependent E3 ubiquitin
ligases in activated effector CD4+ T cells (Figure 3.1a).
The first aspect of this approach used stable isotope labeling of amino acids in culture
(SILAC) in combination with tandem ubiquitin binding entities (TUBEs) to enrich polyubiquitylated
proteins from mixed WT and Ndfip deficient cell lysates. I reproducibly obtained SILAC ratios
(WT/DKO) for ~2500 proteins (Figure 3.1b). In parallel, I performed whole proteome analysis of
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un-enriched DKO and WT CD4+ T cells. I then calculated the unenriched ‘input’ ratio (DKO/WT)
for each protein and applied this correction to the TUBE-enriched SILAC ratio for the same
protein across each biological replicate (Figure 3.1c and Figure 3.2a,b).
Peptides derived from trypsin cleavage of ubiquitylated proteins contain a di-glycine
remnant (K-ε-GG) on modified lysine residues (Peng et al., 2003). The vast majority of such
diglycine peptides (>90%) are derived from ubiquitin linkages (Kim et al., 2011). To limit the
analysis to proteins showing direct modification by ubiquitin, I utilized an antibody against the Kε-GG motif to enrich modified peptides from WT CD4+ T cells (Udeshi et al., 2013b; Xu et al.,
2010), achieving greater than 50% specificity (data not shown). I identified approximately ~1000
modified proteins/experiment.
Analyzing proteins with at least three TUBE-SILAC ratios and at least one modified lysine
(~1000 proteins, Figure 3.1d) indicated good reproducibility across replicates (Figure 3.1e).
Thus, despite technical limitations imposed by analyzing primary lymphocytes (e.g., limited
starting material), this combinatorial approach yields reproducible data with good depth of
proteome coverage.

Ndfip1 and Ndfip2 promote Itch and Nedd4-2 activity
I sought to validate this screen by identifying Nedd4 family E3 ligases with Ndfipdependent function in effector T cells. Ndfip1 and Ndfip2 bind and activate the enzymatic function
of several Nedd4 family E3 ubiquitin ligases in vitro; once active, these ligases promote their own
ubiquitylation (Cristillo et al., 2003; Harvey et al., 2002; Jolliffe et al., 2000; Konstas et al., 2002;
Mund and Pelham, 2009). Therefore, in effector T cells active Nedd4 family ligases should have
K-ε-GG peptides; if these same ligases depend on Ndfips for function, increased ubiquitylation in
WT cells would result in high WT/DKO TUBE-SILAC ratios. Among Nedd4 family members, only
Nedd4-2 and Itch had both K-ε-GG peptides and TUBE-SILAC ratios. The corrected TUBESILAC ratios (WT/DKO) for both ligases indicated significantly more ubiquitylation in WT cells
compared to Ndfip deficient cells (Figure 3.1c and Figure 3.2c).
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Figure 3.1. Identification of differential ubiquitylation by proteomics.
a) Schematic of the three proteomics methods used. (b) Area proportional Venn diagram
illustrating the reproducibility of proteins identified as having SILAC ratios after TUBE enrichment
in 3 out of 4 biological replicates. (c) SILAC-TUBE ratios (WT/DKO) for each protein were
corrected using “input” ratio (DKO/WT) as calculated by label free quantification of whole
proteome DKO and WT datasets. The average corrected ratio is plotted against the average
number of unique peptides observed per protein across 4 whole proteome LC-MS/MS
experiments. Plot is limited to 40 average unique peptides for clarity. Itch and Nedd4-2 (indicated)
have log2 transformed corrected ratios >1 at the protein level. Itch=1.57+/-0.17 and Nedd42=3.18+/-0.226. (d) Overlap of proteins with corrected SILAC-TUBE ratios (observed in at least 3
experiments) and proteins identified with at least one K-ε-GG peptide (in at least one of three K-εGG immunoprecipitation experiments). (e) Heat map illustrating reproducibility of corrected
SILAC-TUBE ratios (WT/DKO, log2 transformed, observed in at least 3 of 4 experiments) for
proteins identified with K-ε-GG peptides.
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Figure 3.2. Unmodified protein SILAC-TUBE ratios compared to corrected protein SILACTUBE ratios and Nedd4 family E3 ligase analysis.
a) Uncorrected log2 transformed SILAC-TUBE ratios, averaged over 4 biologic replicates,
compared to corrected SILAC-TUBE ratios (log2 transformed) averaged over 4 biologic replicates
and limited to proteins with KGG peptides. Median uncorrected log2 SILAC-TUBE ratio observed
as WT/DKO=0.054 over 2376 proteins, median corrected ratio WT/DKO=0.23 over 2376 proteins,
median corrected ratio limited to KGG proteins=0.239 over 925 proteins. (b) Average log2
transformed corrected SILAC-TUBE ratios plotted by average number unique peptides
observed/protein over 4 whole proteome experiments. (c) Corrected SILAC-TUBE ratios for
Nedd4-2 and Itch across 4 biological replicates. Log2 transformed ratios (WT/DKO). (d) Western
blot analysis for purity of recombinant Ndfip-GST proteins and Itch utilized in TR-FRET
ubiquitylation assay. * Indicates Ndfip-GST cleavage product.
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Itch is known to interact with, and be activated by, Ndfip1 in T cells, while Nedd4-2 has
been shown to work with either Ndfip1 or Ndfip2 (Heikamp et al., 2014; Oliver et al., 2006).
Therefore, in Ndfip doubly deficient T cells, decreased activity of Itch/Nedd4-2 could indicate E3
ligase dependence on Ndfip1 and Ndfip2, or either Ndfip1 or Ndfip2 alone. I first assessed
binding of Ndfip2 to Itch and Nedd4-2 using cytoplasmic domains of either Ndfip1 or Ndfip2 to
isolate the endogenous E3 ligases from T cell lysates. Both Ndfip1 and Ndfip2 were sufficient to
isolate Itch and Nedd4-2 from WT CD4+ T cells; analysis of Ndfip1/2 deficient cells yielded similar
results, and confirmed that Itch and Nedd4-2 show increased expression in double knockout T
cells (Figure 3.3a). Mutations in the PY motifs of either Ndfip1 or Ndfip2 abrogated binding to the
E3 ligases (data not shown).
I then tested the ability of Ndfip1 and Ndfip2 to activate Itch enzymatic function, which is
restrained through autoinhibition (Bruce et al., 2008; Gallagher et al., 2006; Mund and Pelham,
2009; Riling et al., 2015). Using a time-resolved fluorescence resonance energy transfer (TRFRET) assay (Marblestone et al., 2012), I observed Itch ubiquitylation activity only in the
presence of Ndfip1 or Ndfip2 (Figure 3.3b). While unequal purity of the GST fusion Ndfips made
quantitative comparisons of activation difficult (Figure 3.2d), I can conclude that both Ndfip1 and
Ndfip2 are sufficient to activate the E3 ligase function of Itch. The Oliver lab recently determined
that Ndfip1 activates Itch catalytic activity by promoting ubiquitin charging of Itch (Riling et al.,
2015); the role of Ndfip2 in this process is unknown. Consistent with the similarity of Ndfip1 and
Ndfip2 PY motifs, either Ndfip1 or Ndfip2 is sufficient for E2-mediated ubiquitin charging of Itch
(Figure 3.3c), indicating that Ndfip1 and Ndfip2 activate Itch via the same molecular mechanism.
Thus, both Ndfips could promote the ubiquitylation activity of Itch inferred from the proteomic
analysis.
Next I tested whether Nedd4-2 is activated by Ndfips, as suggested from the proteomic
data. Under these cell-free in vitro conditions Nedd4-2 was not autoinhibited; nevertheless, an
increased rate of Nedd4-2 activity was evident when Ndfip1/Ndfip2 were included in the reaction

65

Figure 3.3. Ndfip1 and Ndfip2 promote Itch and Nedd4-2 activity.
a) Immunoblot of Itch and Nedd4-2 co-precipitated from activated WT or Ndfip1/Ndfip2 DKO
CD4+ T cell lysates by Ndfip1 and Ndfip2 GST fusion proteins. Coomassie stain for the GST
fusion proteins revealed full-length products for each construct as well as a GST cleavage
product (indicated with *). (b) Itch activity, in the absence or presence of Ndfip1 or Ndfip2, was
analyzed using by TR-FRET polyubiquitylation assay. (c) E2/E3 transthiolation assay was used to
test whether Ndfip2 promotes ubiquitin ‘charging’ of Itch. Biotinylated ubiquitin non-covalently
bound to Itch was analyzed by western blot using fluorescent streptavidin (top); total protein was
visualized by Coomassie stain (bottom). (d,e) As in (b) Nedd4-2 activity was assessed alone or in
the presence of Ndfip1 or Ndfip2 by TR-FRET. Data for each panel is representative of a
minimum of three independent experiments.
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(Figure 3.3e). Thus, while Ndfips are not required for function of Nedd4-2 in these assays, they
potentiate its catalytic activity. Taken together, these proteomic and biochemical data indicate
that Nedd4-2 and Itch are expressed in activated T cells, are ubiquitylated, and their function is
promoted by Ndfips.

Jak1 degradation is dependent on Ndfip1/Ndfip2
Having validated that this screen can identify Ndfip-dependent ubiquitylation, I turned to
substrate identification. Candidate substrates of Ndfip-dependent ligases (Table 2) had positive
corrected ratios (WT/DKO) in all replicates, low error across replicates, and multiple K-ε-GG
peptides. I identified Jak1 and Jak2 as differentially ubiquitylated in Ndfip deficient cells, and
observed K-ε-GG peptides from all four Jak family members (Figure 3.4a,b).
Analysis of Jak2, which is known to be monoubiquitylated, and for which SOCS-mediated
degradation has been demonstrated under interferon stimulation (Ungureanu et al., 2002),
revealed that Jak2 is not robustly degraded during TCR stimulation (Figure 3.4c,d). Although
Jak1 ubiquitylation has never been shown in T cells, Jak1 is known to have a short half-life (Katz
et al., 2014). Consistent with ubiquitylation of Jak1, in the K-ε-GG immunoprecipitation I
consistently observed multiple peptides from Jak1 covering several distinct lysines. Jak1 is a key
component in signaling via common γ chain containing cytokine receptors, and can drive survival,
proliferation, and differentiation of activated T cells (Ashino et al., 2014; Gatzka et al., 2006; Haan
et al., 2011; Lischke et al., 1998; Rochman et al., 2010; Zhu et al., 2003). Therefore, I
hypothesized that Jak1 degradation in CD4+ T cells depends on Ndfip1 and Ndfip2.
Jak1 was robustly degraded in TCR-stimulated WT cells treated with cycloheximide, a
translational inhibitor (Figure 3.5a). Ndfip deficient CD4+ T cells showed significantly less
degradation (Figure 3.5a,b). I also observed increased phosphorylation of STAT5a/b after
stimulation of Ndfip deficient cells compared to WT cells (Figure 3.5c,d). I did not observe any
change in Jak1 stability or p-STAT5a/b signal in CD4+ T cells from Ndfip1 cKO mice (Figure
3.5a-d) or in Itchy mutant CD4+ T cells (Figure 3.6), suggesting that neither loss of Itch or Ndfip1
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alone is sufficient to affect Jak1 stability and STAT5 activity. Levels of total STAT5a/b were not
significantly increased in cDKO CD4+ T cells, nor did STAT5 show cycloheximide sensitivity
(Figure 3.5e,f), consistent with previously published data (Yu and Burakoff, 1997). Thus
increased levels of p-STAT5 are indicative of increased Jak1 activity in Ndfip deficient cells.

Table 2. Top candidate substrates for Ndfip-dependent ligases

a

a

Limits imposed on data: positive corrected TUBE ratio in 4/4 experiment with low SEM relative to
corrected ratio average. Peptides in 3/3 K-ε-GG immunoprecipitation experiments, minimum of 5
spectral counts.
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Figure 3.4. Jak family proteomics.
a) Corrected SILAC-TUBE ratios for Jak family members across 4 biological replicates. Log2
transformed ratios (WT/DKO). Tyk2 was not reproducibly identified after TUBE enrichment. (b)
Sum of Jak family protein observed peptides with diglycine remnant on lysine (total spectral
counts of modified peptides) after three individual K-ε-GG IP experiments using two distinct
stimuli on WT CD4+ T cells: PMA/ionomycin stimulation done for 4 hrs with 2hrs addition of 10µM
MG132, 50µM chloroquine; or αCD3/CD28 stimulation done for 4hrs with antibody-coated beads,
no inhibitors, sum of 2 immunoprecipitation experiments with double injections. (c,d)
Immunoblotting of restimulated WT and cDKO CD4+ T cells. Cycloheximide was added 2hrs after
αCD3/CD28 stimulation; cells were then incubated an additional 2hrs. (d) Level of Jak2 was
normalized to GAPDH. The stability of Jak2 was determined by normalizing the relative Jak2
remaining after stimulation to the amount of Jak2 at 2hrs. Data shown are average +/- SEM from
3 biologic replicates.
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Jak1 levels are controlled by a balance of protein synthesis and degradation: during T
cell activation, Jak1 translation is halted and existing Jak1 is degraded (Katz et al., 2014). For
both WT and Ndfip deficient cells, relative levels of Jak1 remaining after stimulation were not
altered by cycloheximide (Figure 3.5a,b,g), with Ndfip doubly deficient cells showing increased
Jak1 stability after stimulation in either condition. Therefore, Jak1 protein synthesis is terminated
normally in stimulated cDKO cells. Furthermore, this indicates that increased stability of Jak1 in
stimulated Ndfip deficient cells cannot be explained by indirect effects downstream of new protein
synthesis (e.g., production of cytokines). Over the course of six hours of restimulation, Jak1
degradation was significantly faster in WT CD4+ T cells compared to cDKO cells (Figure 3.5h).
Surprisingly, Jak1 degradation during the first hours of TCR stimulation was intact in Ndfip
deficient cells; however, further Jak1 degradation was aborted, slowing the overall degradation
rate (Figure 3.7a,b). This was not observed in the absence of Ndfip2 alone (Figure 3.7c).
If Jak1 degradation is mediated by Ndfip-dependent E3 ubiquitin ligases, then
unstimulated cells, with ongoing Jak1 synthesis, should show increased Jak1 over time in the
absence of Ndfips. In unstimulated cells, I found that Jak1 in WT cells was stable, but in the
absence of Ndfip1/Ndfip2 levels steadily increased (Figure 3.5i). After 24 hours in the absence or
presence of TCR— after translational recovery occurs in TCR stimulated cells—Jak1 was
significantly increased in cDKO CD4+ T cells as compared to WT cells (Figure 3.5j).

Ndfip deficient T cell hyperactivity can be reversed by Jak inhibition
High Jak activity can lead to increased cell viability and proliferation through STAT
activation and subsequent transcription of STAT5 target genes (Degryse et al., 2014; Knoops et
al., 2008; Maude et al., 2015; Parampalli Yajnanarayana et al., 2015; Stepkowski et al., 2002).
Consistent with this, I observed increased expression, but not aberrant degradation, of cyclin D2,
a STAT5 target gene (Gatzka et al., 2006; Martino et al., 2001; Moon et al., 2004), in stimulated
Ndfip1/Ndfip2 deficient CD4+ T cells (Figure 3.7d). Similarly, surface expression of the IL-2
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Figure 3.5. Jak1 degradation is dependent on Ndfip1/Ndfip2.
a-j) Immunoblotting of restimulated WT and cDKO CD4+ T cells. (a) Cycloheximide was added
2hrs after stimulation; cells were then incubated an additional 4hrs. (b) Level of Jak1 was
normalized to GAPDH. The stability of Jak1 was determined by normalizing the percent Jak1
remaining in cDKO or cKO cells to the percent remaining in experiment-matched control cells.
Data shown are average +/- SEM from 3-5 biologic replicates in more than 3 experiments. (c,d)
p-STAT5 was quantified relative to tubulin. Relative levels of p-STAT5 in cDKO and cKO CD4+ T
cells were normalized to experiment matched control cells at 2hrs and 6hrs of restimulation. Data
shown is average +/- SEM for two biologic replicates. (e,f) Immunoblotting of total STAT5 in
restimulated WT and cDKO CD4+ T cells treated as in (a). (f) Level of Jak2 was normalized to
GAPDH. The stability of Jak2 was determined by normalizing the relative Jak2 remaining after
stimulation to the amount of Jak2 at 2hrs. Data shown are average +/- SEM from 3 biologic
replicates. (g,h,i,j) Levels of Jak1, normalized to GAPDH, at various timepoints following
restimulation of WT and cDKO CD4+ T cells relative to Jak1 in IL-2 rested cells at time 0. (h)
Rate of Jak1 degradation in relative units/hour over 6 hours of stimulation. (i,j) Levels of Jak1,
normalized to GAPDH, at various timepoints following rest in the absence of IL-2/TCR of WT and
cDKO CD4+ T cells relative to Jak1 in IL-2 rested cells at time 0. (j) As in (g,i) Levels of Jak1,
normalized to GAPDH, 24 hours +/-TCR stimulation of WT and cDKO CD4+ T cells relative to
Jak1 in IL-2 rested cells at time 0. Data shown in (g-j) average +/- SEM from 2-4 biologic
replicates in more than 3 experiments. P value calculated by two sample, unpaired t-test *p<0.05.
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Figure 3.6. No difference in Jak1 stability during stimulation of CD4+ Itchy mutant T cells.
a-e) WT and Itchy mutant CD4+ T cells were isolated from spleen, stimulated, rested/expanded in
IL-2, and restimulated for a total of 6hrs with αCD3/CD28. (a) Representative blotting of digitonin
soluble cytosolic Jak1 over timecourse of restimulation. (b) Quantification of Jak1 stability at 6hrs
relative to 2hrs, as fold change over the average stability observed in experiment matched WT
cells. Mean shown +/-SEM n=3. Representative of two experiments with 3-4 Itchy mice in each
(c) Quantification as in (b) of Jak1 in CD4+ T cells IL-2 starved for 24hrs, relative to Jak1 in the
resting cells. Mean shown +/-SEM n=2-4. (d) Representative blot of pSTAT5a/b in digitonin
insoluble cell lysate from restimulated Itchy mutant and WT CD4+ T cells at 2 and 6hrs. (e)
Quantification of pSTAT5 after 6hrs of restimulation, relative to pSTAT5 at 2hrs of restimulation,
relative to experiment matched WT cells. Mean shown +/- SEM, n=2-4.
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Figure 3.7. Ndfip1/Ndfip2 deficient T cells have aborted Jak1 degradation and increased
protein expression of STAT5 target genes.
a,b) Jak1 degradation as shown in Figure 7g for WT (a) and cDKO (b) CD4+ T cells fits to
significantly different one phase exponential decay curves (p=.0201). (c) Jak1 degradation in
Ndfip2-/- cells is not significantly different from WT cells. (d-g) STAT5 targets show increased
expression in DKO CD4+ T cells. (d) Cyclin D2 immunoblotting in restimulated DKO and WT
CD4+ T cells. Cycloheximide was added 2hrs after αCD3/CD28 stimulation; cells were then
incubated an additional 2hrs. Representative of 5 biologic replicates (either cDKO or
Ndfip1/Ndfip2-/-). (e-g) Naïve CD4+ T cells were sorted from age-matched cDKO and control
mice, CFSE labeled, and stimulated for 5 days with plate-bound αCD3/CD28. (e) CD25 was
evaluated on day 5 by flow cytometry and quantified relative to the MFI of CD25 on experiment
matched WT CD4+ T cells. (f) Naïve CD4+ T cells were sorted from age-matched cDKO and
congenic CD45.1 WT mice, mixed in a 1:1 ratio, CFSE labeled, and stimulated for 5 days with
plate-bound αCD3/CD28. CD25 was assessed as in (e). (g) CD25 MFI on WT and cDKO CD4+ T
cells cultured as in (e) in the presence of increasing amounts of Jak inhibitor I, quantified relative
to experiment matched untreated WT cell CD25 MFI. (e,f) Quantified relative to experiment
matched WT cells, average shown +/-SEM, n=6-17. P values calculated by one sample t-test
against the normalized WT value of 1. (g) Quantified relative to experiment matched untreated
WT cells, average shown +/-SEM, n=3-6 at each inhibitor dose. P values calculated by unpaired
two sample t-test. * p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001.
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receptor α (IL-2Rα, aka CD25), another STAT5 target (Nakajima et al., 1997), was increased on
stimulated cDKO cells compared WT CD4+ T cells, even when these cells were co-cultured
(Figure 3.7e,f). CD25 decreased in both WT and cDKO CD4+ T cells in a dose-dependent
manner in response to Jak inhibition, as expected for a STAT5 target gene (Figure 3.7g).
To determine if Jak1 stabilization mediates the observed in vitro and in vivo
hyperactivation and hyperviability of Ndfip deficient CD4+ T cells, I tested whether Jak inhibition
could normalize cDKO levels of proliferation/survival. cDKO CD4+ T cells stimulated in vitro in the
presence of a Jak inhibitor showed reduced proliferation, down to WT levels, in a dose dependent
manner; WT cell proliferation was responsive to Jak inhibition but did not show dosedependence, suggesting complete Jak inhibition occurred at a lower dose (Figure 3.8a,b).
Strikingly, cDKO CD4+ T cells showed a robust decline in viability, down to WT levels, when
treated with the Jak inhibitor (Figure 3.8a,c). WT cell viability was minimally affected, suggesting
that Jak signaling in stimulated WT T cells is not sufficient to impact survival.
To determine if sensitivity to Jak inhibition was dependent on increased cytokine
availability, I co-cultured WT and cDKO CD4+ T cells and treated with the Jak inhibitor. This
revealed distinct regulation of viability and proliferation. WT cells cultured with cDKO cells now
showed dose-dependent decreases in proliferation in the presence of Jak inhibition, although
they still proliferated less than cDKO cells (Figure 3.9a,b). In contrast, the effect of Jak inhibition
on viability was independent of increased cytokine production: the enhanced viability of cDKO
cells was lost upon treatment with the Jak inhibitor, which had limited effect on WT cell viability
(Figure 3.9c). From this I conclude that, following activation, the increased survival and
proliferative capacity of cDKO CD4+ T cells is due to increased Jak-dependent cytokine
signaling. This increase in cell viability is independent of increased cytokine production, and can
be normalized by Jak inhibition.

74

Figure 3.8. Ndfip deficient T cells show persistent cytokine signaling.
a-c) Sorted naïve CD4+ T cells from WT and cDKO mice were stimulated with αCD3/CD28 in the
presence of JAK inhibitor I and analyzed on day 5 by flow cytometry. (a) Representative plots of
CFSE dilution and viability staining in WT and cDKO CD4+ T cells +/- Jak inhibitor (31.2nM). (b,c)
Quantification of (b) percent of cDKO and WT cells divided 4 or more times relative to DMSO
treated experiment matched WT cells and (c) viability of cDKO and WT CD4+ T cells normalized
to DMSO treated experiment matched WT cells. Data shown is average +/- SEM from 6 biologic
replicates. P values calculated by multiple t-test with Holm-Sidak correction. (d,e) pSTAT5
staining in cDKO and WT CD4+ T cells rested in the absence of IL-2 overnight then treated +/αCD3/CD28 beads before addition of IL-2. (d) Representative flow cytometry histograms. (e)
Quantification of pSTAT5 MFI across 8-9 biologic replicates and four independent experiments,
showing average +/- SEM. P values calculated by two way ANOVA with Holm-Sidak test for
multiple comparisons. *p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001.
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Ndfip deficient T cells show persistent cytokine signaling
Given these results, I hypothesized that stabilization of Jak1 in the absence of Ndfips
drives increased signaling via Jak1-dependent cytokine receptors, promoting cell survival and
proliferation. During acute TCR signaling, cytokine responsiveness to γ chain receptors is
robustly decreased; Jak1 degradation is thought to be required for this desensitization (Katz et
al., 2014; Lee et al., 1999; Zhu et al., 2000). In TCR stimulated CD4+ T cells, decreased
induction of STAT5 phosphorylation downstream of the IL-2 receptor limits effector cell expansion
by inducing growth arrest and apoptosis (Lee et al., 1999). To test whether Jak1 stabilization in
Ndfip deficient T cells allows persistent cytokine signaling, I examined STAT5 phosphorylation
after IL-2 treatment in cells that were or were not receiving TCR signals (Figure 3.8d,e). In
unstimulated cells, pSTAT5 was significantly increased in cDKO CD4+ T cells relative to WT cells
upon IL-2 treatment, consistent with the increased levels of Jak1 in observed in cDKO cells at this
time (Figure 3.5h). Strikingly, WT CD4+ T cells stimulated through their TCR failed to
phosphorylate STAT5 in response to IL-2, while in cDKO cells there was no difference in the
pSTAT5 response to IL-2 in the presence or absence of TCR signaling (Figure 3.8d,e).
Indeed, cDKO cells exhibited strong STAT5 phosphorylation under TCR stimulation alone,
without addition of exogenous IL-2 (Figure 3.8e). This was significantly decreased when IL-2 was
blocked in TCR stimulated cDKO CD4+ T cell cultures, indicating that cDKO cells persistently
signal through IL-2 in an autocrine or juxtacrine fashion while actively signaling through the TCR
(Figure 3.9d). Thus, Ndfip1 and Ndfip2 are required for TCR-induced cytokine desensitization,
and, in the absence of Ndfips, stabilization of Jak1 can drive persistent IL-2 signaling to promote
cell survival and proliferation.
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Figure 3.9. Ndfip1/Ndfip2 deficient T cells respond to Jak inhibition in a cell-intrinsic
fashion.
a-c) Naïve CD4+ T cells were sorted from age-matched cDKO and congenic CD45.1 WT mice,
mixed in a 1:1 ratio, CFSE labeled, and stimulated for 5 days with plate-bound αCD3/CD28 in the
presence of increasing amounts of Jak inhibitor I. (a) Representative histograms of CFSE dilution
in cocultured WT and cDKO CD4+ T cells in the absence or presence of a Jak inhibitor.
Previously gated on live singlets, CD4+, CD45.2+ or CD45.1+ (b,c) Quantification of (b) cells
divided 4+ times and (c) %CD45.2 or %CD45.1 on day 5 of coculture. (b) Quantification of cell
division normalized to cocultured WT cells. (b,c) Quantifications shown as average +/- SEM from
4 biologic replicates. P values calculated by multiple t-test with Holm-Sidak correction. (d)
Quantification of pSTAT5 staining in cDKO and WT CD4+ T cells rested in the absence of IL-2
overnight then treated +/- αCD3/CD28 beads in the presence or absence of αmouse IL-2 blocking
antibody. Average MFI shown +/- SEM, n=5-7. P values calculated by two-way ANOVA. * p<0.05,
** p<0.01, ***p<0.001, ****p<0.0001.

77

Discussion
Previous work has detailed roles in vivo for Ndfip1 and one of its cognate E3 ubiquitin
ligases, Itch, in limiting aberrant naïve CD4+ T cell activation (Altin et al., 2014; Beal et al., 2012;
Oliver et al., 2006; Ramos-Hernandez et al., 2013). This work has shown that Ndfip1 and Ndfip2
together limit effector CD4+ T cell pathogenic potential. While Ndfip1 is clearly the dominant
negative regulator of naïve T cell activation and TH2 differentiation, my work indicates a robust
role for Ndfip2 in limiting expansion and effector function of previously activated CD4+ T cells.
However, nothing is known about how Ndfips intrinsically regulate T effector cells. To investigate
this, I developed a proteomics workflow in primary CD4+ T cells for unbiased identification of E3
ubiquitin ligase substrates. This proteomic work revealed that, of the nine mammalian Nedd4
family ligases, Nedd4-2 and Itch are most likely enzymatically active during stimulation of effector
CD4+ T cells. Biochemically, I show that catalytic function of both Itch and Nedd4-2 can be
activated or potentiated by Ndfip1 and Ndfip2, validating that this screen successfully identifies
Ndfip-dependent ubiquitylation events.
Using this proteomics approach I identified Jak1 as a novel substrate of Ndfip-dependent
ubiquitin ligases. Jak1 has multiple ubiquitylated lysines, and was more stable in Ndfip deficient
CD4+ T cells. The hyperviability and hyperproliferation of Ndfip-deficient T cells was blocked by
Jak inhibition. These inhibitor experiments revealed that, while hyperviability was dependent on
increased Jak signaling independent of cytokine production, the role of Jak in proliferation was
proportionate to cytokine availability. During acute TCR signaling, Jak1 degradation prevents
common γ chain signaling and cytokine responsiveness. Ndfip deficient cells failed to undergo
TCR-mediated cytokine non-responsiveness—stimulated Ndfip deficient cells remained sensitive
to IL-2, activating signaling cascades downstream of Jak1 that promote survival and proliferation.
Notably, in the absence of Ndfips, Jak1 degradation did occur after TCR stimulation, but
was limited temporally. Thus, initial Jak1 degradation is Ndfip-independent. One possibility is that
Itch and/or Nedd4-2 are activated by an Ndfip-independent mechanism downstream of early TCR
signaling, allowing them to ubiquitylate Jak1. Activation of these ligases can occur via
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phosphorylation (Itch) and calcium binding (Nedd4-2) (Gao et al., 2004; Wang et al., 2010b).
However, after termination of these early signaling events, ligase activity may depend on Ndfip1/
Ndfip2. Alternatively, Nedd4 family E3 ligases may be dispensable for early Jak1 degradation.
Nevertheless, Ndfip-independent degradation of Jak1 in CD4+ T cells is clearly not sufficient to
terminate cytokine signals, as Ndfip-deficient cells fail to undergo TCR-mediated cytokine nonresponsiveness.
Surprisingly, single deficiency in either Ndfip1 or Ndfip2 was not sufficient for Jak1
stabilization. These data suggest that Ndfip1 and Ndfip2 can compensate for one another in
promoting Jak1 degradation in restimulated effector CD4+ T cells, in contrast to the unique role
for Ndfip1 in enforcing costimulation during stimulation of naïve CD4+ T cells. Of note, in these
previously activated cells, expression of both Ndfips is induced equally well, while in naïve CD4+
T cells, Ndfip1 is induced much more highly at the RNA level during early TCR stimulation. The
timing of this expression suggests that having both Ndfip1 and Ndfip2 highly expressed in effector
T cells may relate to increased sensitivity of previously activated T cells to TCR restimulation.
Increased signal strength may necessitate increased action of Ndfip-dependent E3 ligases to
prevent aberrant responses; therefore, increased overall expression of Ndfips is required to
increase efficient activation of a larger pool of these E3s, and this is achieved through production
of both Ndfip1 and Ndfip2 at high levels.
Although highly homologous, the sequences of Ndfip1 and Ndfip2 differ in ways that may
relate to function. Ndfip1 contains solvent accessible lysine residues in close proximity to its PY
motifs, which may be preferentially ubiquitylated when Ndfip1 interacts with and activates Nedd4
family E3 ligases (Kamadurai et al., 2013). Ndfip2 does not have these lysines— while this may
negatively impact its ability to activate Nedd4 family E3 ligases (Kamadurai et al., 2013), it may
also extend its half-life in vivo, thereby providing a longer lasting, although less efficient,
activation signal for Nedd4 E3 ligases. Indeed, preliminary work expressing tagged versions of
Ndfip1 and Ndfip2 in primary T cells from cDKO mice supports that the half-life of Ndfip2 during T
cell stimulation is longer than that of Ndfip1.
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Interestingly, deficiency in Itch was insufficient to recapitulate the Jak1 stabilization
observed in Ndfip doubly deficient CD4+ T cells, suggesting a dominant role for another E3 ligase
(e.g., Nedd4-2) or functional compensation at the level of the E3 ligases and their ability to be
activated by Ndfips. The fact that Jak1 degradation is normal in the absence of Itch, and in single
deficiency of Ndfip1, indicates that the observed alteration of Jak1 degradation in cDKO T cells
cannot be explained by inherent differences in Jak1 stability in TH2 cytokine producing CD4+ T
cells compared to TH1 cells. While it is somewhat surprising that Itchy mutant cells degrade Jak1
normally, this may be consistent with the fact that the inflammation in Ndfip1-/- and mice with
Ndfip1/Ndfip2 doubly deficient T cells is much more severe than the inflammation observed in the
absence of Itch, with much more rapid onset. It is thought that in the case of Ndfip1 deficiency
this implicates other Ndfip-dependent E3 ligases as negative regulators of T cell
activation/effector function, beyond the activation of JunB degradation (Ramos-Hernandez et al.,
2013). My data in Ndfip doubly deficient cells suggest that other Nedd4 family E3 ligases likely
play negative regulatory roles in activated T cells, which may help explain the severe
inflammatory phenotype in mice lacking Ndfip1/Ndfip2. Future experiments will specifically test a
role for Nedd4-2 in Jak1 degradation, as well as possible functional compensation of Itch and
Nedd4-2 in this process.
While this work directly relates to IL-2 promotion of survival and proliferation, increased
IL-2 signaling has other effects on T cells. Increased phosphorylation of STAT5 downstream of
IL-2 receptor signaling promotes TH2 differentiation, a primary phenotype in Itchy mutant mice
(Cote-Sierra et al., 2004; Fang et al., 2002; Zhu et al., 2003), and limits TFH differentiation, which
is defective in the absence of Itch (Johnston et al., 2012; Xiao et al., 2014). Similarly, Nedd4-2
negatively regulates TH2 differentiation via the same mechanism proposed for Itch—degradation
of JunB (Heikamp et al., 2014). While degradation of Nedd4 family substrates besides Jak1,
namely FoxO1 and JunB, promotes TFH and limits TH2 differentiation, respectively, regulation of
Jak1 levels and cytokine signaling could augment these pathways in a cooperative or synergistic
manner.
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Figure 3.10. Proposed model of Ndfip1/Ndfip2 function in previously activated CD4+
effector T cells.
In resting previously activated cells, cells receive survival and proliferation signals through
common γ chain receptors (IL-2, IL-7, IL-15). In response to these Jak1/3 dependent cytokines,
STAT proteins are phosphorylated to driver transcriptional programs and promote continued
proliferation and survival. When the TCR is engaged, Jak1 is rapidly degraded in an Ndfipdependent fashion, terminating cytokine signaling, even when the cytokine is still available. This
prevents cytokine-driven survival and proliferation signals from “over-riding” signaling programs
induced by the strength of TCR signal, thereby preventing aberrant activation/function of CD4+ T
cells that fail to receive appropriate TCR signals.

I propose a model in which Ndfip1 and Ndfip2 work together to limit cytokine signaling by
promoting Jak1 degradation (Figure 3.10). In effector T cells not undergoing TCR stimulation,
Ndfip1 and Ndfip2 maintain Jak1 levels in balance with protein synthesis. When T cells are
activated via their TCR, Ndfip1 and Ndfip2 enforce a period of cytokine non-responsiveness to
restrict the effector pool. Promoting TCR-mediated downregulation of cytokine signaling is a
previously unknown role for Ndfip1 and Ndfip2 and their cognate E3 ligases. I propose that Ndfipdependent degradation of Jak1 is critical in determining effector CD4+ T cell numbers that, when
disrupted, leads to pathologic accumulation of effector CD4+ T cells.
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CHAPTER 4: QUANTITATIVE PROTEOMICS TO PREDICT
FUNCTIONAL CONSEQUENCES OF UBIQUITYLATION EVENTS
DURING T CELL STIMULATION
Introduction
The post-translational attachment of ubiquitin to cellular proteins can alter their function
and half-life and thus profoundly impact signaling and cell fate decisions. Ubiquitin is covalently
attached to solvent accessible lysines on a target protein via a series of enzymatic steps,
involving E1 activating enzymes, E2 conjugating enzymes, and E3 ubiquitin ligases which bind
substrates specifically (Komander, 2009). Protein ubiquitylation can serve as a quality control
mechanism, facilitating the degradation of misfolded or aggregated proteins during protein
synthesis, and also as a regulatory signal during signal transduction to promote or terminate
function of signaling intermediaries (Xu and Jaffrey, 2013).
As such, the consequences of protein ubiquitylation are highly context dependent, with
ubiquitylation of a single substrate having distinct consequences depending on the type of
ubiquitin modification (e.g., chain type and length) that is added. Targeted approaches, such as
knockout/knockdown or over-expression of E3 ubiquitin ligases/DUBs, have aided in our
understanding of how ubiquitylation affects specific cellular processes or particular protein
substrates targeted by the ubiquitylation cascade. However, identification of ubiquitylation events
is insufficient to allow inferences about the type of ubiquitin modification added to the substrate,
or what downstream fate is determined for the protein substrate by ubiquitylation, and these
targeted approaches are limited in scope. New quantitative proteomics platforms have recently
been developed that have the potential to reveal relationships between ubiquitylation and protein
fate in a more global fashion.
Development of an antibody against the ubiquitin remnant motif found on ubiquitylated
lysines following trypsin cleavage (Peng et al., 2003) has revolutionized the ability to catalog
ubiquitylated lysines. Direct immunoprecipitation of ubiquitin remnant, or K-ε-GG, peptides after
enrichment on tagged ubiquitin significantly enriches the percent and number of ubiquitylated
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lysines and proteins identified compared to affinity purification of ubiquitin alone (Xu et al., 2010).
Without K-ε-GG peptide enrichment, proteins with ubiquitin remnant peptides are typically
observed at ~0.5-1% of total protein identifications—with further decreased abundance at the
peptide level—even when ubiquitin is enriched prior to LC-MS/MS analysis (Peng et al., 2003).
The initial report using a monoclonal αK-ε-GG antibody to enrich for ubiquitin remnant peptides
characterized only several hundred unique modified lysines in a similar number of proteins,
however, this effectively doubled the known number of ubiquitin-modified lysines in the human
proteome (Xu et al., 2010). Subsequent studies, also in human cell lines, have significantly
improved upon this. By omitting the tagged ubiquitin affinity purification step and using direct
antibody enrichment of trypsinized proteins from unmanipulated cells, several labs report 5000 to
20,000 ubiquitylation sites identified in several thousand proteins within a single experiment (Kim
et al., 2011; Udeshi et al., 2013b; Wagner et al., 2011). This ubiquitin remnant “profiling” has
made ubiquitylation the second most abundant post-translational modification annotated in the
human proteome (second only to phosphorylation) (Wagner et al., 2011).
Unbiased profiling of ubiquitin remnant sites is a valuable tool for identifying and
quantifying dynamic ubiquitylation events during cell signaling cascades and cellular
differentiation. However, few studies to date have taken this global approach to quantify changes
in ubiquitylation of protein substrates during a regulated cellular response. Reports of regulated
lysine ubiquitylation in this regard typically refer to increased or decreased abundance of
ubiquitylated peptides during treatment of cell lines with inhibitors of major cellular processes,
such as proteasomal degradation, deubiquitylation, cell cycle progression and protein translation
(Kim et al., 2011; Udeshi et al., 2012; Udeshi et al., 2013b; Wagner et al., 2011; Xu et al., 2010).
Two studies, one using ubiquitin remnant profiling and one enriching for ubiquitin itself, have
characterized changes in ubiquitylation in cells exposed to a physiological stimulus using cell line
response to EGF, which initiates a very well characterized signal transduction response (Akimov
et al., 2011; Argenzio et al., 2011). This cell line model system, though highly tractable, is limited
with regards to in vivo relevance. However, the large quantity of starting material required for
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these profiling experiments poses a significant hurdle for applying this to non-transformed primary
cells undergoing a physiological response. Furthermore, to truly characterize regulation of protein
ubiquitylation, ubiquitin remnant profiling is insufficient. Identification of K-ε-GG peptides from a
protein, even if this peptide shows changes in abundance over time or during treatment/stimulus,
identifies only the lysine that was modified. As ubiquitin is a highly dynamic and variable
modification, identification of lysine ubiquitylation alone does not allow predictions for how the
protein half-life, function, or localization might be affected by ubiquitylation. For this, additional
context is required that allows inference of ubiquitin chain type or the ability to track changes to
the activity/abundance of the protein over time.
Activation of T cells during an immune response requires post-translational modifications
downstream of several critical receptors. Global phosphoproteome studies have characterized
dynamic phosphorylation events that occur during engagement of the T cell receptor (TCR) and
costimulatory molecules (Brockmeyer et al., 2011; Chylek et al., 2014; Ji et al., 2015; Navarro et
al., 2011; Navarro et al., 2014; Roncagalli et al., 2014; Salek et al., 2013). Similar studies have
yet to be done for ubiquitylation in T cell activation, despite growing appreciation that
ubiquitylation plays a critical role in T cell activation, T helper cell differentiation, and effector T
cell function (Gomez-Martin et al., 2008; Liu, 2004; Park et al., 2014). Consistent with this, I
observe that proteolytic degradation is critical for T cell activation, suggesting that ubiquitylation
events change dynamically during T cell activation
In this study, I address feasibility of using ubiquitin remnant profiling to quantify
ubiquitylation site dynamics in primary murine CD4+ T cells undergoing a physiological
stimulation. Ubiquitin remnant profiling in CD4+ T cells yielded approximately ~1000 ubiquitylated
proteins, with approximately 3000 ubiquitin remnant peptides, per run. Despite this comparatively
low number of ubiquitin remnant sites, this suggested that assessing ubiquitylation in primary
CD4+ T cells using ubiquitin remnant profiling is a viable option. Therefore, I sought to determine
whether quantitative proteomics could be used to identify proteins for which changes in
ubiquitylation alter protein abundance in a signal-dependent manner. To this end, I utilized stable
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isotope labeling of amino acids in cell culture (SILAC) in combination with immunoprecipitation of
ubiquitin remnant peptides and mass spectrometry to quantify changes in protein-specific
ubiquitylation in CD4+ T cells stimulated via the TCR compared to resting T cells. This SILAC
quantification revealed dynamic changes in ubiquitylation of hundred of proteins, including key
signaling transducers, during TCR stimulation.
To determine whether the changes in protein ubiquitylation are simply indicative of
increased or decreased protein abundance, or whether this might suggest post-translational
control of protein abundance or function, I performed whole cell proteomic analysis to quantify
changes in relative protein abundance during T cell activation. Comparing changes in
ubiquitylation with changes in protein abundance in stimulated CD4+ T cells, I identify subsets of
proteins for which ubiquitylation is correlated to protein abundance both in ways that suggest
post-translational control over protein function or levels and ways that suggest ubiquitylation
increases and decreases in coordination with protein synthesis. This combined proteomic
approach allows prediction of the downstream consequences of ubiquitylation on specific protein
substrates, including inference of ubiquitin chain type. These data are consistent with the existing
literature, and have the potential to reveal new ubiquitylation events with regulatory roles in T
cells. This study demonstrates feasibility of ubiquitin remnant profiling during a physiological
response of an untransformed primary cell. Furthermore, quantification of dynamic ubiquitylation
in parallel with whole proteome abundance creates a predictive tool for interpretation of
ubiquitylation events during TCR engagement. Going forward, these results will serve as a
resource for defining ubiquitylation events that are critical to post-translational regulation of T cell
activation and effector function.

Results
Early ubiquitin-proteasomal events are required for T cell activation
I first sought to understand how the ubiquitin-proteasome system might regulate T cell
activation. To this end, I isolated murine CD4+ T cells, expanded these in vitro, and subjected the
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cells to restimulation in the presence of inhibitors of protein translation, proteasomal degradation,
and lysosomal maturation. Using the early activation marker CD69 (Hara et al., 1986) as a
quantitative readout, I assessed the affect of these inhibitors on the ability of these T cells to
become activated when stimulated through the TCR and the costimulatory molecule CD28.
Surprisingly, T cells failed to upregulate CD69 when stimulated in the presence of the
proteasomal inhibitor MG132 (Figure 4.1a). The decrease in surface CD69 expression was
similar to what I observed when cells were stimulated in the presence of cycloheximide (CHX),
which inhibits translation of CD69 thereby preventing its expression (Figure 4.1b). In contrast,
stimulation in the presence of the lysosomal inhibitor chloroquine did not have a significant effect
of CD69 expression (Figure 4.1b). Proteasomal inhibition blocked synthesis of CD69, as
intracellular staining for total CD69 did not show any difference from what was observed with
surface staining (Figure 4.1c). This effect was not unique to TCR stimulation, as bypassing early
TCR signaling events through the use of the pharmacological activators PMA and ionomycin
yielded similar results (Figure 4.1d). Comparing cells in which the inhibitors were added at the
beginning of stimulation (Figure 4.1e) to cells treated with inhibitors two hours after stimulation
(Figure 4.1f) I observed that CD69 expression was largely intact in cells treated with either
cycloheximide or MG132 two hours after stimulation. This suggests that CD69 expression is
upregulated early in stimulated T cells, and this depends on a functional ubiquitin-proteasome
system. I obtained similar results for upregulation of the AP-1 family member, JunB, during T cell
stimulation (data not shown), suggesting that this is not unique to expression of CD69, but rather
a broader inhibition of the T cell activation program.

Reproducible ubiquitin remnant profiling in primary murine CD4+ T cells
Having observed that inhibition of proteasomal degradation profoundly dysregulated T
cell activation, I sought to understand more globally the ubiquitylation events that occur during
stimulation of primary CD4+ T cells. Ubiquitin remnant profiling by K-ε-GG
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Figure 4.1. Proteasomal inhibition prevents early T cell activation events.
a-d). CD4+ T cells were isolated from mouse splenocytes, stimulated with plate-bound
αCD3/CD28, expanded in IL-2, and restimulated with αCD3/CD28 beads for 4 hours in the
presence or absence of inhibitors. CD69 expression was examined on CD3+CD4+ T cells by flow
cytometry. (a) Representative histogram showing CD69 expression on resting (gray), TCRstimulated (black) and TCR-stimulated cells + 10µM MG132 for the duration of stimulation. (b)
Quantification of CD69 surface MFI as fold change relative to unstimulated cells in TCR
stimulated cells treated with several inhibitors (CHX=cycloheximide, chloro=chlorquine) over 4
experiments with 6-8 mice total. (c). As in (b), but cells were stained for both surface and
intracellular CD69. (d) As in (b), but cells were treated with either αCD3/CD28 or PMA/ionomycin.
N=3. (b-d) Mean shown +/- SEM, p values calculated by one-way ANOVA against TCR treated
cells, with Holm-Sidak correction for multiple comparisons. * p<0.05, ** p<0.01, ***p<0.001,
****p<0.0001. (e-f) CD4+ T cells were stimulated with inhibitors for 4hrs (e), or inhibitors were
added 2hrs into the 4hr stimulation (f). Representative of two mice.
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immunoprecipitation has been carried out extensively in cell lines, in which thousands of
ubiquitylated lysines are identified after fractionation of complex whole lysate. I first sought to
determine if large numbers of ubiquitin remnant peptides could be identified by this method in
primary murine CD4+ T cells. After isolating, stimulating and expanding large numbers of CD4+ T
cells in vitro, I restimulated these previously activated cells against the TCR and the costimulatory
molecule CD28 to activate T cell function prior to lysis, fractionation, and peptide
immunoprecipitation (Figure 4.2a). Knowing that proteasomal inhibition negatively impacts T cell
activation, I elected not to add MG132 to the restimulated T cells, despite the fact that this does
increase the number of ubiquitin remnant peptides that can be identified following K-ε-GG
immunoprecipitation (Udeshi et al., 2012; Udeshi et al., 2013b).
In pilot experiments I determined that increased amount of peptide input, without
increased antibody, improved specific immunoprecipitation of K-ε-GG peptides from 10% to close
to 50% of all peptide spectra following LC-MS/MS analysis (data not shown). Increased specificity
with increased peptide input has also been seen in cell lines (Udeshi et al., 2013b). To deal with
decreased specificity due to limited input material, I recombined peptides into only 3 fractions
after basic reverse-phase chromatography, using approximately 1mg of peptide per fraction for
immunoprecipitation.
Following immunoprecipitation and LC-MS/MS analysis, per experiment (sum of three
fractions) I identified approximately 1000 proteins with at least one ubiquitylated peptide;
however, close to 50% of these proteins had only a single K-ε-GG peptide spectral count,
suggesting limited depth of proteome coverage (Figure 4.2b). Summing all ubiquitin remnant
peptides in a single experiment, these single spectra represented only ~13% of total K-ε-GG
peptides, indicating that abundant sequences from highly ubiquitylated proteins likely mask
detection of rare ubiquitylation events, or ubiquitylated low-abundance proteins, due to the
minimal fractionation strategy (Figure 4.2b). To improve upon this without sacrificing peptide
material/fraction (and thereby specificity), I adopted a strategy of double injections of eluted
peptides following immunoprecipitation, and summed these injections. This significantly reduced
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the number of proteins identified with only a single K-ε-GG peptide spectral count: an average of
~25% of proteins were identified with only a single K-ε-GG peptide after pooling data from two
injections (Figure 4.2c).
From double injections of a single immunoprecipitation, I achieved 50% enrichment at the
protein level of proteins identified with at least one K-ε-GG peptide (Figure 4.2d). At the peptide
level, 45% of all peptides were ubiquitin remnant peptides (Figure 4.2e). To address
reproducibility with this workflow, I repeated this experiment, again with double injections of three
fractions. Comparing the two experiments showed 75% reproducibility of proteins identified with
at least one K-ε-GG peptide (Figure 4.2f). Thus, despite relatively poor depth of proteome
coverage, proteins with ubiquitylated peptides can be reproducibly identified in stimulated primary
CD4+ T cells.

Quantitative ubiquitin remnant profiling during T cell activation
These proof of concept experiments suggested that, despite the low number of K-ε-GG
peptides sequenced from primary stimulated CD4+ T cells, K-ε-GG peptide immunoprecipitation
in T cells yields reproducible identification of ubiquitylated peptides and proteins that might
facilitate analysis of ubiquitylation site dynamics during T cell activation. Therefore, I sought to
determine if K-ε-GG peptides are dynamically regulated during activation of CD4+ T cells by
quantitatively analyzing K-ε-GG peptide abundance in rested cells, cells stimulated for one hour,
and cells stimulated for four hours (Figure 4.3a).
To quantitatively determine the K-ε-GG peptide abundance under these three conditions,
I developed a “super SILAC” workflow, in which CD4+ T cells were labeled with C13 throughout
the culture period, stimulated under the conditions described above, and then lysate from each of
the three conditions was pooled in a 1:1:1 ratio to create a heavy reference proteome that was
mixed 1:1 with C12 CD4+ T cells, cultured in parallel for each stimulation timepoint. These SILAC
mixes were then subjected to fractionation and K-ε-GG immunoprecipitation. I also sought to
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Figure 4.2. Ubiquitin remnant immunoprecipitation yields reproducible K-ε-GG peptides
from primary T cells.
a) Primary murine CD4+ T cells were harvested from spleen and lymphnodes of WT mice, CD4+
T cell enriched, stimulated for 4 days with plate-bound αCD3/CD28 antibody, expanded in IL-2 for
three days, and then restimulated for 4 hours with αCD3/CD28 coated beads. Cells and cells
bound to the beads were lysed in urea buffer, and trypsin digested. Peptide was quantified and
subjected to off-line basic RP-LC, recombining into three fractions of ~1mg peptide/fraction
before immunoprecipitation of each fraction with αK-ε-GG antibody and analysis by LC-MS/MS.
(b) For the average 3 fraction experiment, approximately 1000 proteins are identified with at least
one K-ε-GG peptide. Close to 50% of these proteins are identified by only a single modified
peptide (spectral count), corresponding to 13% of all spectral counts. Average of 4 experiments.
(c) Duplicate injections of the same fractions improves protein identifications modestly, but
decreases proteins identified by a single modified spectral count to 25%. A similar improvement is
seen at the peptide level, comparing these single spectral counts which identify a unique protein
to total spectral counts. Average of two experiments with double injections. (d) >50% of proteins
identified (yellow) in a single experiment with double injections have at least one modified lysine
(green). (e) Of all peptide spectra (yellow), 45% are K-ε-GG modified peptides (green). (f)
Comparing two experiments (replicate A=blue, replicate B-yellow) shows 75% reproducible
identification of proteins with at least one K-ε-GG peptide (green).
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make inferences about the relationship between the changes in ubiquitin remnant peptide
abundance and the effect of ubiquitylation on the protein. To this end, I also analyzed the whole
proteome of unenriched, C12 labeled cells prior to SILAC mixing and K-ε-GG
immunoprecipitation.
Knowing that primary stimulated CD4+ T cells yield limited quantities of protein and
peptide, I pooled CD4+ T cells isolated from nine WT mice and expanded these in vitro to
~500x10^6 C12 and C13 labeled CD4+ T cells. Purity after this culture remained high (Figure
4.3b). The majority of cells that easily eluted from the beads after four hours of stimulation had
upregulated the early activation marker CD69 when analyzed by flow cytometry (Figure 4.3b).
Many cells were still bound to stimulation beads, suggesting that this is an underestimate of the
percent activation (data not shown). To capture the maximum amount of protein, beads and cell
pellets were both lysed in equal volumes and pooled prior to quantification and SILAC mixing.
Analysis of the three timepoints (rested cells, one hour stimulation, and four hour
stimulation) at the level of the whole proteome yielded good depth of proteome coverage, with
greater than 90% of proteins identified at all three timepoints (Figure 4.3c). As expected, there
was much less reproducibility in protein identification in the SILAC quantified K-ε-GG
immunoprecipitation samples, where only approximately 600 proteins were observed with SILAC
ratios for K-ε-GG peptides at all three timepoints (Figure 4.3d). Including proteins with K-ε-GG
peptide quantification at two of three timepoints increased this dataset to ~800 proteins, the
majority of which were also identified in at least two timepoints in the whole proteome analysis
(Figure 4.3e). Proteins found only by K-ε-GG, but that were observed in at least two timepoints,
are listed in Supplementary Table 1. GO term analysis indicated significant enrichment for
ubiquitin ligase binding (Benjamini Hochberg FDR corrected pvalue = 8.21E-09) and ubiquitintransferase activity (corrected pvalue = 4.19E-05) in the ubiquitin remnant dataset as compared
to the whole cell proteome, supporting that ubiquitin remnant immunoprecipitation does not
simply identify K-ε-GG peptides from the most abundant proteins in the cell, despite limited
fractionation.
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Figure 4.3. Quantitative ubiquitin remnant profiling in primary CD4+ T cells.
a) WT CD4+ T cells were bulk purified from spleen/lymphnodes, activated in either C12 or C13
SILAC media, and expanded in IL-2. 1/3 of each culture was left unstimulated, 1/3 was stimulated
for 1hr with αCD3/CD28 beads, and 1/3 was stimulated 4hrs. A 1:1:1 protein mix of C13 lysate
from each time point was combined 1:1 with C12 rested, 1hr stimulated, or 4hr stimulated cell
lysate prior to fractionation, IP, and LC-MS/MS analysis. (b) Purity and efficiency of stimulation
was assessed after 4hrs of stimulation by flow cytometry, staining for CD3, CD4, and CD69. (a,c)
Whole proteome samples were fractionated by SDS-PAGE prior to in-gel digestion and LCMS/MS. ~5400 proteins were identified in all three timepoints. (d) K-ε-GG peptide SILAC ratios
were obtained at all three timepoints for ~600 proteins. (e) The overlap of proteins identified with
a K-ε-GG peptide SILAC ratio at two or more timepoints and proteins identified in the whole
proteome at two or more timepoints. LC-MS/MS data were processed using Maxquant.
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Within the K-ε-GG dataset I observed that approximately 50% of all proteins identified
with an ubiquitin remnant peptide had only one unique peptide—that is to say, only one
ubiquitylated lysine was identified with a SILAC ratio (Figure 4.4a). The remaining 50% of
proteins had two or more unique peptides, corresponding to two or more modified lysines. Of
proteins observed to have only a single ubiquitin remnant peptide, many of these proteins only
had a SILAC ratio at one timepoint (Figure 4.4b). As these proteins might be rare, or rarely
ubiquitylated, they were not considered in downstream analysis. The majority of proteins with a
SILAC ratio at a single timepoint had only a single modified lysine identified; however, for a small
subset of proteins identified at only one timepoint, multiple unique lysines were identified. Multiple
lysines suggests that ubiquitylation of these proteins is not rare, but rather that loss of these
ubiquitylated peptides might be associated with T cell stimulation (Supplementary Table 2). To
limit the analysis of both the whole proteome and the K-ε-GG proteome to proteins I could
analyze throughout the stimulation, only proteins observed at two or more timepoints were
considered for further analysis. I observed ubiquitin remnant peptides for all seven lysines of
ubiquitin itself, some of which had ratios that changed dramatically during T cell stimulation
(Figure 4.4c). When these same peptides ratios were analyzed proportionate to the number of
spectral counts associated with each, K48 was revealed as the most abundant linkage in both
resting and stimulated T cells (Figure 4.4d).
To compare change in ubiquitylation or whole protein abundance over the course of T
cell stimulation, I first analyzed the whole cell proteome using label free quantification. Proteins
were normalized to their sequence length, timepoints were normalized for total number of
peptides, outliers were removed, and log2 transformed data was subjected to Bayesian principal
component analysis to impute missing values (proteins with values at 2/3 timepoints). The
resulting data was then scaled to a mean of 0 with standard deviation of 1. I examined
reproducibility of the quantification by comparing the values at four hours of stimulation in two
injections (Figure 4.4e). Minor variations were observed, consistent with day-to-day variation in
instrumentation. Analysis of the SILAC ratios followed a similar course, however no sequence
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length or total count normalization was required. Where proteins were identified with multiple
unique peptides, I calculated a protein SILAC ratio from the median of the peptide ratios (Udeshi
et al., 2012). Reproducibility of this quantification was also analyzed by comparing values for
each protein in two injections (Figure 4.4f).

Protein ubiquitylation is dynamic during T cell activation
Following data processing, I assessed how proteins changed over the course of
stimulation in the whole cell proteome and in the K-ε-GG ubiquitylome, examining the fold change
of protein abundance at one and four hours of stimulation relative to the resting cells (Figure
4.5a). I applied k-means clustering (k=9) to identify groups of proteins with similar or divergent
changes in the whole cell proteome abundance and in ubiquitylated protein abundance during T
cell stimulation (Figure 4.5b-c). This analysis revealed distinct clusters of proteins (Figure 4.6),
which were either regulated in the same direction in the whole proteome and the modified
proteome, or diverged in ways suggestive of post-translational impacts on the protein abundance
or function.
I identified a large cluster of proteins that had increased ubiquitin remnant peptides over
time, and varied changes in the abundance of the total protein (Cluster 4, Figure 4.7a). This
cluster illustrates a limitation of this clustering approach, as time-order was not preserved. As
such, within this cluster I find proteins that decrease over the course of stimulation, in a way that
corresponds to increased K-ε-GG peptide abundance, and proteins that are unchanged or
increase in abundance but also show an increase in ubiquitylated peptide abundance. One
striking example of the latter is Cyclin D2, which exhibits periodic changes in expression
corresponding to cell cycle, and is known to be targeted for ubiquitylation during mitosis
(Ajchenbaum et al., 1993). My own work has shown that Cyclin D2 has a short half-life during T
cell restimulation, but that its levels increase during TCR stimulation, consistent with an increase
in protein synthesis (Chapter 3).

94

a

b

#protein IDs

600

1 timepoint
2 timepoints
3 timepoints

400

200

Total=578

9
>1
0

8

7

5

6

4

3

2

1

0

#unique peptides/protein

d

1.6

SILAC ratio L/H
multiplied by count

1.2
1.0
0.8

20

0

f

4
3
2
1
0
-1
-2
-3
-4

-3

-2

-1

0

1

2

3

4

SILAC median ratio 4hr_rep2 (log2)

4

1

0

timepoint

e
Label-free quant 4hr_rep2 (log2)

40

0

0.6

-4

K29
K33
K48
K6
K27
K63
K11

4

SILAC ratio L/H

1.4

60

1

c

timepoint
3
2
1
0
-1
-2
-3

-3

-2

-1

0

1

2

3

4

SILAC median ratio 4hr_rep1 (log2)

Label-free quant 4hr_rep1 (log2)

Figure 4.4. Reproducible quantification of changes in modified lysines following ubiquitin
remnant profiling
a) Among all proteins with K-ε-GG SILAC ratios at any timepoint, the majority of these proteins
were identified with one modified lysine. Approximately 50% of proteins identified with
modification had two or more unique peptides quantified, corresponding to 2 or more distinct
modified lysines. (b) Among proteins identified with a single modified lysine, approximately 50%
were observed at only one of the three timepoinst analyzed. (c,d) Peptides with SILAC ratios
were identified at all timepoints for the seven lysines of ubiquitin, and show distinct patterns of
change over time. (d) Weighting peptide SILAC ratios according to abundance, calculated by
multiplying each ratio by the H/L count for that peptide, suggests relative contributions of distinct
peptides to changes over time in ubiquitylation of the protein. (e) Following data preprocessing,
log2 transformed protein abundances in the whole cell proteome are reproducible in multiple
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Figure 4.5. Clustering of changes in whole cell proteome abundance and modified protein
abundance relative to unstimulated cells.
a) Fold change in log2 transformed, BPCA imputed values for the whole cell proteome
abundance (WCP) and ubiquitin remnant abundance (K-ε-GG) at 1hr and 4hr of stimulation
relative to unstimulated cells, scaled to a mean of 0 with standard deviation of 1. (b) k-means
clustering (k=9) of WCP fold change and K-ε-GG fold change at 1hr and 4hr of stimulation
represented by principal component analysis of the datasets. (c) Heatmap based on hierarchical
clustering (dendogram) of WCP and K-ε-GG fold changes with the 9 k-means clusters
represented as colors to the left.
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In contrast, CD3ε, which is a component of the CD3 complex that is known to promote
TCR internalization and degradation (Borroto et al., 1999; Valitutti et al., 1997), decreases
robustly after one hour of stimulation and remains decreased, relative to unstimulated cells, at
four hours. This corresponds to a striking increase in K-ε-GG peptide abundance at both
timepoints. Within this same cluster I find CD247, or CD3ζ/CD3η, which increased over the
course of stimulation and showed a striking increase in ubiquitin remnant peptides. Much
previous work has looked at degradation of CD3ζ during T cell activation (Valitutti et al., 1997;
Wang et al., 2010a), and the whole cell proteome data appears in conflict with this. Of note,
peptides (modified or unmodified) from CD3ζ and CD3η cannot be distinguished, which may
complicate interpretation of this data. However others have suggested that CD3ζ homodimers or
CD3ζ/CD3η heterodimers are internalized and degraded separately from other CD3 components
(Liu et al., 2000). Consistent with this, LAPTM5 degradation of CD3ζ leads to specific lysosomal
degradation of CD3ζ, leaving other CD3 chains untouched; additionally, this degradation is
specific for intracellular CD3ζ, not for surface expressed CD3ζ (Kawai et al., 2014; Ouchida et al.,
2008). Regardless, these data indicate that the CD3 complex is one of the most ubiquitylated
proteins during TCR stimulation, and that this ubiquitylation increases after TCR engagement.
Several proteins decreased robustly during T cell stimulation, but showed varied changes
in K-ε-GG peptide abundance (Cluster 6, Figure 4.7b). In some cases, increases in relative
abundance of ubiquitin remnant peptides appears to correlate well with the decrease in protein
abundance observed in the whole cell proteome, suggestive of degradative ubiquitylation events.
In other cases, the relative abundance of K-ε-GG peptides is stable during stimulation; however
as the protein level is decreasing one interpretation of this is that an increased proportion of
protein is modified by ubiquitin. Jak1, which others (Katz et al., 2014) and I (Chapter 3) have
shown decreases robustly during T cell stimulation in an ubiquitin dependent manner, is found
within this cluster. Jak1 exhibits decreased abundance in the whole
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Figure 4.6. Clustering results shows evidence of differential ubiquitylation during T cell
activation.
k-means clustering of whole cell proteome (WCP) changes in protein abundance during
stimulation and changes in abundance of K-ε-GG peptides. Cluster members plotted as log2 fold
change relative to resting cells. In clusters 3, 4, 7, and 9, differences in fold change between the
1hr and 4hr WCP timepoints are colored red if the were less than -0.5, and blue if greater than
0.5. These colors are maintained in the K-ε-GG graph. Similarly, in clusters 1, 2, 5, 6, and 8,
differences in fold change between the 1hr and 4hr K-ε-GG timepoints are colored red if the were
less than -0.5, and blue if greater than 0.5. These colors are maintained in the WCP graph.
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Figure 4.7. Evidence of differential ubiquitylation during T cell activation.
a,b) k-means clustering of whole cell proteome (WCP) changes in protein abundance during
stimulation and changes in abundance of K-ε-GG peptides. Cluster members plotted as log2 fold
change relative to resting cells. In (a), differences in fold change between the 1hr and 4hr WCP
timepoints are colored red if they were less than -0.5, and blue if greater than 0.5. These colors
are maintained in the K-ε-GG graph. Similarly, in (b), differences in fold change between the 1hr
and 4hr K-ε-GG timepoints are colored red if they were less than -0.5, and blue if greater than
0.5. These colors are maintained in the WCP graph.
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proteome analysis and shows slightly increased K-ε-GG peptide at both one and four hours of
stimulation, suggesting that this pattern might be indicative of degradative ubiquitylation events.
Several other proteins known to be downregulated during TCR stimulation are also found
in this cluster, including the CD3γ chain (Dietrich et al., 1994) and the IFNγ receptor α chain
(Maldonado et al., 2009; Skrenta et al., 2000). CD3γ plays a critical role in TCR downmodulation
during TCR ligation: phosphorylation of CD3γ constitutes a robust and rapid internalization signal
that targets the TCR complex for lysosomal degradation (Dietrich et al., 1994). Likewise, protein
levels of IFNγRα decrease during T cell stimulation, in an IFNγ-independent manner, although
regulated ubiquitylation of this receptor has not been explored (Maldonado et al., 2009; Skrenta
et al., 2000). Together, these data suggest that this cluster of proteins is likely to contain
substrates of ubiquitylation that are targeted for degradation, either proteasomal or lysosomal.

Evidence for activity of ubiquitylation enzymes in ubiquitin remnant profiling
I further analyzed several protein families with known activity in the ubiquitylation
cascade, as activity of these proteins is often correlated to changes in ubiquitylation of lysines
within their own sequence. In T cells, TRAF, Cbl, HECT-type, TRIM, and Cullin ligase families all
have published roles in signaling of activated T cells. I also selected the USP family of
deubiquitylating enzymes (DUBs) to examine, as this is the largest DUB family and also has
known roles in activated T cells (Figure 4.8).
Few of these ubiquitylation proteins showed dramatic changes in overall protein
abundance during T cell activation, however, in many cases, increased abundance of K-ε-GG
peptides during T cell stimulation correlates well with literature describing activity of these
proteins in T cells. For example, Itch (Liu, 2007; Venuprasad et al., 2015), TRIM28 (Chikuma et
al., 2012; Zhou et al., 2012), Cbl-b (Chiang et al., 2000; Paolino and Penninger, 2010; Paolino et
al., 2011), and Cul3 (Mathew et al., 2014; Mathew et al., 2012) all have published roles in T cells.
Indeed, among their respective family members, these ligases are those for which the most
functions have been described in T cells. For Cullin RING ligases (CRLs) increased K- ε-GG
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peptide abundance is strongly indicative of increased activity, as the activating Nedd8
modification of Cullins also results in K-ε-GG peptides following trypsin cleavage (Kim et al.,
2011; Peng et al., 2003; Zhao and Sun, 2013). In contrast, agreement between K-ε-GG peptide
abundance during T cell stimulation and proposed activity of USP DUBs in T cells was relatively
poor—the major USP DUB with published roles in T cells, USP9x (Mouchantaf et al., 2006; Naik
et al., 2014; Park et al., 2013), was not identified with K-ε-GG peptides. This suggests either a
paucity of specific literature on these enzymes in T cells or that ubiquitylation of DUB lysines is
not indicative of activity the way it may be for E3 ligases. Consistent with the latter interpretation, I
did not identify any ubiquitin remnant peptides from the known proteasome-associated DUBs
required for proteasome function (Koulich et al., 2008), despite identification of K- ε-GG peptides
for a significant proportion of the core proteasomal subunits and immunoproteasome subunits
(Figure 4.9).
The TRAF family of E3 ligases was particularly interesting in this analysis—TRAF6, the
most highly published TRAF in T cell biology (King et al., 2008; King et al., 2006; Xie et al., 2013),
was the most abundant in the whole cell proteome, but no ubiquitin remnant peptides were
identified. In contrast, TRAFS 1-3—which also have known roles in T cells though less is known
mechanistically about their function (So et al., 2011b; Tsitsikov et al., 2001; Xie et al., 2011)—had
abundant K-ε-GG peptides, despite low expression in the whole cell proteome relative to Traf6.
Together, these data suggest that comparison of ubiquitin remnant abundance and whole
proteome abundance may reveal the functional state of ubiquitylation enzymes, and suggest
previously uncharacterized roles for E3 ligases in T cell activation.
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Figure 4.8. K-ε-GG abundance for proteins with known roles in ubiquitylation.
Domain searches were conducted to identify E3 ligases and deubiquitylating enzymes by
presence of a RING or HECT domain (E3 ligase) or ubiquitin specific protease (USP) domain
(DUB). Fold changes in whole cell proteome (WCP) abundance and K-ε-GG peptide abundance
relative to resting cells were compared.

Identified with K- -GG peptides

1i
2i

PA28

5i

PA28

Immunoproteasome

modified from Hedhli & Depre, 2010

Figure 4.9. Significant enrichment in proteasomal subunits after K-ε-GG
immunoprecipitation.
GO term analysis conducted in GOrilla indicated significant enrichment for the core proteasome,
accessory proteasome, and regulatory particle complexes after K-ε-GG immunoprecipitation
compared to the whole proteome analysis (Benjamini-Hochberg FDR corrected p-value for core=
6.72E-09, accessory= 4.65E-04, regulatory particle= 5.47E-03).

103

Discussion
The initial observations that inhibition of the proteasome pharmacologically prevents T
cell activation events strongly suggests a fundamental role for ubiquitylation in stimulated T cells,
beyond what has previously been identified in targeted, gene knockout studies, in which single
substrates of a specific E3 ligase or DUB have been identified in TCR signaling cascades.
Rather, these observations suggest that enacting transcriptional programs downstream of TCR
engagement requires proteasomal degradation in a way that is unlikely to be explained by
changes in the ubiquitylation state of a single protein. To begin probing ubiquitylation events in
stimulated T cells more globally, I turned to proteomic assessment of ubiquitylation. Here I
present proof-of-concept data that ubiquitin remnant profiling is a viable tool to probe dynamic
ubiquitylation events in primary CD4+ T cells, and develop a workflow conducive to interpreting
ubiquitylation events in context to predict consequences of changes in ubiquitylation state.
Technically, primary cells represent a unique challenge for this type of proteomic
profiling, due to limiting starting material and the inherent experimental variability of biologic
replicates. In initial optimization experiments I recapitulated several findings reported by Udeshi
and colleagues (Udeshi et al., 2013a; Udeshi et al., 2013b), namely that chemical crosslinking of
the αK-ε-GG antibody to the beads is essential, and that decreased antibody:peptide ratios yield
drastically improved specificity. Despite the limitations of working with primary lymphocytes, I
observed, from three 1mg peptide fractions, approximately 1000 ubiquitylated proteins with a
45% enrichment of modified peptides to unmodified peptides. This is strikingly similar to the
specificity reported in Jurkat cells for a similar antibody:peptide ratio when cells were not treated
with proteasomal inhibitors, indicating that, technically, the enrichment of K-ε-GG peptides from
primary cells is comparable to that achieved in cell lines. However, due to the large number of
primary T cells needed to achieve even ~1mg of peptide/fraction, the total number of fractions
and the amount of peptide per fraction is much lower than what has been used in optimized
workflows; as such there is a corresponding drop in ubiquitylome coverage relative to previous
reports using almost twice the amount of peptide/fraction and twice as many fractions (Udeshi et
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al., 2013a; Udeshi et al., 2013b). Despite this, identification of ubiquitylated proteins and peptides
in replicate experiments is reproducible, indicating that ubiquitin remnant profiling in
unmanipulated primary T cells is feasible. Undoubtedly, further improvements in this technique
will facilitate greater depth of coverage from limited starting material, and allow greater use of this
technique in primary cell types as opposed to transformed cell lines in which many signaling
events occur abnormally.
The ubiquitylated proteins in stimulated T cells are enriched for proteins involved in the
ubiquitylation cascade and components of the proteasome, many of which are not found when
the whole proteome is analyzed. This suggests that K-ε-GG immunoprecipitation specifically
enriches for highly modified proteins, which do not correspond to highly abundant proteins
observed by whole proteome analysis. There may be several reasons for this. K-ε-GG peptides
are not favored in complex peptide mixtures, even when these peptides are from an ubiquitinenriched protein digest, and may be masked (Xu and Jaffrey, 2013). This may be a particular
issue for identifying ubiquitin-modified smaller proteins, which have few tryptic sites, within the
whole proteome analysis. Biologically, heavily ubiquitylated proteins may be rapidly turned over
once modified, decreasing the likelihood of observing peptides in whole proteome analyses. I see
some evidence of this in the analysis of stimulated T cells, in which I identified more peptides for
proteins at the whole proteome level that increase during T cell stimulation compared to proteins
that decrease.
Of particular interest are proteins that are only identified after ubiquitin remnant
immunoprecipitation. In some cases, this is unlikely to reflect relevant ubiquitylation, but rather
reflects ambiguities in the reference protein database or within the ubiquitin remnant peptide. For
example, GAPDH was identified with two protein isoforms, one of which only appeared in the
ubiquitin remnant immunoprecipitation, while the distinction between Cul4a and Cul4b, which are
distinct gene products, could be made in the whole proteome but not with K-ε-GG peptides.
Others, however, are likely of biologic relevance, such as LAPTM5 which I observed with K-ε-GG
peptides at all three timepoints and which has a known role in CD3ζ chain degradation (Kawai et
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al., 2014; Ouchida et al., 2008). However, in the absence of the ability to compare ubiquitylation
state to whole proteome abundance or another measure of protein abundance/function, making
predictions for downstream consequences of ubiquitylation for these proteins is not possible.
By comparing changes in the ubiquitylation of proteins to how the overall abundance of
that protein changes during T cell stimulation, this study moves beyond ubiquitin remnant profiling
to predict functional consequences of ubiquitylation during a physiological stimulation. Comparing
these predictions based on the patterns of change in K-ε-GG abundance and protein abundance
to what is known about degradation/ubiquitylation for some specific proteins with T cell relevance,
I find good correlation. However, validation studies are clearly needed. In particular, the analysis
of ubiquitin remnant data follows the previously established method of determining a protein’s
ubiquitylation by calculating the median value of the peptide SILAC ratios (Udeshi et al., 2012).
While in many cases considering alternative approaches is not an issue because only one unique
peptide was observed, for proteins with multiple distinct K-ε-GG peptides it may be more relevant
to weight the peptides based on abundance, thereby favoring the SILAC ratios or values obtained
from the most abundant K-ε-GG peptide. However, if distinct lysines are regulated differentially,
then use of any averaging approach might mask dynamic changes in a single regulated lysine.
These different analytic approaches will need to be compared to published data and validation
data for several proteins about which distinct predictions can be made to determine what analytic
workflow is most likely to yield reliable predictions about how ubiquitylation regulates any given
protein.
This dataset can be used as a tool to predict the functional outcomes of ubiquitylation, as
well as a resource of relevant ubiquitylation sites in primary T cells. Broadly speaking, this type of
data may be able to distinguish degradative ubiquitylation events, which are most likely to be
mediated by K48 chains, and signaling ubiquitylation events, which are likely to involve K63
linked chains. However, all lysine chains except K63 can lead to proteasomal degradation, and
even K63 linked chains can lead to lysosomal degradation. Further complicating attempts to
predict the type of ubiquitylation chain on a protein is the fact that mono/multi-monoubiquitylation
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will be grouped as a signaling modification. In this regard, validation of proteins that are likely to
be degraded is much more straight-forward experimentally than confirming protein ubiquitylation
that leads to altered trafficking or serves as a signaling scaffold. Follow-up experiments to
validate basic degradation/signaling predictions may be able to shed some light on the specific
chain at play for individual proteins through use of available K48 and K63 chain-specific reagents.
There is also support in this dataset for the notion that E3 ubiquitin ligases, when highly active,
will themselves be ubiquitylated. Thus, in addition to predicting substrates of the ubiquitylation
cascade, ubiquitin remnant profiling may also be of utility in predicting ubiquitylation proteins with
high activity under specific stimulation conditions.
This work, though preliminary, supports the use of paired ubiquitin remnant/whole
proteome analyses for developing specific, hypothesis driven studies to identify new ubiquitylation
events with relevance in, and functional impact on, T cell activation. Targeted validation of
predictions made using these data will further support additional ubiquitin profiling experiments in
stimulated T cells to understand more globally how ubiquitylation is activated and terminated to
promote appropriate T cell activation and function. This global ubiquitin remnant profiling
approach, when paired with orthogonal methods such as whole proteome analysis, has great
potential to identify critical degradative events that are required for T cell activation to occur but
may as yet be unknown.
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Supplementary Table 1.Proteins identified only after K-ε-GG immunoprecipitation
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Supplementary Table 2. Proteins identified with >1 modified lysine at a single timepoint.
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CHAPTER 5: Conclusions and future directions
Ubiquitylation is a post translational modification critical for basic cellular processes and
for more complex signaling cascades involved in response to cell-extrinsic stimuli. As such, it is
not surprising that perturbation of ubiquitylation--either in a targeted manner by ablation of
specific functional proteins or in a more global manner through pharmacological inhibition—can
dramatically alter cellular functions and phenotypes. In this regard, effects of perturbing
ubiquitylation are particularly apparent in CD4+ T cells, which differentiate along distinct T helper
lineages and provide distinct effector responses upon activation of multiple signaling cascades
downstream of the TCR, coreceptor/costimulatory molecules, and cytokine receptors. T cells are
exquisitely sensitive to the strength of signal provided by engagement of cell surface receptors,
and also to the presence or absence of signals like cytokines and costimulation. Knockdown of
substrate-specific players in the ubiquitylation cascade has led to the identification of important
ubiquitylation events in signaling downstream of the TCR, cytokine receptors, and costimulatory
molecules, that, when altered leads to inappropriate activation and differentiation of CD4+ T cells,
often with detrimental effects on host immunity.

Targeted approach for identifying novel substrates of Nedd4 family
E3 ligases
Following this paradigm, in this work, I took a targeted approach to understand how
CD4+ T cell activation and/or effector cell differentiation would be affected in the absence of an
activator of one family of catalytic E3 ubiquitin ligases with known roles in T cells. My studies
showed that loss of the Nedd4 family ligase activator Ndfip2 had no or limited impact on
functionality of CD4+ T cells, and that this may be due to the known role of the only Ndfip2
homologue, Ndfip1, which activates the same family of E3 ligases, in preventing aberrant naïve T
cell activation and TH2 polarization. Supporting this, mice with T cells lacking both Ndfip1 and
Ndfip2 show exacerbated inflammatory disease compared to mice lacking Ndfip1 alone,
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suggesting that Ndfip2 may serve as a second line of defense against inappropriate T cell
activation/function, particularly in CD4+ T effector cells.
To determine the mechanism of this CD4+ T effector cell hyperactivity, I used a novel
combination of newly developed proteomics techniques to probe for aberrant protein
ubiquitylation in the absence of Ndfip1 and Ndfip2, and identified Jak1 as a new target of Ndfipdependent E3 ubiquitin ligases. Consistent with stabilization of Jak1, Ndfip-deficient cells fail to
undergo TCR-induced cytokine nonresponsiveness upon TCR engagement, and remain sensitive
to cytokine signals, whether exogenously provided or via new protein synthesis during
restimulation. Interestingly, stabilization of Jak1 was not observed in Itch deficient cells,
implicating another Ndfip1/Ndfip2 dependent ligase in this process. Through this work, I have
added to the known substrates for Nedd4 family E3 ligases, and have learned that these ligases
have roles in cytokine receptor signaling in addition to their published roles in signaling
downstream of the TCR.
Though highly homologous, Ndfip1 and Ndfip2 clearly play distinct roles in naïve and
activated T cells. I propose that part of the reason these proteins are not fully functionally
redundant lies in the distinct expression patterns observed at the mRNA level for Ndfip1 and
Ndfip2 during T cell stimulation. These data suggest that upon restimulation of effector CD4+ T
cells, when the increase in message for Ndfip1 and Ndfip2 is equivalent, Ndfip1 and Ndfip2 could
be functionally redundant. My data agree with this in the case of Jak1 regulation, as neither
Ndfip1 nor Ndfip2 deficiency alone recapitulated the Jak1 stabilization observed in the absence of
both Ndfips, supporting that either protein can promote continued Jak1 degradation during
restimulation of effector cells. However, whether this is generally the case remains to be tested
for other Nedd4 family E3 ligase targets. Further study may uncover additional examples of
functional redundancy for Ndfips during T cell restimulation, or may reveal distinct roles for Ndfip1
and Ndfip2 in previously activated T cells, perhaps in ligase specificity or substrates affected.
The sequences of Ndfip1 and Ndfip2, though highly homologous, may suggest differential
function. Ndfip1 has several lysines close to its PY motifs, while Ndfip2 does not. Perhaps this
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serves to make Ndfip1-mediated E3 ligase activation a self-terminating signal—Ndfip1 is
upregulated, interacts with Nedd4 family E3 ligases to promote their activity, and, in so doing, is
itself rapidly degraded. Indeed, given the known role of Ndfip1 in negatively regulating T cell
activation, it is likely that, under appropriate stimulation of naïve T cells, it would be beneficial to
have temporally limited expression of this potent negative regulator. Ndfip2 lacks these lysines,
which may prolong its half-life in activated T cells. However, biochemically, the literature and my
data suggest that Ndfip2 may be a weaker activator of Nedd4-family ligases (Kamadurai et al.,
2013), promoting function with slower kinetics. Thus, more prolonged, but less efficient, Ndfip2mediated activation of Nedd4 family ligases might serve as a molecular fail-safe—allowing a lowlevel, sustained activation of specific Nedd4 family E3 ligases upon termination of the more
transient Ndfip1-mediated activation. This hypothesis would suggest that this two-phase
activation of Nedd4 family ligases would be specific to memory or effector CD4+ T cells, again
based on the expression pattern of Ndfip1 and Ndfip2. While my phenotypic evidence indicates
that previously activated cells are more impacted by loss of Ndfip1 and Ndfip2 than naïve CD4+ T
cells, specific experiments to compare activation/differentiation events in naïve T cells and
previously activated effector or memory CD4+ T cells have not been done. Bi-phasic activation of
the same or distinct Nedd4 E3 ligases by Ndfip1 and then Ndfip2 could account for shared
regulation of certain target proteins, like Jak1, but also unique interactions between Ndfip1 or
Ndfip2 and cognate E3 ligases, as during the course of T cell stimulation distinct signaling
intermediates are activated and expressed.
The high levels of phosphorylated STAT5 observed in Ndfip deficient CD4+ T cells during
TCR restimulation are highly suggestive that elevated STAT5 activity may be a driving force in
the hyperactivated TH2-skewed phenotype of Ndfip-deficient T cells. The potent role IL-2 and its
main downstream effector, STAT5, play in differentiation of almost all CD4+ T cell effector
lineages is often given less importance than their more general roles in T cell activation and cell
cycle progression. Specifically, with regards to TH2 cells, IL-2 and pSTAT5 are required for
differentiation, while one of the TH2 lineage defining transcription factors, STAT6, is in fact

113

insufficient for TH2 polarization both in vitro and in vivo (Cote-Sierra et al., 2004; Le Gros et al.,
1990; Zhu et al., 2003). Thus, increased phosphorylation of STAT5 may actually promote the TH2
bias observed in Ndfip deficient mice.
With regards to other TH lineages, my data suggest that strong STAT5 signaling early in
T effector differentiation would also lead to the observed decrease in in vitro TH17 differentiation
previously seen in the absence of Ndfip1 (Ramon et al., 2012) and also observed in Ndfip doubly
deficient cells (data not shown), which I recapitulated in the T cell transfer colitis in vivo model.
Somewhat counter-intuitively, increased STAT5 signaling could also lead to the decrease in
regulatory T cell differentiation observed in vitro and ex vivo. While IL-2 is required for FoxP3
upregulation and maintenance of regulatory T cells, inhibiting signaling through IL-2/STAT5
during initial TCR engagement is actually much more effective at promoting Treg development in
vitro (Guo et al., 2013). In addition, IL-2/STAT5 inhibits TFH differentiation, which has been shown
to be defective in the absence of the Nedd4 E3 ligase Itch, but was not investigated in Ndfip
deficient mice (Johnston et al., 2012; Xiao et al., 2014).
The observation of similar defects in T effector differentiation in mice deficient only in
Ndfip1 or Itch—in which I did not observe Jak1 stabilization—and mice doubly deficient in Ndfip1
and Ndfip2, which do show stabilization of Jak1, raises the question of whether Jak1 stabilization
is sufficient for these observed phenotypes. However, it seems unlikely that Jak1 stabilization
alone leads to loss of TCR-induced cytokine responsiveness. Rather, it is likely that this also
requires increased production of cytokine. Common γ chain cytokine production (including IL-2,
IL-4) is greatly enhanced in the absence of Itch and Ndfip1. This alone is likely sufficient for
increased STAT5 signaling and the lineage skewing observed as a result of this, although it is
unlikely to be sufficient for loss of TCR-induced cytokine non-responsiveness during acute TCR
engagement. Thus, enhanced cytokine production from loss of Ndfip1 or Itch may set the stage
for increased
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Figure 5.1. Model of Jak1-dependent activation of STAT5 in Ndfip deficient CD4+ T cells.
In WT and Ndfip2-/- CD4+ T cells, normal action of Ndfip1/Itch prevents aberrant production of
Jak1-dependent cytokines, such as IL-2 and IL-4. Ndfip2 and/or Ndfip1, with an alternative Nedd4
family ligase (such as Nedd4-2), enforce cytokine non-responsiveness during TCR engagement
by promoting continue Jak1 degradation. In the absence of Ndfip1/Itch, increased cytokine leads
to some persistent signaling during TCR engagement due to increased receptor occupancy
despite normal Jak1 degradation. In Ndfip doubly deficient cells, increased cytokine production in
combination with loss of Ndfip1/Ndfip2-dependent sustained Jak1 degradation drives further
increases in cytokine signaling during TCR engagement. This leads to increased STAT5 activity,
with consequences for lineage commitment and stability of distinct TH subsets.
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cytokine responsiveness during TCR stimulation which is then further exacerbated by stabilization
of Jak1 when both Ndfip1 and Ndfip2 are lacking (Figure 5.1).
Beyond the proteomic data and testing Jak1 half-life, I was unable to show that Jak1 is
less ubiquitylated in Ndfip doubly deficient T cells. Analysis of Jak1 ubiquitylation in restimulated
cDKO T cells is complicated by the increased propensity of Ndfip deficient T cells to activate in
response to in vitro TCR stimulation. An increased proportion of activated cells would lead to
increased expression of the microRNA previously reported to mediate Jak1 transcript destruction
(Katz et al., 2014), decreasing Jak1 expression in cDKO CD4+ T cells compared to WT cells
independent of ubiquitylation. This may explain why initial Jak1 downregulation in Ndfip doubly
deficient T cells is identical to that observed in WT cells. This hypothesis could be tested by
assessing upregulation of the Jak1-targeting microRNA, as well as by performing a cycloheximide
timecourse to identify changes in Jak1 half-life earlier in T cell restimulation. To further validate
the Jak1 proteomic and in vitro data, Ndfip1 and Ndfip2 could be transiently knocked down in
previously activated WT CD4+ T cells to test whether acute ablation of Ndfip-dependent ligase
function leads to stabilization of Jak1 in a similar fashion to what was observed in Ndfip doubly
deficient cells. Ubiquitylation of Jak1 could be quantified in Ndfip deficient and sufficient cells
using a mass spectrometry approach. Endogenous Jak1 could be immunoprecipitated from
restimulated WT or cDKO CD4+ T cells, and eluted proteins could be fractionated on a gel and
assayed by LC-MS/MS to determine the quantity of ubiquitin peptides in gel fractions containing
Jak1. The initial, rapid loss of Jak1 makes this more experimentally challenging, and might
necessitate overexpression of epitope-tagged Jak1 in WT and Ndfip deficient T cells.
While I have correlated increased Jak1 levels and stability with persistent response to
cytokine during TCR stimulation, I did not here address whether increased Jak1 stability directly
leads to increased phosphorylation of STAT5 or can promote the hyperactive/hyperviable
phenotype of Ndfip deficient effector CD4+ T cells. Both of these issues bear consideration, and
could be further probed both in vitro and in vivo. In Ndfip doubly deficient CD4+ T cells, use of a
Jak1 specific inhibitor during TCR restimulation would help address whether increased STAT5
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phosphorylation is mediated directly through Jak1. The Jak1 inhibitor could also be utilized in
vivo, to determine if mice with Ndfip doubly deficient T cells show dose-dependent changes in the
abundance, number, or lineage-specificity of effector CD4+ T cells. In WT CD4+ T cells,
expression of a microRNA resistant Jak1 construct would be predicted to increase Jak1
expression during T cell restimulation, allowing direct testing of whether Jak1 downregulation is
required for TCR induced cytokine non-responsiveness. In my ubiquitin remnant datasets, there
is evidence for ubiquitylation of seven distinct lysines in Jak1. Thus, a somewhat cruder
experiment to test the effect of expressing stabilized Jak1 in T cells would be to express a Jak1
mutant without these lysines in WT CD4+ T cells prior to restimulation, and assess whether this
stable Jak1 can promote persistent cytokine responses. Mutation of each of these lysines
individually, and expression of these Jak1 point mutation constructs in T cells, would be an
important experiment to determine if Jak1 ubiquitylation depends on a single lysine. CRISPR
could be utilized to translate promising in vitro transduction experiments to an in vivo setting, to
determine if expression of stable Jak1 is sufficient to promote aberrant STAT5 phosphorylation,
and perhaps T cell hyperactivation, TH2 skewing, and T cell hyperviability.
In this targeted study, I brought to bear global proteomic analysis of Ndfip deficient and
sufficient primary CD4+ T cells to identify aberrant ubiquitylation/degradation of relevant
substrates of Ndfip-dependent Nedd4 family ligases. However, despite use of these unbiased
techniques, and a robust list of potential targets, I validated only a single protein, Jak1, in my
mechanistic studies. As with other, similar types of studies using targeted approaches to identify
new substrates of specific ubiquitylation enzymes or pathways, a major limitation to this work is
that dysregulation of a single protein—which in the case of regulation by ubiquitylation is unlikely
to lead to a total loss or gain of function—is extremely unlikely to be sufficient to recapitulate a
complex cellular or in vivo phenotype. Indeed, in my own study, several other proteins on the list
of potential substrates for Ndfip-dependent ligases are likely worth examining, as they too would
fit with the observed cellular phenotypes (for example, Lck and Itk). Several of these proteins are
known to function in opposition or in collaboration in T cells and in other cell types, suggesting
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that the observed decrease in ubiquitylation for some or many of these proteins may be an
indirect effect of Ndfip deficiency (e.g., Cul5 and Apobec3, Cul5 and Jak1, Parp9 and Dtxl3),
perhaps related to different effector cell phenotypes of WT and Ndfip deficient cells. Some of
these proteins have no known roles in T cells, such as RNF213 or Clint1, but the fact that they
show differential ubiquitylation in T cells lacking Ndfip1/Ndfip2 suggests that they may indeed
have important functions in T cell biology, for which their ubiquitylation is important, that have yet
to be determined. Further characterization of these other potential Ndfip-dependent E3 ligase
targets would undoubtedly inform our understanding of how Ndfip1 and Ndfip2, and their cognate
ligases, work to regulate CD4+ T cells.
Clearly, lacking from this study, as well as previous targeted studies, is a broader
characterization linking multiple discrete ubiquitylation events, affected by targeted knockdown of
certain ubiquitylation enzymes, to understand how together these affect T cell fate, function, and
promote the cellular phenotype observed in vivo. Further, these studies fail to integrate with other
known ubiquitylation events of relevance. Certainly ubiquitylation has critical roles in maintaining
DNA integrity, regulating intracellular trafficking, shaping the epigenetic landscape, and
controlling cell division (Komander and Rape, 2012), all of which are important events in
stimulated T cells that are impinged upon by proximal TCR signaling events. An additional
challenge, specifically considering known ubiquitylation events in activated T cells, is integration
of discoveries from targeted studies, such as my studies on Ndfip deficient T cells, with previously
identified substrates identified either in similar signaling pathways or for the same protein players.
This is especially difficult as effects on specific ubiquitylation events can be exceedingly hard to
reproduce, which suggests that often there is incomplete understanding of the molecular
mechanisms involved in specific protein ubiquitylation during a complex cellular response like T
cell activation.
The only signaling cascade in which ubiquitylation is typically thought to actively
propagate signals downstream of the TCR, through both degradative and signaling ubiquitin
chains, is in activation of NF-κB. Here, ubiquitylation events have been well characterized and
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reproduced in multiple experimental models. However, proposed and validated substrates of
ubiquitylation enzymes in T cell activation are found in all signaling cascades initiated during
normal T cell activation and effector cell differentiation—not just in NF-κB signaling. In other
signaling cascades downstream of the TCR or costimulatory molecules, ubiquitylation is primarily
understood at the level of individual substrates, and not as a critical signal transducer. Thus
substrate specific studies might suggest that ubiquitylation is less critical for these other signaling
cascades, primarily serving to remove signaling intermediates or inhibitors by promoting their
degradation. However, what seems more likely is that there is a failure to integrate existing
experimental data from targeted studies into a broader model of ubiquitylation as a key signaling
molecule in the majority of signaling cascades activated downstream of TCR, costimulatory
molecule, and cytokine receptor engagement.

Unbiased ubiquitin profiling in primary T cells
Unlike phosphorylation, for which targeted and global experimental approaches have
been applied to generate consensus models of critical phosphorylation events in T cell activation,
similar work has yet to be done for ubiquitylation in T cells. Definitive identification of critical
phosphorylation events required moving beyond ablation of protein kinase expression to
identification of the modified residues, and subsequent mutation of those residues on target
proteins. Identification of ubiquitylation sites has only recent become possible in a highthroughput manner, and this ubiquitin remnant profiling technique has never been applied in
primary T cells, activated or unstimulated.
To begin moving beyond targeted deletion of specific proteins to identify substrates of
those ubiquitylation cascade components, I sought to determine if large-scale identification of
ubiquitylated lysines was feasible in T cells, and if this could be used as a tool to predict regulated
ubiquitylation events in T cells undergoing TCR stimulation. I have now shown that this technique
generates reproducible data, albeit with reduced proteome coverage due to limited starting
material. Furthermore, ubiquitin remnant profiling can be done in conjunction with SILAC labeling
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for quantitative proteomic analysis of changes in ubiquitylation over time, either at the level of
specific lysines or at the protein level.
These ubiquitin profiling datasets are a valuable resource that may allow more targeted
experiments on proteins that are already known or thought to be ubiquitylated during T cell
stimulation, and/or have previously been published as targets of specific E3 ubiquitin ligases or
DUBs. In many cases, only a single lysine was identified as modified, and while it is unlikely that
this is the only lysine that can be ubiquitylated in these proteins it suggests that this is a highly
accessible lysine that may be preferentially ubiquitylated in vivo. Point mutations of these single
lysine residues may prove valuable in validating direct effects of E3 ligases on proposed
substrates and in identifying ubiquitylation events which are critical for normal T cell activation to
occur, analogous to what has been done with phosphorylation of TCR proximal signaling
proteins. Although it is possible that point mutations to a specific lysine will simply result in an
alternative lysine being ubiquitylated, this point mutation approach was recently used with
success for a lysine of RIPK3, discovered via LC-MS/MS analysis of RIPK3 in WT and A20-/MEFs (Onizawa et al., 2015).
These ubiquitin remnant datasets pose challenges, however. Quantification of ubiquitin
remnant sites is done at the level of the unique peptide (almost always containing a unique
lysine). To get a sense of how a protein is regulated as a whole, particularly if a comparative
analysis will be done using protein expression levels, it is desirable and necessary to sum or
average these unique K-ε-GG peptides. In doing so, site-specific information is often masked.
While it seems likely that distinct lysine residues are differentially ubiquitylated, or ubiquitylated in
response to distinct stimuli, there appear to be no clear consensus motifs around ubiquitylated
lysines that might indicate preferential ubiquitylation of one solvent accessible lysine over another
(Kim et al., 2011). To-date, there is limited evidence for signal specificity of ubiquitylated residues.
In the case of my experimental system, in which I used the median SILAC ratio when multiple
ubiquitin remnant peptides were quantified, low abundance peptides that changed drastically over
time would skew the change in ubiquitylation calculated at the level of the protein. This might be
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beneficial, if it identifies true signal-responsive peptides compared to peptides ubiquitylated as
part of protein quality control mechanisms, however it is also likely to favor artifacts introduced by
observation of rare peptides.
Comparing protein ubiquitylation to changes in whole proteome abundance is critical as a
means to distinguish regulated ubiquitylation, with possible signaling consequences, from “housekeeping” ubiquitylation of newly translated proteins during folding in both the ER and cytosol. In
agreement with reports from ubiquitin profiling in cell lines, in which it was seen that inhibition of
translation greatly reduced abundance of many ubiquitin remnant peptides, I find many proteins
that are known to undergo increased transcription/translation in stimulated T cells with
proportionately increased K-ε-GG peptide abundance. Newly synthesized proteins with increased
ubiquitylation due to increased synthesis are unlikely to show signal dependent regulation by
ubiquitin, and it is likely that addition of a translational inhibitor following initial T cell activation
would dramatically reduce abundance of ubiquitin remnant peptide for these proteins (such as
OX40, CD44). Inclusion of a translational inhibitor would also help distinguish K-ε-GG peptides
associated with new synthesis of secreted proteins versus internalization and possible lysosomal
degradation of these same proteins, many of which were identified only after K-ε-GG enrichment
(for example Galectin-1, somatotropin).
The ubiquitin remnant data set was heavily enriched for components of the
transcriptional/translational machinery: I observed many ribosomal, RNA processing and
spliceosome-associated proteins with K-ε-GG peptides. While proteasomal degradation is known
to function in tandem with new protein synthesis to destroy mis-translated polypeptides, in a form
of quality control known as cotranslational ubiquitylation (Bengtson and Joazeiro, 2010;
Brandman et al., 2012; Comyn et al., 2014; Wang et al., 2015b), regulatory ubiquitylation is
critical for function of proteins involved in polypeptide synthesis as well. Research in this
emerging field has been greatly aided by new experimental reagents and techniques, such as the
αK-ε-GG monoclonal antibody and K48/K63 specific TUBEs, which have revealed regulatory
ubiquitylation of protein synthesis machinery in many cell models (Higgins et al., 2015; Werner et
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al., 2015), although this is best characterized in budding yeast (Panasenko et al., 2009; Silva et
al., 2015; Spence et al., 2000).
In these data, I observe that ribosomal subunits themselves are extremely stable over the
stimulation, but that ubiquitylation of half of these identified ribosomal components is increased by
four hours of stimulation. This would be consistent with existing reports that ubiquitylation of these
proteins is primarily K63-linked (Silva et al., 2015; Spence et al., 2000). The substantial increase
in new protein synthesis that occurs soon after TCR engagement (Kay et al., 1971; Kleijn and
Proud, 2002) might lead to a translational stress response, perhaps similar to the type of
translational stress responses in which increased ribosomal K63 ubiquitylation has been
observed in other systems (Silva et al., 2015; Spence et al., 2000). The purpose of this regulatory
ubiquitylation of ribosomal subunits is only now being understood, and may provide fundamental
insight into T cell biology. Recently, it was published that regulation of translational machinery by
ubiquitylation plays an important role in determining cell type specification during development of
neural crest cells by altering the translational program of progenitor cells, beyond what was
specified by chromatin modifications (Werner et al., 2015). While T cells are a terminally
differentiated cell type, the ability of CD4+ T cells to undergo further effector cell specification
during activation, which can be observed at the level of epigenetic changes (O'Shea and Paul,
2010; Vahedi et al., 2013), suggests that, similar to its role in embryonic cell fate decisions,
regulatory ubiquitylation of ribosomal machinery may further specify the translational programs of
effector CD4+ T cells during lineage differentiation.
Comparing changes in the ubiquitylation state of a protein and changes in protein
abundance has great promise as a predictive tool. However, there is a great need for validation of
this prediction method. In a limited survey of proteins identified in this dataset and proteins which
are published targets of ubiquitylation in activated T cells, I identify many instances in which
predicted degradation (decreased protein at the whole cell proteome level, increasing or stable
ubiquitin remnant peptide abundance) conforms to what I and others have observed by flow
cytometry or western blotting. Validating predictions of regulatory ubiquitylation (no change in
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protein at whole cell proteome level, dynamic changes in ubiquitin remnant abundance), which
might be observed with monoubiquitylation or K63 linked ubiquitylation, will be more difficult, as
these events are less well annotated in the literature and more technically challenging to identify.
However, new reagents for specific polyubiquitin chains may be useful in this regard (e.g., K63
and K48 TUBE). Additionally, given my success with the pan-ubiquitin chain TUBE reagent, a
simple way to distinguish K63, or alternatively linked chains, from mono/multi-monoubiquitylation
signaling events would be to compare the protein identifications obtained from ubiquitin remnant
profiling, whole cell proteome analysis, and pan-ubiquitin chain TUBE enrichment. Validation of
this large dataset will necessitate additional high throughput LC-MS/MS experiments, such as use
of cycloheximide in activated CD4+ T cells prior to ubiquitin remnant profiling to distinguish cotranslational ubiquitylation from signal-dependent ubiquitylation, using various TUBE reagents to
identify proteins with K48-linked chains or with atypical ubiquitin chains, and optimizing the
technique workflow to allow analysis of early timepoints in TCR activation. All of these
approaches can be paired with quantification of protein phosphorylation, which may be
particularly important for TCR signaling intermediates.
Ubiquitin profiling and whole proteome analysis in activation of primary T cells represents
a natural progression, and significant advance, beyond initial studies that examined regulation of
ubiquitylation in transformed cells undergoing non-physiological stress responses. However,
identifying dynamic and regulatory ubiquitylation events during T cell activation is also
complicated by the outcomes of T cell stimulation, such as cytokine production, metabolic
changes, and differential transcription. Teasing apart direct effects of ubiquitylation events, which
may be transient, versus ubiquitylation events that arise further downstream of T cell activation
will require a more nuanced approach, likely with additional timepoints and alternative peptide
labeling approaches. As ubiquitin remnant profiling in primary cells becomes more common, it is
likely that improvements upon this technique will make these studies more scalable, allowing for
more thorough profiling experiments. Important issues remain, however, for use of ubiquitin
remnant profiling to understand fundamental aspects of T cell biology. For example, how does
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one interpret studies done in the presence of inhibitors of the proteasome or lysosome, knowing
that this profoundly impacts T cell activation? Seeking validation in the literature for ubiquitylation
of proteins observed by K-ε-GG immunoprecipitation, it is difficult to find experimental evidence of
ubiquitylation, or absence of ubiquitylation, that is not complicated by use of these common
inhibitors. Indeed, due to the challenging nature of many of these experiments, it is not
uncommon to see validation experiments carried out in an irrelevant cell line. And, pressingly,
how do ubiquitin profiling studies inform, corroborate, or disagree with data from more targeted
approaches?

Integrating proteomics in discovery and characterization of
ubiquitylation enzymes and targets
In many ways, the work described here parallels broader efforts in the field to examine
ubiquitylation in immune cells. I began with a targeted approach, using traditional gene knockout
mouse models, and typical phenotypic analysis to identify relevance (or irrelevance) of a protein
of interest in immune function. This targeted approach has significant disadvantages, as often,
after much investment, attempts to identify a specific role for the protein of interest yield limited
results of interest. Indeed, this was my initial experience with Ndfip2 deficient mice. Many studies
end here, unless there are clear reasons to pursue genetic ablation of the same target in more
specific cell types or in the context of another gene (as I did with the Ndfip1/Ndfip2 doubly
deficient mice). Should a robust immunological phenotype be apparent, mechanistic studies are
undertaken to identify novel substrates of the perturbed ubiquitylation cascade. Often these are
hypothesis driven efforts, but many times mechanism is derived through use of more unbiased
techniques, such as transcriptome or, more recently, proteome analysis. With a complicated
inflammatory phenotype, it is likely that many substrates will be discovered in this type of targeted
workflow, as has been the case for several E3 ligases and DUBs (such as Itch and A20). While it
is unlikely that any single substrate will emerge as causal for an observed in vivo phenotype, it is
also unusual for studies to link many known substrates for the particular enzyme of interest in one
or many pathways that show dysregulation in these loss-of-function studies.
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As the ubiquitin field moves from targeted studies to more global efforts to identify
ubiquitylation events with regulatory importance, immunologists interested in ubiquitin should
follow suit. Applying new proteomics techniques to primary T cells has great potential to inform
targeted studies in gene knockout mice, but can also be used as a jumping off point for new
research. Hypothesis generating experiments, such as ubiquitin remnant/whole proteome
profiling, could be used to identify the most relevant ubiquitin ligases or DUBs in T cells, or other
immune cells, undergoing a stimulation of interest. I find excellent correlation between presence
of K-ε-GG peptides and the known activity of various E3 ligases, both catalytic and non-catalytic,
in T cells. Though not presented here, I also identified many RING-type E3 ligases with no as-yet
published role in T cells that showed abundant modifications by ubiquitin. Further, I find a specific
subset of E2 conjugating enzymes that may also have particular roles in immune cells that have
not been explored. While I fail to see similar correlation between proposed DUB activity and
ubiquitin remnant peptides, I find good agreement at the protein level for increased abundance of
DUBs with known roles in T cells. Thus, for DUBs, comparison of whole proteome abundance
among distinct cell types or CD4+ effector T cell lineages might reveal cell type or lineage specific
DUBs for further investigation.
Ubiquitin remnant profiling and other proteomic methods for dissecting the ubiquitylation
cascade can be integrated into targeted workflows. Upon identification of an exciting
immunological phenotype using gene knockout or knock-in approaches, use of proteomics
techniques described here provide an unbiased and high throughput manner for examining
possible substrates that are aberrantly regulated. This type of unbiased experimentation also
provides a rapid method to validate previous findings in the experimental system of interest,
hopefully linking new findings with previous data obtained in more targeted workflows.
Furthermore, pairing ubiquitin remnant profiling with an expression dataset, in this case whole
proteome analysis, is a predictive tool for identifying ubiquitylation of key T cell signal transducers
or regulatory proteins that can be probed specifically in animal and cell culture models.
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Integration of unbiased proteomic analysis can speed typical, targeted workflows while
also providing a platform for observing effects on multiple substrates, known or hypothesized, that
may facilitate a more holistic understanding of the role for ubiquitylation in immune cells, and in
CD4+ T cell activation specifically (Figure 5.2). This type of integration of ubiquitylation
proteomics with targeted approaches has great potential to rapidly expand our knowledge of the
T cell ubiquitylome, its dynamics, and its role in T cell activation and effector cell specification.
Beyond predicting specific ubiquitylation fates for individual proteins, it is likely that whole
proteome analysis and ubiquitin remnant profiling can be paired productively with
phosphoproteome, RNAseq, and ChIPseq approaches to develop more complete pictures of
effector T cell programs enacted at multiple levels of regulation.
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Identify likely activator/inhibitor
of substrate-specific
ubiquitylation events

Compare with orthogonal dataset
(whole proteome, RNAseq)
Determine expression in T cells

Predict functional players
in ubiquitylation events
Knockout globally or in
T cell specific manner

Quantitative
ubiquitin remnant profiling
in primary T cells under
conditions of interest

Phenotype

Targeted mechanistic experiments
suggested based on phenotype alone
or by global expression studies
under relevant conditions
Predict proteins with
robust post-translational
control of funtion
or abundance

Identify new ubiquitylation
target, validate

Determine effect of
ubiquitylation on protein
stability or function

Figure 5.2. Proposed integration of ubiquitin remnant profiling in targeted studies of
ubiquitylation in T cells.
Ubiquitin remnant profiling, particularly when paired with expression datasets, has great potential
to improve upon traditional workflows for identification of relevant ubiquitylation events in T cells.
Ubiquitin profiling can be used to generate hypotheses about specific enzymes or potential
targets and also to inform mechanistic studies to identify dysregulated proteins in loss or gain of
function genetic models.
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APPENDIX
Materials and Methods
Mouse strains
fl/fl

Ndfip1-/-, Ndfip1 CD4Cre+, and Itchy mutant mice have been described (Oliver et al., 2006;
Perry et al., 1998; Ramos-Hernandez et al., 2013). CD45.1+ (C57BL6.SJL-Ptprca Pepcb/BoyJ)
and Rag1-/- (B6.129S7-Rag1tm1Mom/J) were purchased from Jackson Laboratory are
maintained in house. Ndfip2 knockout/GFP knock-in mice were generated by Taconic
Biosciences, Inc (TaconicArtemis) as described in Figure 2.1. Animals were used at 5-7 weeks of
age unless otherwise noted. Control animals were Ndfip1

fl/fl

Cre-, Ndfip1/Ndfip2+/+, or CD45.1 as

appropriate. Ndfip1/2 DKO mice were generated by breeding Ndfip2-/-Ndfip1+/- females to
fl/fl

Ndfip2+/-Ndfip1+/- males. cDKO mice were generated by breeding Ndfip2-/-Ndfip1 CD4Crefl/+

mice to Ndfip2-/-Ndfip1 CD4Cre+ mice. Mice were maintained in a barrier facility at the
Children’s Hospital of Philadelphia. All procedures were approved by the Institutional Care and
Use Committee of the Children’s Hospital of Philadelphia. Ndfip2 KO/KI alleles were detected
using the following primers on genomic DNA: WT_F 5’-CCCTGTGCCACCTCCGTACAGTG-3’;
WT_R 5’-GCTGAGGCAGTGCGCAGACTTAC-3’; KO/KI_F 5’-CTTCAAGCAGACCTACAGCAAG3’; KO/KI_R 5’-CCTGTTATCCCTAGCGTAACG-3’. The FLP transgene was detected using the
following PCR primers on genomic DNA: FLP_F 5’ GACAAGCGTTAGTAGGCACAT 3’; FLP_R 5’
GGCAGAAGCACGCTTATCG 3’. All animals used in experiments described were FLP negative.
Genotyping primers for Ndfip1 knockout alleles, Ndfip1 flox alleles, and CD4Cre have been
described previously.

Flow cytometry and immunoblot antibodies.
The following flow cytometry antibodies were purchased from Biolegend: CD4 (GK1.5), CD8α
(53-6.7), CD44 (IM7), IL-17A (TC11-18H10.1), CD3ε (17A2), B220 (RA3-6B2), CD45.2 (104),
CD45.1 (A20), CD24 (M1/69). Antibodies against IFNγ (XMG1.2), CD69 (H1.2F3) and Ki67 (B56)
were purchased from BD Biosciences. The remaining antibodies for flow cytometry were
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purchased from eBioscience: IgM (II/41), CD25 (PC61.5), CD62L (MEL-14), GATA3 (TWAJ), IL-4
(11B11), IgM (II/41), T-bet (4B10), FoxP3-biotin (FJK-16s), CD93/AA4.1 (AA4.1). Biotinylated
αFoxP3 was detected with fluorophore-conjugated streptavidin (S32354 Invitrogen). αpSTAT5a/b
for flow cytometry was purchased from BD (pY694, 47). The following primary antibodies were
used for immunoblotting: rabbit αJak1 (3332; Cell signaling Technologies), rabbit αpSTAT5a/b
(C11C5; Cell signaling Technologies), monoclonal mouse αtubulin (B-5-1-2; Sigma), monoclonal
mouse αgapdh (mab374; Millipore), monoclonal mouse αItch (32; BD Biosciences), rabbit
αNedd4-2 (4013, Cell Signaling Technologies), rabbit αCyclin D2 (M-20, Santa Cruz
Biotechnology), rabbit αSTAT5a (E289, Abcam).

GST pulldown
Ndfip cytoplasmic domain constructs were prepared as previously described(Riling et al., 2015).
Plasmids were transformed into BL21(DE3) E. coli and purified by glutathione sepharose 4B (GE
Life Sciences). WT and Ndfip1/Ndfip2 knockout CD4+ T cells were cultured as described below.
Rested cells were restimulated for 4 hours with PMA/ionomycin as described below, lysed in 1%
NP40 (1% NP40, 150mM NaCl, 50mM TrisHCl with phosphatase and protease inhibitors),
precleared with GST, and then incubated with 10µg recombinant Ndfip1, Ndfip2 or GST protein.
Protein was collected on glutathione sepharose beads, and eluted by addition of 4x Laemmli
sample buffer with boiling. Bound protein was analyzed by SDS-PAGE and western blotting as
described below.

Polyubiquitylation assay and ubiquitin charging assay
Polyubiquitylation was monitored using a homogeneous E3 ligase TR-FRET assay (Progenra,
Inc) as described(Marblestone et al., 2012). Ubiquitylation Mix containing Itch or Nedd4-2 was
combined with varying doses of Ndfip1/2 and HTRF Detection Mix. TR-FRET was monitored in
real time using a PerkinElmer Envision plate reader (Ex 340nm; Em1 520nm; Em2 480nm); TRFRET ratio was calculated as Em520/Em480. Ubiquitin charging assay and expression of
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recombinant Itch were described by Riling et al (Riling et al., 2015). Ubiquitylated products were
resolved by SDS-PAGE and western blotting as described below.

Tissue processing and flow cytometry
Spleens, thymii and lymphnodes were harvested and mashed through 70µM nylon filters using
cold HBSS. Spleens were red blood cell lysed using ACK lysis buffer, washed, filtered again and
resuspended in cold HBSS. Bone marrow was isolated by flushing femur and tibia with cold
HBSS, red blood cell lysing and passing through a 70µM filter. Lungs were flushed with cold PBS
immediately after euthanasia; small bowel and lung were processed as described (Beal et al.,
2012). The cells were then sorted; CD4 enriched; stimulated for 4hrs with PMA (30ng/mL,
Calbiochem), ionomycin (1µM, Abcam), and Brefeldin A (1µg/mL, Sigma) for intracellular cytokine
staining; or directly stained for flow cytometry. Cells were washed in serum free HBSS or PBS,
stained with live/dead fixable blue dead cell stain (L-23105; Invitrogen), Fc blocked (αCD16/32,
2.4G2; BD Biosciences) and stained with the appropriate antibody mixtures. After staining 25
minutes at 4 degrees, samples were fixed using the FoxP3 fix/perm kit (eBioscience). Intracellular
staining was done for 1 hr at 4 degrees. In Figure 4.1, bulk isolated CD4+ T cells were stimulated
and rested as described below, then restimulated with mouse T cell activator beads (Invitrogen)
at a 1:1 cell:bead or with PMA/ionomycin for four hours in the presence or absence of 10µM
MG132 (Calbiochem), 50µM chloroquine (sigma), or 10µg/ml cycloheximide (Sigma). In Figure
2.2, Ndfip2+/- (GFP+) cells were analyzed directly, without fixation, for expression of GFP. In
Figures 3.8 and 3.9 bulk isolated CD4+ T cells were stimulated and rested as described below,
rested one additional night in the absence of IL-2 and then restimulated with mouse T cell
activator beads (Invitrogen) at a 1:1 cell:bead ratio for 5.5 hours +/- 20µg/ml αIL-2 blocking
antibody (BD Bioscience, S4B6) before treatment with 50U/ml IL-2 for 20 minutes. Samples were
immediately fixed with 2% PFA, permeabilized in methanol, and then stained for pSTAT5 and
surface markers together. Samples were acquired on an LSRFortessa (BD Biosciences), and
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analyzed using FlowJo version 9.8 (Flowjo LLC). Events analyzed were singlets, (FSC-A x FSCH), live (viability dye negative), and within the lymphocyte gate (FSC-A x SSC-A).

T cell isolation and culture
Total CD4+ T cells were isolated from spleen and lymphnode by negative selection using rat
αmouse CD8α (2.43; ATCC) and rat αmouse I-A/I-E (M5/114.15.2; Biolegend). Cell suspensions
were incubated with the antibodies in complete DMEM for 1 hr with end-over-end rotation at 4C,
washed and incubated with Biomag goat αrat IgG magnetic beads (Qiagen) for 15 minutes with
end-over-end rotation at room temperature; unbound cells were collected using a Dynal magnet
(Invitrogen). Purity after isolation and subsequent culture was greater than 85% CD4+CD3+ T
cells. Naïve cells were sorted from and lymphnode single cell suspensions stained with
antibodies against CD4, CD8α, CD44, CD25, and CD62L. Cells were filtered through 35µM filter
cap polystyrene FACS tube (BD Biosciences), and sorted under high speed on a MoFlow Astrios
(Beckman Coulter) or a FACs Aria (BD Biosciences). Naïve cells were identified as
CD4+CD62L

high

CD44-CD25-. Cells were resuspended at 1x10^6 cells/mL before stimulation with

5µg/mL plate-bound αCD3 (145-2C11; Biolegend) and αCD28 (37.51; Biolegend) for the times
indicated. All cultured cells, unless otherwise noted, were cultured at 10% CO2 in DMEM
(Mediatech) supplemented with 10% fetal calf serum (Atlanta Biologicals), 1% pen/strep
(Invitrogen), 1% Glutamax (Invitrogen) and 0.12 mM betamercaptoethanol (Sigma). Unless
otherwise noted, after 4 days of stimulation, bulk isolated CD4+ T cells were rested/expanded in
recombinant human IL-2, 50U/mL (obtained through the AIDS Research and Reference Reagent
Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National
Institutes of Health) for 3 days, and then restimulated. Naïve cells were stimulated five days. In
Figures 2.4 and 2.9, naive CD4+ T cells were polarized: Th1: αIL4 (20µg/mL, 11B11;
BioLegend), IL-12 (10ng/mL Peprotech), IL-2 (50U/mL); Th2: αIL-12/23p40 (20µg/mL, C17.8;
Biolegend), αIFNγ (20µg/mL, XMG1.2; Biolegend), IL-4 (7.5ng/mL Peprotech), IL-2 (50U/mL);
iTreg: IL-2 (50U/mL), TGFβ (5ng/mL Peprotech); Th17: IL-23 (50 ng/mL R&D Systems), IL-6 (20
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ng/mL eBioscience), TGFβ (0.5ng/mL Peprotech), IL-1β (20 ng/nl Peprotech). In Figure 2.9,
iTreg differentiation was carried out in the presence or absence of 20µg/ml αIL-4 blocking
antibody (Biolegend, 11B11). On day 5 of culture, polarized cells were restimulated with PMA
(30ng/mL), ionomycin (1µM), and brefeldin A (1µg/mL) for intracellular cytokine staining or
stained directly. For CFSE labeling (Figures 2.12, 3.8 and 3.9), cells were washed in PBS,
resuspended at less than 1 × 10^7/mL in 500uL room temperature PBS and mixed at a 1:1 ratio
with CFSE (2.5µM final concentration, Life Technologies) in PBS for 3 min with constant
agitation. Labeling was quenched with FCS and cold DMEM. In Figure 2.2, Ndfip2+/- (GFP+)
cells were labeled with ef670 cell proliferation dye prior to stimulation according to manufacturer’s
instructions (eBioscience). For cocultures (Figures 2.12 and 3.9), naïve CD4+ T cells were
sorted from WT CD45.1 and cDKO (CD45.2) spleen and lymphnodes. Cells were mixed in a 1:1
ratio and then CFSE labeled before being stimulated.

Western blotting and cycloheximide treatment
Bulk isolated CD4+ T cells were resuspended at 1x10^6 cells/mL in complete DMEM and
stimulated with αCD3/CD28 for 4 days. Cells were rested and expanded in recombinant human
IL-2 at 50U/mL (3-4 days) prior to restimulation with plate-bound αCD3/CD28 for the indicated
periods. Where noted, cycloheximide (Sigma) was added at 10µg/mL after 2 hrs of restimulation,
and cells were incubated for an additional 2-4 hrs. Cells were harvested with cold PBS, pelleted
and lysed for 15 minutes on ice with digitonin lysis buffer (Gharbi et al., 2013). Lysates were then
centrifuged at 4500 rcf for 4 minutes, and separated from the pellet. Digitonin insoluble pellet was
subsequently lysed in 1% SDS, 10mM tris, 20µg/mL DNase I and Roche complete inhibitor tablet
with boiling. Alternatively, cell pellets were lysed in the TUBE lysis buffer described below. 4x
Laemmli buffer was then added to 1x final concentration and samples were boiled 5 minutes.
Lysates were loaded by cell number equivalents on pre-cast Criterion Tris-HCL gels (Biorad) and
subjected to SDS-PAGE. Protein was transferred to PVDF (Millipore) using a semi-dry transfer
apparatus. Membrane was blocked in Roche blocking reagent (11096176001). Protein was
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visualized on an Odyssey imager (LICOR) using AF680 goat αrabbit (Invitrogen), IRdye 800
donkey αmouse (LICOR), and IRdye 800 donkey αgoat (LICOR) secondary antibodies. Bands
were quantified using Image Studio Lite (LICOR).

Quantitative PCR
qPCR was performed as previously described(Beal et al., 2012). 10 ng of cDNA was added to
TaqMan Gene Expression Master Mix and TaqMan Gene Expression primer/probe mix specific
for Ndfip1 or Ndfip2 (Applied Biosystems) for a final reaction volume of 20µl. qPCR was
performed using an Applied Biosystems 7500 Real-Time PCR system. Each sample was
assayed in triplicate along with the endogenous control (actin). ACTB primer/probe (4352933E)
was obtained from Applied Biosystems. Ndfip1 and Ndfip2 custom primer and probe sequences
are as follows: Ndfip1_F 5’-GCTCCTCCACCATACAGCAGC-3’; Ndfip1_R
5’CGATGGGGGCTTTGGAAATCCAG-3’; Ndfip1 Taqman MGB probe 5’TTTGGAAATCCAGATTCATCTTTG-3’; Ndfip2_F 5’-AGCAGCATCACTGTGGAAGCT-3’;
Ndfip2_R 5’-GGCACAGGGTAAAACTCACTATACAC-3’; Ndfip2 Taqman MGB probe 5’CTACCACTTCAGATACTG-3’.

Fetal liver chimeras
Fetal liver from WT (CD45.1+), Ndfip1−/− (CD45.2+), Ndfip2-/- (CD45.2) and Ndfip1/2 DKO
(CD45.2) embryos was processed into a single-cell suspension by mashing through a 35-µm
filter. Embryos were genotyped at the time of harvest. Cells were resuspended in freezing media
(90% FCS, 10% DMSO) and kept at −80°C until used. Thawed cells were washed, counted,
mixed 1:1 CD45.1:CD45.2, resuspended in sterile PBS and injected i.v. into sublethally irradiated
6 week old Rag1−/− recipients, 1 × 10^6 cells/mouse. Chimeras were weighed twice weekly and
analyzed approximately 6 weeks after transfer, when inflammation and weight loss were
observed.
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Histology
Skin, esophagus and distal colon were dissected and fixed in 10% formalin for at least 24 h. Lung
was perfused with formalin. All organs were then embedded in paraffin, sectioned, and stained
with H&E.

T cell transfer colitis
Naïve CD4+ T cells from WT, Ndfip2-/-, Ndfip1fl/flCD4Cre+ and Ndfip2-/-Ndfip1fl/flCD4Cre+ mice
were sorted from spleens and lymphnodes as described above. Cells were resuspended at
5x10^6/mL in sterile PBS and 0.5x10^6 cells were injected intraperiotneally into 6-8 week old
Rag1-/- mice. Mice were weighed every 2 to 3 days. Recipients were co-housed. Clean cage
bedding was mixed with dirty bedding such that cages were only fully changed every 2 weeks.
Mice were sacrificed when recipients showed weight loss of 30% starting weight. At sacrifice,
mice were weighed, spleens were weighed and processed for flow cytometry as described above,
colons were measured for contraction and distal colon sections were fixed for histology. Crypt
depth was measured at 3 different points/slide on H&E stained colon sections, and
averaged/animal.

TUBE affinity purification and whole proteome analysis
Bulk isolated CD4+ T cells were isolated as described above. Dialyzed fetal calf serum was used
in SILAC DMEM/SILAC RPMI during isolation. Cells were stimulated in SILAC media with platebound αCD3/CD28 for 3 days. SILAC media components are as follows: SILAC RPMI (Hyclone),
C13 or C12 L-arginine:HCl and L-lysine:2HCl (Cambridge Isotope Laboratory), 1% MEM NEAA
(Invitrogen), 1% sodium pyruvate (Invitrogen), 1% Glutamax (Invitrogen), 1% pen/strep
(Invitrogen), 10% Dialyzed FCS (Life Technologies), 2% HEPES (Fisher Scientific), 0.12 mM
betamercaptoethanol (Sigma). After stimulation, cells were rested in IL-2 for 3 days. Cells were
restimulated at 4x10^6/mL SILAC media using PMA (30ng/mL) and ionomycin (1µM) for 4 hrs.
MG132 (10µM/mL; Calbiochem) and chloroquine (50µM/mL; Sigma) were added during the final
2 hours of stimulation. Cells pellets were lysed using the recommended lysis buffer for product
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UM604 from Lifesensors. Protein was quantified by BCA. ~30µg of “input” unmixed lysate was
mixed 1:1 with 4x Laemmli sample buffer and saved for whole proteome analysis. Equal amount
of heavy and light lysate was mixed (1.2mg of each) and diluted 1:10 in lysis buffer with no
detergent. Samples were rotated at 4 degrees with 50µg biotinylated pan-TUBE (UM301;
Lifesensors) for 2 hrs. 250ul/sample Dynabeads MyOne Streptavidin c1 (Invitrogen) were washed
and added to samples, which were rotated an additional 2hrs at 4 degrees. Beads were collected
and washed in cold PBS 3 times. Samples were eluted using 1x Laemmli sample buffer and
boiling, and were stored at -80 C.

SILAC quantified K-ε-GG immunoprecipitation
Spleen and lymphnodes from 9 WT mice were harvested, CD4 enriched and cultured with T cell
stimulation in C12 or C13 SILAC media (described above), rested/expanded 3 days in 50 U/ml IL2 and then either harvested as “resting” cells or restimulated with αCD3/CD28 beads (Invitrogen)
at a 3:1 cell:bead ratio for 1hr or 4hrs. Cells were then prepared for K-ε-GG immunoprecipitation
as described below.

In gel digest
TUBE enriched SILAC lysates, whole proteome TUBE “input” samples, and whole proteome C12
samples from the T cell stimulation timecourse were run ~2cm past the stacking gel in 10%
Criterion pre-cast Tris-HCL gels (Biorad). Gels were fixed overnight and stained briefly with
Coomassie blue. Each lane of the Coomassie-stained gel was divided into ten 2mm x 9mm
3

‘pixels,’ each cut into 1 mm cubes (Shevchenko et al., 1996). They were destained with 50%
Methanol/1.25% Acetic Acid, reduced with 5 mM dithiothreitol (Thermo), and alkylated with 40
mM iodoacetamide (Sigma). Gel pieces were then washed with 20 mM ammonium bicarbonate
(Sigma) and dehydrated with acetonitrile (Fisher). Trypsin (5ng/uL in 20 mM ammonium
bicarbonate, Promega) was added to the gel pieces and proteolysis was allowed to proceed
overnight at 37 ºC. Peptides were extracted with 0.3% triflouroacetic acid (J.T.Baker), followed
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by 50% acetonitrile. Extracts were combined and the volume was reduced by vacuum
centrifugation.

K-ε-GG peptide immunoprecipitation
Bulk CD4+ T cells were stimulated and expanded in IL-2, as above, prior to restimulation for 4hrs
with PMA/ionomycin (30ng/1µM) including MG132 (10µM/mL Calbiochem) and chloroquine
(50µM/mL) for 2hrs, or with 4hrs with mouse T cell activator beads (Invitrogen) at a 3:1 cell:bead
ratio in the absence of inhibitors. SILAC labeled K-ε-GG samples were cultured as noted above.
Cell pellets (and bead-cell pellets in the case of CD3/CD28 stimulated cells) were lysed in urea
buffer, protein concentration was measured via micro BCA assay (Thermo), and peptides were
prepared and immunoprecipitated as described (Udeshi et al., 2013a; Udeshi et al., 2013b).
~250x10^6 total CD4+ T cells at the start of stimulation yielded ~3mgs of total peptide. For the
“super SILAC” labeling of CD3/CD28 stimulated cells, C13 labeled cells from the rest, 1hr and 4hr
timepoints were mixed at a 1:1:1 ratio after BCA quantification, and then C12 (individual timepoint
samples) and C13 labeled cells were mixed at a 1:1 protein ratio before peptide preparation.
Peptides were off-line basic reverse phase fractionated and recombined noncontiguously into 3
fractions of ~1mg peptide/fraction for immunoprecipitation. For the T cell activation SILAC
timecourse, ~0.8mg of peptide was used per fraction, and fractionated samples were recombined
into 4 fractions instead of 3. PTMscan ubiquitin remnant antibody, noncovalently conjugated to
beads (Cell Signaling Technologies) was crosslinked as described (Udeshi et al., 2013b), and
validated by SDS-PAGE. 31µg crosslinked antibody was used for each 1mg peptide fraction. The
following modifications were made to the published protocol: step 6: alkylation was done with
20mM IAM; step 10: peptides were acidified by 1% formic acid (final concentration); step 37:
wash beads 2x with IAP, followed by 2X IAP plus 0.05% RapiGest SF surfactant (Waters),
followed 3X PBS; step 41: the eluted K-ε-GG peptides were desalted via Oasis HLB uElution
plate 30µM (Waters). All mass spec samples were prepared in 0.1% TFA/water and analyzed as
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described below. After LC-MS/MS analysis, greater than 50% of peptides were modified (data not
shown).

LC-MS/MS
Tryptic digests were analyzed by LC-MS/MS on a hybrid LTQ Orbitrap Elite mass spectrometer
(Thermofisher Scientific) coupled with a nanoLC Ultra (Eksigent). Peptides were separated by
reverse phase (RP)-HPLC on a nanocapillary column, 75µM ID × 15 cm Reprosil-pur 3µM (Dr.
Maisch, Germany) in a Nanoflex chip system (Eksigent). Mobile phase A consisted of 0.1%
formic acid (Thermofisher Scientific) and mobile phase B of 0.1% formic acid/80% acetonitrile.
Peptides were eluted into the mass spectrometer at 300 nL/min with each RP-LC run comprising
a 90 minute gradient from 10 to 25% B in 65 min, 25-40%B in 25 min, followed by column reequilibration. The mass spectrometer was set to repetitively scan m/z from 300 to 1800 (R =
240,000 for LTQ-Orbitrap Elite) followed by data-dependent MS/MS scans on the twenty most
abundant ions, with a minimum signal of 1500, dynamic exclusion with a repeat count of 1, repeat
duration of 30s, exclusion size of 500 and duration of 60s, isolation width of 2.0, normalized
collision energy of 33, and waveform injection and dynamic exclusion enabled. FTMS full scan
AGC target value was 1e6, while MSn AGC was 1e4, respectively. FTMS full scan maximum fill
time was 500 ms, while ion trap MSn fill time was 50 ms; microscans were set at one. FT
preview mode; charge state screening, and monoisotopic precursor selection were all enabled
with rejection of unassigned and 1+ charge states.

Data analysis
TUBE-SILAC data were analyzed using Maxquant verison 1.5.0.30 using the Uniprot complete
mouse reference proteome, including isoforms, (updated Sept 19, 2013) and common laboratory
contaminants with a minimum peptide length of 6 amino acids and a peptide and protein false
discovery of 1%. The 4 biologic replicates for TUBE-SILAC experiments were analyzed together,
with match between runs and requantify turned on. SILAC ratios were calculated in MaxQuant.
Whole proteomes were analyzed together in MaxQuant version 1.5.1.2, using the Uniprot
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complete mouse reference proteome (updated Aug 18, 2014) and common lab contaminants with
a minimum peptide length of 6 amino acids and 1% false discovery rate; requantify and match
between runs were turned off. Unique peptide counts were used to generate semiquantitative
ratios representing relative protein abundance, DKO/WT. Proteins analyzed had a minimum of 3
unique peptides identified. In the case of missing values, 0 count was defined as 1. To correct
TUBE-SILAC ratios for input proteome ratios for each protein, the log2 transformed average
unenriched DKO/WT input ratio was added to the log2 transformed normalized TUBE-SILAC ratio
(WT/DKO). TUBE-SILAC ratios were corrected for each of 4 biologic replicates, including one
isotope swap. K-ε-GG data was searched using SEQUEST, and visualized in Scaffold Viewer
version 4.3.4 (Proteome Software, Inc.). Proteins with at least one modified peptide were
considered for further analysis. The 2 biologic replicates of αCD3/CD28 stimulated CD4+ T cells
in the absence of inhibitor were each analyzed twice by LC-MS/MS, and data from these
technical replicates were summed for further analysis. Protein identifications and SILAC ratios,
whole proteome ratios, and K-ε-GG peptides from the proteomic studies in Chapter 3 are
provided electronically. In Chapter 4, CD3/CD28 timecourse proteomic data (whole cell proteome
and SILAC labeled K-ε-GG immunoprecipitation) were analyzed together in Maxquant version
1.5.1.2, with match between runs and requantify turned on, using the Uniprot complete mouse
reference proteome (updated Aug 18, 2014) and common lab contaminants with a minimum
peptide length of 7 amino acids and 1% false discovery rate. All timecourse data was analyzed in
R version 3.2.0, with data processing as described in the text, using the following bioconductor
packages: bpca, fpc, gplots and Rcolorbrewer. In Figures 3.1 and 4.8, the heatmaps were
generated by one-matrix CIM with columns and rows clustered by average linkage and Euclidean
distance with quantile bins (http://discover.nci.nih.gov/cimminer/). All area proportional Venn
diagrams were generated with eulerAPE version 3.0 (http://www.eulerdiagrams.org/eulerAPE/).
GO term analysis was done using GOrilla, http://cbl-gorilla.cs.technion.ac.il.
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Statistical analysis
Data were graphed and analyzed for statistical significance in Prism version 6 (Graphpad
Software, Inc), or Excel (Microsoft). The following statistical tests were used as appropriate and
as noted in the figure legends: T-test, one-way ANOVA, two-way ANOVA, repeated measures
ANOVA, one phase exponential decay fit. All data are shown as average +/- SEM, with a cutoff of
p<0.05 for statistical significance: * p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001.
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